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^ptosis is a process that deletes cells from living tissues. It constitutes a stereotyped sequence of events
culminate in the fragmentation of the cell and the ingestion of its remains by mononuclear phagocytes,
se structural changes are the result of proteolytic cleavage of key cellular substrates and reflect common
linal effector events. Members of a family of cysteine proteases, called caspases, are activated during
itosis and are implicated as key mediators of these proteolytic events. Caspase 2/human ICH-l/mouse
3D-2 was identified as a member of the caspase family based on sequence similarity to prototype caspases
)3 and caspase 1/ICE. Its specific role in apoptosis has not yet been clearly defined,
rder to define the role of caspase 2 in apoptosis, three rabbit polyclonal antibodies were raised against
erially expressed recombinant caspase 2 polypeptides. Two anti-caspase 2 antibodies were successfully
id and the specificity of those antibodies to the prodomain and the small subunit was confirmed by
unoblot and ELISA analysis. Both antibodies proved unsuitable for the use as immunocytochemical and
unohistochemical reagents, were however valuable tools in Western blotting.
ommercially available anti-caspase 2 monoclonal antibody, generated against recombinant caspase 2, was
vn by immunoblot analysis to detect a cellular protein of the appropriate molecular weight for procaspase
'his antibody was used to investigate caspase 2 expression by immunoblot analysis in various human
es and cell lines. Protein expression was found at various levels in all 11 tissues extracts analysed and
unoreactivity was localised within the cytosol in several human tissues. Activation of caspase 2 in
itosis was analysed in two human cell lines in response to three different apoptotic stimuli: etoposide,
osporine and Fas ligation. Immunoblotting with the Transduction Laboratories monoclonal anti-caspase
■tibody revealed no change in the quantity or molecular weight of the detected epitope during apoptosis.
mation obtained from immunohistochemistry or Western blotting using the Transduction Laboratories
caspase 2 monoclonal antibody was proved to be irrelevant to the study of caspase 2, as the protein
cted by this antibody was shown not to be caspase 2.
tern blotting analysis with the two polyclonal anti-caspase 2 antibodies raised and two other non-
mercial antibodies to caspase 2 established activation of caspase 2 during apoptosis in response to
oside, anti-Fas and staurosporine treatment. The kinetics of caspase 2 activation were shown to be similar
ispase 3 activation and PARP cleavage.
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The word 'apoptosis' is derived form a Greek word describing the process of
leaves falling from trees or petals from flowers. It was introduced to describe a
morphologically distinct form of cell death whereby single cells are deleted from living
tissues (Kerr et al, 1972). Apoptosis is now known to be effected by a common set of
endogenous events, amongst them the activation proteases, called caspases, because
they contain a cysteine residue at their active site and selectively cleave peptide bonds
adjacent to aspartic acid residues. One of these, caspase 2 (ICH-1), is the subject of
this thesis.
1.2MORPHOLOGYOFAPOPTOSIS
Cells undergoing apoptosis exhibit a characteristic set of morphological
changes, which occur in apoptosis regardless of the cell type (reviewed by Arends et
al, 1994).
In the nucleus events of apoptosis begin with the condensation of chromatin, which
progressively becomes more condensed and either forms a single chromatin aggregate
or collapses against the nuclear membrane and forms several separate aggregates in
hemilunar caps. Subsequently the nuclear membrane undergoes convolutions and the
condensed nucleus fragments to form spheres of dense nuclear material. These nuclear
changes are associated with a redistribution of nuclear pores, disassembly of the
nuclear lamina and endonuclease dependent DNA fragmentation (Wyllie et al, 1980A;
Lazebnik et al, 1993; Enari et al, 1998). The DNA is cleaved first into large (50-
300kb) fragments, referred to as 'domain' cleavage, followed by cleavage in the
internucleosomal linker regions, which arc spaced regularly at approximately 180-200
base pair (bp) intervals along eukaryotic chromatin, into single and multiple
nucleosomes fragments (Wyllie, 1980B). These chromatin fragments can be observed
by agarose gel electrophoresis as a DNA ladder pattern of bands of intiger multiples
of about 200bp.
Cytoplasmic features of apoptosis include a loss of cell volume, aggregation of
organelles and disintegration of organelle structure. The endoplasmic reticulum dilates
and form expanded vesicles, which sometimes fuse with the plasma membrane giving
1
it a pitted appearance. Other cytoplasmic organelles remain largely unaffected. The
dying cell violently extrudes and withdraws finger-like extensions (blebs), shrinks in
cell volume and eventually fragments into membrane bound apoptotic bodies of
various sizes some, containing condensed chromatin.
1.3. SIGNIFICANCE OFAPOPTOSIS
"No self-respecting cell would be seen dead other than by apoptosis these
days" (Allen et al, 1995). Apoptosis occurs in most , if not all, multicellular animals,
plants, probably even fimgi, and possibly some unicellular organisms including
Trypanosoma cruzi and Tetrahymena thermophilia (Cornillon et al, 1994; Davis et al,
1992; Ameisen et al, 1995). It thus seems that many cells, regardless of the
phylogenetic origin or physiological specialisation may ultimately die by apoptosis.
Apoptosis occurs under physiological conditions during embryogenesis and
morphogenesis in which it is involved in sculpturing of organs and deleting unneeded
structures. It is essential for tissue atrophy and normal homeostasis of multicellular
organisms by removing redundant cells, which include cells that have fulfilled their
lifespan, are non-functional or abnormal. It is also a means to precisely regulate cell
numbers and is particular important in the developing nervous system (Raff et al,
1993) and in the development and effective functioning of the immune system
(reviewed by Williams, 1994). Apoptosis is also triggered in response to pathological
stimuli including viral invasion and is thus an important mechanism for removal of
infected and potentially hazardous cells. The crucial importance of apoptosis,
however, becomes clear from well-studied examples of animal development (reviewed
by Jacobson et al, 1997). Digit formation in some higher vertebrates is blocked by
selective inhibitors of the effector pathway of apoptosis (Milligan et al, 1995,
Jacobson et al, 1996). Apoptosis-deficient flies die early in development (White et al,
1994A) and mice in which one critical effector caspase (caspase 3) has been deleted
by target gene disruption die perinatally with a vast excess of cells in their central
nervous system (see also chapter 1.6.3.3.).
In humans defective apoptosis has been implicated in several diseases, including a
variety of neurodegenerative diseases, immune system disorders and carcinogenesis
(reviewed by Savill, 1994; Thompson, 1995, Haecker et al, 1995; Martin et al, 1995;
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Nicholson, 1996). Diseases related to impaired apoptosis can be divided into disorders
of excessive apoptosis and those where insufficient apoptosis occurs. Thus failure to
regulate apoptosis negatively, resulting in too much cell death has been associated
with degenerative diseases of the central nervous system such as Alzheimer's disease
in which progressive and irreversible memory and cognitive loss appears to be the
result of premature hippocampal neuronal death (Su et al, 1994; Lassmann et al,
1995; Smale et al, 1995) and clinical AIDS resulting from the gradual depletion of
CD4 T cells during HIV infection (reviewed by Gougeon, 1996). Failure to regulate
apoptosis positively, resulting in insufficient apoptosis, may be a component in some
autoimmune diseases like lupus erythematosus, where a failure to complete apoptosis
at the engulfment stage results in the recognition of cryptic epitopes, which are
normally proteolytic cleaved during the apoptotic pathway, by lupus autoantibodies
(Williams, 1994; Tan, 1994; Casciola-Rosen et al, 1994A; Casciola-Rosen et al,
1995). Failed apoptosis may also be a feature in carcinogenesis and may be the
strategy of persistent and sustained viral infections (Evan et al, 1995; Osborne, 1995;
White, 1995).
1.4. MOLECULAR REGULATION OFAPOPTOSIS
In the past decade and especially in the past three years, it has become clear
that apoptosis is controlled by a large number of genes. These seem to be
evolutionarily conserved from simple eukaryotic organisms, through nematodes to
mammals and some have also been adopted by viruses. First evidence of these genes
came from studies on the nematode worm Caenorhabditis elegans (reviewed by Ellis
et al, 1991, Driscoll, 1992; Miura et al, 1996; Hengartner, 1996). The nematode
generates 1090 cells during its development of which 131 die by apoptosis. Each
individual cell, programmed to die, does so at a certain time of development and each
of the deaths can be followed by light microscopy, due to the transparency of the
nematode worm. Genetic screening of viable nematode mutants which are deficient in
apoptosis has led to the isolation ofmany alleles that affect the apoptotic pathway. So
far 14 nematode genes have been found to be involved in developmental cell death.
These genes have been placed in a developmental pathway of apoptosis, divided into
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four distinct steps: determination/commitment, execution, engulfment and
degradation.
Specific cells All dying cells
II
EXECUTION OF DEATH ENGULFMENT DEGRADATION
Figure 1.1. The genetic pathway of apoptosis in C. elegans. The proposed regulatory
interactions between adjacent genes in the pathway are indicated: arrow, positive interaction; bar,
negative interaction (adapted from Miura et al, 1996).
Three genes lie at the centre of the regulation of cell death in the nematode, namely
ced3, ced4 and ced9. CED3 is a caspase and effects death. It is the prototype of the
cysteine protease family of which one mammalian member is the subject of this thesis.
CED4 protein activates CED3 and CED9 inhibits this activation. All three genes are
direct homologues of genes with similar function in mammals. In the following
sections, the roles of these three gene families are described.
1.4.1. Regulation of the apoptotic pathway by CED9 and its mammalian
counterparts
The ced9 gene consists of a 1.3kb mRNA that is highly expressed in C.
elegans embryos and encodes a negative regulator of developmental cell death
(Hengartner et al, 1992). Gain of function mutations in the ced9 gene prevent
apoptosis in C. elegans, whereas loss-of-function mutations in ced9 cause ectopic cell
death that result in C. elegans embryonic lethality. Ced9 is an element of a
polycistronic locus that also contains the gene cyt-1, which encodes a protein similar
to cytochrome b560 of complex II of the mitochondrial respiratory chain (Hengartner
et al, 1994). Ced9 encodes a protein of 280 amino acids that shares significant amino
acid sequence similarity to the human Bcl-2 family of cell death regulators (reviewed
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by Hale et al, 1996; Hermann et al, 1996; Park a/, 1996; Yang et al, 1996;
Kroemer, 1997A; Kroemer e/ a/, 1997B).
The bcl-2 gene was the first member to be identified of the multigene bcl-2 family. It
was first detected as a putative oncogene located near the t(14;18)(q32;q21)
translocation breakpoint common to many human follicular lymphomas and was first
recognised as a survival factor without significant mitogenic activity by Vaux et al,
1988. Bcl-2 is widely expressed during early murine foetal development and in adults
Bcl-2 expression is found mainly in tissues that are renewed from stem cells, are long
lived, or have proliferative ability. Together with many other members of the Bcl-2
family, Bcl-2 is predominantly localised in the outer mitochondrial membrane, but is
also present in the endoplasmic reticulum and the nuclear membrane. Overexpression
of bcl-2 protects from apoptosis by a variety of stimuli in many cell types and bcl-2
expression in C. elegans can substitute for ced9 loss of function mutations and
suppress apoptosis. Ectopic or dysregulated expression of bcl-2, however, does not
suppress all types of physiological cell death, including negative selection of
thymocytes, lymphocytes and apoptosis by the Fas pathway following treatment with
anti-Fas antibody (Chiu et al, 1995; Strasser et al, 1995; Sarfaz et al, 1995; An et al,
1996), which suggests that there are at least two pathways of apoptosis, one bcl-2
dependent and another bcl-2 independent.
In place of the single C. elegans negative regulator of apoptosis, CED9, mammalian
apoptosis appears to be regulated by multiple genes. Protein homologues to Bcl-2
have been identified by a number of approaches, including coimmunoprecipitation
with Bcl-2 and polymerase chain reaction (PCR) cloning, using degenerate primers.
Evidence to the subcellular functions of individual Bcl-2 homologues from yeast two-
hybrid assays and from structural analysis and has shown that the Bcl-2 family
comprises both death-inducing and death-inhibitory members. Death antagonists
include Bcl-2, Bcl-xl, Bcl-w, Bfl-1, Brag-1, Mcl-1 and Al and death agonists include
Bax, Bak, Bad, Bid, Bik, Hrk and Bcl-xs (an alternative RNA splice product to bcl-xl
from the bcl-x transcript). Individual Bcl-2 family members differ in their tissue- and
activation-dependent expression patterns, as well as in structural features.
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Gene knock-out studies of individual Bcl-2 family members in mice support the theory
that different members may be required for cell survival or deletion in particular
tissues. Null mice of the death antagonist bcl-2 or the agonist box are viable and
initially develop normally. Tissue and cell type specific abnormalities, due to defective
cell survival of various cell types, become apparent only after birth and include
thymocyte and B cell hyperplasia and male infertility. In contrast homozygous bcl-x
knock-out mice show massive apoptosis in haematopoitic cells and central nervous
system neurons. The homozygous null animals die at about embryonic day 13. These
results suggest selective functions of the bcl-2 family members at certain times and in
specific tissues, whilst at other times and situations there may be substantial functional
redundancy.
Structural analysis has shown that most members, with the exception of Bid and Bad,
possess a COOH-terminal transmembrane region and variable amounts of the Bcl-2
homology regions (BH1 to BH4). These homology regions together with the
hydrophobic membrane domain determine the subcellular localisation and the capacity
to interact with each other or unrelated proteins. Deletion of the transmembrane
domain of various family members, including Bcl-2 and Bax, prevents targeting to the
mitochondrial membrane and either abrogates or diminishes the function. Yeast two-
hybrid assays and deletion mapping has shown selective formation of homo- and
heterodimers among Bcl-2 family members, involving interactions in different BH
regions, and a hierarchy in the strength of binding between various partners with the
equilibrium state between these dimersations dictated in part by the relative abundance
of each of the interacting proteins. Developmental cell death or survival in mammals
might thus be regulated in a number of different ways and seems to be mediated, at
least in part, by competitive dimerisation between selective pairs of antagonists and
agonists forming a life-death rheostat. Which of the variety of homo- and
heterodimers of family members that have been identified in vitro are true regulators
of apoptosis in vivo is still largely unresolved. Some dimers may form part of
regulatory, higher-order multiprotein complexes. Additional complexity is added by
the finding that some members of the Bcl-2 family in this life-death rheostat might be
common dimerisation partners, such as Bax, which in addition to Bcl-2 and Bcl-xl,
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heterodimerises with MCL1 and Al. In contrast other family members heterodimdrfse
selectively. Thus Bcl-xs only heterodimerises with Bcl-xl and Bcl-2. These
observations suggests potential redundancy and a very wide range of possible death
inhibitory or stimulatory events mediated by the Bcl-2 family. It should be noted,
however, that most studies to date have not addressed the possibility that selective
interactions may be critical at particular intracellular sites, or in certain cell types.
Expression levels and dimerisation, however, may not be the only parameters that
determine the regulatory role of the Bcl-2 family members in apoptosis.
Posttranslational modifications may have a major impact and add further to the
complexity of regulation of apoptosis. Serine-phosphorylation has been shown to
regulate the function of some individual members, which links the apoptotic
regulatory pathway to signal transduction cascades. Inactivation by proteolysis may
also be involved. Bcl-2 is highly susceptible to trypsin and chymotrypsin proteolysis,
and apoptosis in HIV infected lymphocytes has been attributed to cleavage of Bcl-2
by the HIV protease.
The mechanism by which the complex Bcl-2 family regulates apoptosis is not yet
clear, but as the role of mitochondria in apoptosis becomes further elucidated, the
Bcl-2 family of apoptosis regulators emerge as an important link between
mitochondria and apoptosis. Initial evidence for this link came from two independent
studies. Bcl-2 was shown to be localised in the outer mitochondrial membrane (Reed,
1994) and cell-free apoptosis inducing extracts from Xenopus eggs were shown to
require the presence of heavy membrane fractions which are rich in mitochondria
(Newmeyer et al, 1994). Addition of Bcl-2 protein to those extracts blocks their
capacity to initiate apoptosis suggesting a direct link between mitochondrial apoptotic
signalling and negative regulation by Bcl-2. Pharmacological and functional studies
have since revealed that mitochondrial alteration appears to play a central role in the
apoptotic process and suggest that apoptosis might be triggered by a disruption of the
mitochondrial membrane function. The critical observations in this currently confused
area appear to be as follows (reviewed by Martins et al, 1997A; Kroemer et al,
1997B). First, the mitochondrial membrane potential dissipates in apoptosis and, at
least in some systems, appears to be a critical factor in triggering these terminal
7
effector events (see also 1.6.5.). Second, Bcl-2 and its close structural homologue
Bcl-x are structurally reminiscent of bacterial pore-forming proteins and are thus
capable of regulating the flux of ions and larger molecules across the outer
mitochondrial membrane. Third, mitochondria, being the intracellular location of the
terminal respiratory chain enzymes, are promiscuous sites for the sensing of
alterations in cellular redox equilibrium or generation of reactive oxygen species.
Finally, certain additional molecules, amongst them the electron transfer protein
cytochrome c (Liu et al, 1996) and the mitochondrial protease AIF (apoptosis
inducing factor) (Susin et a!, 1996) are released from mitochondria and are essential
for activation of apoptosis (see also 1.6.5 ). It is not too difficult to link these
observations into a single mechanism wherein mitochondrial membrane changes,
induced by reactive oxygen species damage or initiated by modification of Bcl-2 or
Bcl-xl function, lead to the release of sequestered caspase activators. The details of
this putative mechanism are still unproven. Nor is it completely clear whether
mitochondrial depolarisation plays an initiating or secondary role.
Recent advances have identified a novel cytosolic proteins Apaf-1 (apoptotic protease
activating factor) as the potential homologue of the C. elegans death gene ced4 (Zou
et al, 1997). A critical role of Bcl-2 and other antiapoptotic family members appears
to be the inactivation of the linker molecule CED4.
1.4.2. Regulation of the apoptotic pathway by CED4 and its mammalian
counterpart
Like CED9 and CED3 (see chapter 1.6 ), CED4 is required for developmental
cell death in C. elegans (Yuan et al, 1992; reviewed by Miura et al, 1996). The ced4
gene is most abundantly expressed during embryogenesis. Ced4 encodes a 549 amino
acid protein, which is very hydrophilic and contains a structural motif which resembles
a calcium binding domain. Ced4 loss of function mutant animals are structurally
normal despite a general lack of apoptosis and a 30% slower growth rate than wild-
type animals. Overexpression of the ced4 gene causes cells that normally survive to
undergo apoptosis and CED4 thus acts as an activator of developmental cell death.
CED4 activity in C. elegans seems to be negatively regulated by CED9, as mutations
in ced4 can suppress the embryonic lethality of ced9 lack-of -function mutation. Two
splice variants of ced4 have been identified: ced4s and ced4! which exhibit different
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functions (Shaham et al, 1996). Recent studies in yeast and mammalian cells show
that CED4L is a cytosolic protein which binds directly and simultaneously to CED9
and CED3 or to the mammalian homologous Bcl-xl and caspases (Spector et al,
1997; Irmler et al, 1997A; Chinnayan et al, 1997; Wu et al, 1997A; Wu et al,
1997B). Interaction ofCED4 with CED3 seems to be through a novel protein-protein
interaction motif named CARD (caspase-recruitment domain). Thus CED4 could
b#. provide the direct link between CED9 and CED3. The multiple interactions suggest a
mechanism by which CED9 through interaction with CED4 could inhibit the ability of
CED4 to activate CED3. Membrane localisation may be important for this regulation
of CED4 activity as coexpression of ced4 with ced9 targets CED4 to intracellular
membranes (Wu et al, 1997A; Wu et al, 1997B; Spector et al, 1997; Chinnaiyan et al,
1997; Irmler et al, 1997A). The recent identification ofApaf-1, a cytoplasmic 130kDa
human protein with high sequence similarity to CED4 and to caspase 3 adds further
complexity to the regulatory function of CED4 (Zou et al, 1997). Apaf-1 contains
multiple protein-protein interaction motifs, binds cytochrome c and triggers the
activation of caspase 3 in vitro in the presence of both cytochrome c and ATP. This
suggests a model in which the Bcl-2 family of proteins by controlling the release of
cytochrome c might indirectly regulate the cytochrome c dependent Apaf-1 function
of caspases activation (see also chapter 1.6.5.). The regulatory role of CED4 and its
mammalian counterpart(s) is thus only beginning be understood but it is clear that a
major role is to activate the caspases, one ofwhich is the theme of the experiments of
this thesis. Before considering these in detail, however, it is important to discuss how
the terminal effector events of apoptosis and other immediate regulatory mechanisms
are influenced by incoming stimuli of both physiological and pathological nature.
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1.5. MOLECULAR INDUCERS OFAPOPTOSIS
The regulatory mechanisms described in the preceding section are present in
many cell types and the terminal, caspase-dependant pathway also appears to be
common to cells of many lineages resulting from a wide variety of stimuli. The
transduction of these stimuli, however, so as to activate these common terminal
events takes an enormous variety of routes, too diverse to be discussed in detail here
and may depend on the cell type and its characteristic gene expression, the cellular
environment, the state of differentiation, the cell cycle-phase and the dose of the
reagent
In principle, certain generalities about the transduction of apoptotic stimuli are already
apparent. First, both physiological and injury-related stimuli initiate apoptosis under
the appropriate circumstances. Amongst the known injury-related stimuli are those
arising within the nucleus (DNA damage), mitochondria (reactive oxygen species) and
cell membrane (ceramide) and it is clear that other forms of injury may also trigger
apoptosis.
Site ofperturbation Mechanism ofperturbation
Nucleus Perturbation ofDNA integrity
Directly: DNA damage
Indirectly: Inhibition of nuclear enzymes
Alteration of gene expression
Cell surface Activation of cell membrane receptors
Disruption of regulation of plasma membrane solute
flux
Cytosol and organellar Membrane perturbation
compartments Alteration of microtubule organisation
Disruption of actin network
Disruption of the cytosolic milieu
Disruption of intracellular membrane ion gradients
Alteration of protein synthesis
Alteration of protein phosphorylation
Alteration of signal transduction
Table 1.1. Sites and mechanisms of apoptotic induction (adapted from Wertz et at,
1996).
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Physiological stimuli include those resulting from binding of specific cytokines to their '■*
receptors on the cell surface (Fas, tumour necrosis factor receptor (TNFR) and other
members of the TNF receptor superfamily such as death receptors DR3, 4 and DR5)
which can activate the terminal pathway by non-transcriptional means. There are also
more subtle stimuli, most still rather poorly defined, that regulate transcriptional
activation before the terminal effector pathway is affected, such as in apoptosis
induced by transcriptional activation of c-myc and nur77. A variety of oncogene
transcripts also modify the susceptibility to apoptosis (ras, src and abl) (reviewed by
Hoffman et al, 1994; White, 1994B; Evan et al, 1995; Hale et al, 1996; Miura et al,
1996). A further important mechanism in the induction of apoptosis is the activation
of the terminal pathway by specific enzymes transferred from adjacent sites. This is
one part of the mechanism of the killing by CTL, through transfer of the caspase
activating serine protease granzyme B. Finally there are emerging mechanisms that
appear to link these various transduction pathways together. Thus activation of the
TNFR may initiate non-transcriptional activation of caspases, and may also by a
transcriptional mechanism via NFkB activation inhibit apoptosis. Further, some of the
pathways described may be at least partially dependent on others. Thus apoptosis
induced by c-myc or p53 is dependent on the activity of the Fas signalling system
(White, 1996A).
In this thesis experiments are described in which apotosis is induced by three separate
mechanisms- nuclear DNA double strand breaks (through action of the
chemotherapeutic drug etoposide), inhibition of protein kinase C (through treatment
with staurosporine) and stimulation of the Fas signalling pathway.
1.5.1. Reagents acting within the nucleus: etoposide
Etoposide, an antineoplastic drug, induces apoptosis by formation of double
strand DNA breaks through inhibition of topoisomerase II (reviewed by Liu, 1989;
Froelich-Ammon et al, 1995; Capranico et al, 1997). Topoisomerase II binds to DNA
covalently and forms transient single- or double-strand DNA breaks to modulate
DNA topology. Etoposide binds to topoisomerase II and stabilises these covalent
topoisomerase II DNA cleavage complexes and hinders the reclosure of the DNA
breaks. These transient protein-associated breaks are disrupted and are converted into
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permanent double-strand breaks, no longer held to together by proteinaceous bridges,
following the traverse of replication complexes or helicases. DNA damage initiated by
etoposide treatment leads to activation and change in the stability of the tumour
suppressor gene p53. Stabilised p53 activates the transcription of target genes and
induces growth arrest or, alternatively, induces apoptosis in many cell types.
Etoposide is thus commonly used for the induction apoptosis and the study of the role
of caspases in a variety of cell culture systems including human HL60, U937 and ML-
1 leukaemia cells and THP.l monocytic tumour cells (Kaufmann, 1989; Martins et al,
1997; Kaufmann et al, 1993; MacFarlane et al, 1997; Mashima et al, 1995A;
Mashima et al, 1995B; Morana et al, 1996).
1.5.2. Reagents acting in the cytoplasm: staurosporine
Staurosporine, a microbial alkaloid extracted from streptomyces species, is a
nonselective protein serine/threonine kinase inhibitor. Staurosporine induces apoptosis
in many normal and transformed cells in cell culture, including human leukaemia cell
lines such as HL-60 and MOLT-4, Jurkat T cells and human fibroblasts (Bertrand et
al, 1994; Orth et al, 1996A, Na et al, 1996; Jacobson et al, 1993; Jacobson et al,
1996). Staurosporine prevents protein phosphorylation by multiple kinases, which
include protein kinase C, protein kinase A, Ca2/calmodulin dependent kinase II and
tyrosine kinases. It has been proposed to act at high (micromolar) concentrations by
blocking the intracellular signals initiated by extracellular survival factors, which are
often transmitted by protein phosphorylation of one or several cytoplasmic factors
(Herbert et al, 1990; Yanagihara et al, 1991; Bertrand et al, 1994). Ongoing
activation of certain protein kinases, possibly protein kinase C or tyrosine kinases,
thus seems to be involved in maintaining the survival of staurosporine sensitive cells
and their inhibition may mimic a state of factor depletion. Apoptosis induced by
staurosporine can be blocked by Bcl-2 or Bcl-xl (Orth et al, 1996; Chinnaiyan et al,
1996A).
1.5.3. Reagents acting on the cell surface: Receptor ligands
1.5.3.1. Fas/CD95 apoptotic pathway
Fas-induced apoptosis is currently one of the best-characterised apoptotic
pathways (reviewed by Nagata and Golstein, 1995; Nagata, 1996; Yuan , 1997;
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Nagata, 1997). Human Fas/CD95 is a type I membrane protein which consists of 325
amino acids with an NH2-terminal signal sequence, a central membrane spanning
domain and a COOH-terminal cytoplasmic region which carries a conserved domain
of about 80 amino acids, designated the death domain. It belongs to the tumour
necrosis factor (TNF) and nerve growth factor (NGF) receptor family and is the
receptor for Fas ligand (FasL) (Smith el a1, 1994). Fas is expressed in many tissues
including the thymus, liver, heart and kidney, while FasL appears to be predominantly
expressed in activated T-lymphocytes, natural killer cells and immunoprivileged
tissues such as the testis and the eye (Trauth et al, 1989; Vignaux et al, 1995; Anel et
al, 1994).
Fas-mediated apoptosis occurs in the presence of inhibitors of protein and RNA
synthesis and also in enucleated cells, indicating that no specific gene induction is
required (Yonehara et al, 1989; Itoh et al, 1991; Schulze-Osthoflf et al, 1994). Fas-
mediated apoptosis is involved in the down-regulation of immune reactions and T-cell
mediated cytotoxicity and has been implied in cytotoxic T-cell mediated diseases,
including liver destruction in fulminat hepatitis, lymphopenia in acquired
immunodeficiency (AIDS) and the destruction of pancreas in insulitis. Genetic
mutations in murine Fas (lpr mutation) or FasL (gld mutation) lead to defective T cell
receptor-induced cell death of mature T cells, resulting in autoimmune disease that
resembles human systemic lupus erythematosus. A human dominant-negative Fas
mutation leads to autoimmune lymphoproliferative syndrome (Fisher et al, 1995).
Signalling by Fas requires the cross-linking of Fas achieved physiologically by binding
the endogenous FasL, but mimicked by some anti-Fas antibodies (Dhein et al, 1992;
Suda et al, 1994). Receptor engagement with trimerised FasL or aggregated antibody
(IgM class monoclonal Fas antibody or IgG3 class APOl antibody) induces
trimerisation of Fas and the trimerised cytoplasmic region transduces the signal (Itoh
et al, 1993, Tanaka et al, 1997). Within seconds after receptor oligomerisation a
death domain containing adapter, called FADD/MORT1 (Fas-associating protein with
death domain/mediator of receptor induced toxicity 1) binds to trimerised Fas via
interactions between the death domains (Boldin et al, 1995; Chinnaiyan et al, 1995;
Chinnaiyan et al, 1996B; Kischkel et al, 1995). The death effector domain of
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FADD/M0RT1 then.binds to corresponding sequence motifs within the prodomain of
caspase 8/FLICE/MACH and caspase 10/Mch4/FLICE2 which are members of the
effector proteases, which form the main theme of the experiments in this thesis
(Boldin et al, 1996; Muzio et al, 1996; Fernandes-Alnemri et al, 1996; Vinzenz et al,
1997).
How the recruitment of caspase 8 and 10 to the Fas-receptor complex results in the
sequential activation of a caspase cascade is not clear (see also chapter 1.6.5 ). One
a<"
possibility is that interaction of caspase 8 or 10 with FADD/MORT1 may result in
oligomerisation and autocatalytic activation of the caspases which could initiate
proteolytic activation of downstream caspases (Muzio et al, 1997). Other FADD
interacting molecules have been identified, however, suggesting that FADD coupling
to downstream caspases may be indirect or sequential. Amongst these interacting
molecules is a novel member variously called FLIP (FLICE-inhibitory
protein)/FLAME-l (FADD-like antiapoptotic molecule)/CASH (caspase
homologue)/Casper (caspase 8 related protein)/I-FLICE (inhibitor of FLICE)
(Srinivasula et al, 1997; Goltsvec et al, 1997; Shu et al, 1997; Irmler et al, 1997B).
This protein exists in at least six different splice variants with apparently opposing
functions. Different splice variants are recruited to the Fas signalling pathway through
interaction with FADD and can inhibit or induce both Fas- and TNF-induced
apoptosis. Even though not a caspase itself it contains two NH2-terminal death
domains and also contains a caspase domain homology region with high sequence
similarity to caspase 3, caspase 8 and caspase 10. It can therefore interact with all
three caspases and can most likely recruit all of those caspases through FADD to the
Fas/TNF signalling complex.
A variety of models can be built around how FLIP might negatively or positively
regulate apoptosis. One possibility is that it might interfere with the assembly of a
functional death receptor signalling complex. An intriguing possibility is that splice
variants with apoptotic functions might constitute part of an active caspase molecule,
another possibility is that FLIP, which can simultaneously bind caspase 8 and caspase
3, may simply recruit procaspase 3 to the vicinity of caspase 8, where it can be
activated (see chapter 1.6.5.). The importance of the mammalian FLIP molecule in the
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control of apoptosis is further supported by the identification of viral protein
homologues (Hu et al, 1997; Thome et al, 1997; Bertin et al, 1997).
Other Fas pathway interacting molecules, including the ubiquitin-conjugating enzyme
UBC9 (Becker et al, 1997), have been identified. Their function in the Fas-mediated
apoptosis is, however, less clear.
1.5.3.2. Tumour necrosis factor (TNF) induced apoptosis
Tumour necrosis factor (TNF), like FasL, is a cytokine in the TNF family. It
binds to two receptors (TNFR1 and TNFR2) (reviewed by Tewari et al, 1996;
Nagata, 1997). While the main activity of FasL is to trigger cell death, TNF affects
the growth, differentiation and function of multiple cell types and is a mediator for
inflammation, cellular immune responses as well as apoptosis. Signalling by TNFRs
requires cross-linking of TNFRs and can be achieved experimentally with monoclonal
antibodies to TNFRs, with membrane bound TNF or with purified, soluble TNF. The
functional form of soluble TNF exits as a trimer (Tanaka et al, 1997) which upon
binding to TNFR1 induces trimerisation of this receptor. The trimerised cytoplasmic
region of the receptor includes a death domain essential for transduction of the signal,
leading to apoptosis (reviewed by Eder, 1997). Apoptosis induced by TNFR1
trimerization occurs via the death domain-containing protein TRADD (TNFR1-
associated death domain protein) which binds to TNFR1 (Hsu et al, 1995). The death
domain of TRADD then binds to FADD/MORT1 and shares the signal downstream
machinery with Fas signalling recruiting caspase 3, caspase 8 and caspase 10.
Alternatively TRADD binds via interactions of their death domains to RIP (receptor
interacting protein), which is a serine threonine kinase (Stanger et al, 1995). RIP is
also recruited by DR-3/Wsl-l receptor, a recently identified new member of the
TNFR family, and overexpression of RIP results in the induction of apoptosis
(Chinnaiyan et al, 1996C). RIP itself, however, does not contain a death effector
domain and may thus trigger another apoptotic pathway through the recruitment of
another molecule. A potential candidate is the recently identified death domain
containing protein RAIDD/CRADD (RIP-associated ICH-1/CED3 homologous
protein with death domain/caspase and RIP adapter with death domain) (Duan et al,
1997; Ahmad et al, 1997A). RAIDD/CRADD binds RIP through its COOH terminal
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death domain and recruits RIP to caspase 2 (ICH-1) with a caspase 2 NH2-terminal
homology domain. Although a direct connection between RAIDD/CRADD and
DR3AVsl-l and TNFR1 has not been demonstrated RAIDD/CRADD presumably
functions like FADD and might transduce the apoptotic signals from Fas/TNF to the
caspase effector cascade through interaction with procaspase 2 (ICH-1). Apoptosis
induced by both TNF and Fas is inhibitable by the cowpox virus encoded serpin CrmA
and the recently identified novel family of viral death effector domain-containing
molecules (Hu et al, 1997; Bertin et al, 1997; Thome et al, 1997).
In summary, the known elements in the Fas and TNF signalling pathway point to the
possibility of a variety of outcomes depending on the circumstances of cytokine
signalling. Although Fas and TNFR share the effector pathway via FADD, TNFR1
stimulation also activates potential death-inhibitory transcription-dependent
mechanisms through NFKB and specific activation of caspases 3, 8 and 10 may be


























Figure 1.2. Possible interactions of the components of Fas and TNF apoptotic
signalling pathway. A) Fas-induced apoptosis, b), TNF-induced apoptosis. Caspase
8 and 10 acting as a linkage between the signalling complexes and the caspase family.
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1.6. THE EFFECTOR PA THWA Y OFAPOPTOSIS: THE CASPASE FAMIL Y
1.6.1 Discovery of the family of ICE-like proteases/'caspases
Current appreciation of the significance of caspases as effectors of apoptosis
originated from the identification and cloning of the C. elegans ced-3 gene (Yuan et
al, 1990; Yuan et al, 1993). Ced-3 encodes a cytoplasmic cysteine protease of 503
amino acids whose proteolytic activity is absolutely required for the execution of
apoptosis in nematode development (Xue et al, 1996; Hugunin et al, 1996). CED3
shares 29% amino acid identity with the human interleukin-l(3 converting enzyme
ICE/caspase 1 (Yuan et al, 1993). Structurally unrelated to any other known class of
proteases, CED3 and caspase 1/ICE are the founder members of a family of
proteases, named caspases in reference to their catalytic mechanism as cysteine
proteases with a cleavage specificity at aspartic acid residues (Alnemri et al, 1996).
To date known caspase family members include caspase 1/ICE (Thornberry et al,
1992; Miura et al, 1993), caspase 2/ICH-1/NEDD-2 (Wang et al, 1994; Kumar et al,
1994), caspase 3/CPP32/Yama/apopain (Fernandes-Alnemri et al, 1994; Tewari et al,
1995; Nicholson et al, 1995), caspase 4/TX/ICH-2/ICErelII/Mihl (Faucheu et al,
1995; Kamens et al, 1995; Munday et al, 1995, Alnemri, 1997), caspase
5/ICErelIII/TY (Munday et al, 1995; Faucheu et at, 1996), caspase 6/Mch2
(Fernandes-Alnemri et al, 1995A), caspase 7/Mch3/ICE-LA.P3/CMH-l (Fernandes-
Alnemri et al, 1995B; Duan et al, 1996; Lippke et al, 1996), caspase
8/FLICE/MACH/Mch5 (Muzio et al, 1996; Boldin et al, 1996; Fernandes-Alnemri et
al, 1996A), caspase 9/ICE-LAP6/Mch6 (Duan et al, 1996; Alnemri, 1997) and
caspase 10/Mch4/FLlCE2 (Fernandes-Alnemri et al, 1996B; Vincenz et al, 1997).
Phylogenetic analysis of the known caspase family has led to their subclassification















Figure 13. Phylogenetic tree of the caspase family
ICE/caspase 1 was the first mammalian member of the caspase family to be identified
and much of the initial data on caspases was obtained from studies of caspase 1. It
was initially discovered because of its activity as an activator of the cytokine
interleukin-1P (IL-ip) in inflammation and was purified from the cytosol of the
human monocytic cell line THP.l (Thornberry et al, 1992). Caspase 1/ICE cleaves the
inactive 33kDa IL-ip precursor at Aspl 16-Alal 17 to generate the 17kDa fully active
cytokine IL-ip.
1.6.1.1. Discovery of caspase 2: First hint ofmultiple CED3 homologues
In search for genes that are expressed during the development of the
mammalian central nervous system a cDNA library, prepared from mouse neuronal
precursor cells (NPCs) and isolated from the neuronal tube at embryonic day ten, was
probed with mRNA isolated from postnatal and adult brain. Ten independent clones
were isolated and named Nedd for NPC-expressed, developmental^ downregulated
(Kumar et al, 1992). Subsequent characterisation of those mouse genes showed that
one gene, Nedd2 encodes a protein similar to the mammalian enzyme caspase 1/ICE
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and the C. elegans CED3 protein (Kumar et al, 1994). The human Nedd2 gene, vvl'iich
was renamed ICH-1 (ICE and ced3 homologue)/caspase 2, was isolated from a
human foetal brain cDNA library (Wang et al, 1994). ICH-1 mRNA is alternatively
spliced into two different forms. One mRNA species encodes a protein product of 435
amino acids, named ICH-1L which when overexpressed in Rat-1 cells induces
apoptosis. The other mRNA encodes a 312 amino acid truncated version of ICH-1L,
named ICH-1 s, which terminates 32 amino acids after the pentapeptide QACRG of
ICH-1 L. Overexpression of ICH-1 S suppresses Rat-1 cell death induced by serum
deprivation.
ICH-1L
Figure 1.4. Alternative splicing of the caspase 2/ICH-l mRNA. The exons are shown
in bars. The introns are shown in a line. Nucleotides at the intron/exon borders are marked. The
positions of the ICH-1S and ICH-1L stop codons are indicated.
Nothern blot analysis of human foetal heart, brain, lung, liver and kidney, with a probe
that hybridises to both ICH-1L and ICH-1s, show low levels of expression. An ICH-1s
specific probe shows enhanced expression in the embryonic brain than in the lung,
liver and kidney. Northern blot analysis of adult tissues shows detectable levels in all
tissues examined with higher levels of expression in placenta, lung, kidney and
pancreas than in heart brain and skeletal muscle. Chromosome mapping places both
ICH-11 and ICH-1s sequences on chromosome 7q35 (Tiso et al, 1996).
1.6.2. Structure and composition of the caspases: Caspase 1/ICE as the caspase
prototype
Caspase 1/ICE has an open reading frame of 1212 bp encoding a proenzyme
of 404 amino acids with a predicted molecular weight of 45kDa. The mature and
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active form of caspase 1 is derived from this 45kDa precursor by proteolytic cleavage
at Asp-X bonds where X is Serl04, Asnl20, Ser298 andAla317. This results in the
proteolytic removal of the NH2-terminal 119 amino acids and an internal fragment
spanning residues 289-316 and the formation of two subunits of lOkDa (p 10) and
20kDa (p20) molecular weight. Two plO and two p20 caspase 1 subunits
heterodimerise to form the tetrameric active enzyme. (Thornberry et al, 1992; Wilson
et al, 1994, Walker et al, 1994). This oligomerisation occurs by a fairly ill-defined
process most likely involving plO and p20 subunits from different p45 precursor
proteins (Gu et al, 1995A). Caspase 1 and caspase 3 are so far the only family
members with known crystal structure. Global fold, topology and quaternary structure
of both enzymes is unlike that of proteases of other classes (Wilson et al, 1994,
Walker et al, 1994; Rotonda et al, 1996).
Sequence comparisons between the caspase family members show approximately 30%
overall amino acid identity, with a high degree of homology in the domains that make
up the mature proteases, particularly around the active site. For some of the caspases
the exact subunit sizes of the active enzyme are still undetermined. Molecular masses,
however, have been predicted and together with sequence comparison suggest that all
caspase members are synthesised as inactive proenzymes, processed exclusively at
Asp residues and, in most cases, before small amino acids such as Gly, Ala or Ser to
the active enzyme. Differences between individual caspases exist in the overall size of
the proenzyme, the size of the prodomain and the size of the active subunits. The
proenzyme of caspase 2 (ICH-1) (the main subject of this thesis) has a predicted
molecular weight of 48kDa, with subunits of 12kDa and 18kDa, a 1.4kDa linker
peptide and a large prodomain of 16.6kDa (Xue et al, 1996). In comparison, caspase
3 is synthesised as a 32kDa proenzyme cleaved into 12kDa and 17kDa subunits with a
small 3kDa prodomain and no linker region (Nicholson et al, 1995). In addition to the
differences in overall size between individual caspase family members, the prodomains
show, in comparison to the amino acid sequences that make up the active proteases, a
broader divergence in the amino acid sequence, suggesting that these domains contain
additional information and may be responsible for the functional differences between
the family members. One obvious example is the presence of the death domains within
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the prodomain of caspase 2, 8 and 10 permitting their interaction with linker proteins
in the Fas and TNFR pathways (see chapters 1.5.3. and 1.6.5.).
QACRG
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Figure 1.5. Subunit composition of three caspase family members. Diagram of the
protease subunits and their relationship to the protease precursors. The size and the position of each
protease subunit is depicted within the protease precursor. The position of each active site
pentapeptide (QACRG) is indicated by a shaded box. Angled lines underneath indicate proteolytic
cleavage sites and are numbered according to their position in the protease precursor.
The catalytic mechanism and the substrate specificity of caspase 1 have been revealed
by the use of synthetic oligopeptide inhibitors. Synthetic substrates in the form of
small peptides (usually four amino acids) are engineered to mimic the proteolytic
substrate cleavage site of the enzyme and contain the amino acid residues essential for
catalytic recognition. They are synthesised as peptide aldehydes or
chloromethylketones and act as competitive inhibitors that undergo nucleophilic
addition of the catalytic cysteine to form thiohemiacetals and thiohemiketals
(Thornberry et al, 1995). The synthetic tetrapeptide acetyl-Tyr-Val-Ala-Asp-CHO
(Ac-YVAD-CHO) inhibits the catalytic mechanism of caspase 1 by binding covalently
to the sulphur atom of Cys285 (Thornberry et al, 1992). Recent advances in the
design of peptide inhibitors for individual caspase family members has led to the
identification of more specific peptide recognition motifs for caspase 1 and other
family members (Thornberry el al, 1997) (see chapter 1.6.3.2.). Ac-WEHD-CHO is
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thus the preferred-- recognition motif for caspase 1 and is also the most p6fent
reversible, small molecule inhibitor for any caspase.
The inhibition profile of the caspase 1 activity by the peptide inhibitor together with
results from site-directed mutagenesis led to the classification of caspase 1 as a
cysteine protease with substrate specificity for an aspartic acid residue at the PI
position (the first amino acid NH2- terminal to the cleavage site). The catalytic
cysteine is located in the p20 subunit at position 285. The active site, however, is
formed by amino acids from both subunits. Enzyme catalysis requires p20 subunit
amino acids residues His237 and Gly238. Critical elements in the formation of the
binding pocket for the carboxylate side chain of PI Asp are p20 amino acids Argl79,
Gln283 together with plO residues Arg341 and possibly Ser347 (Wilson et al, 1994;
Walker et al, 1994). These important amino acid residues for recognition of PI Asp
and for catalysis of caspase 1 are conserved in every member of the caspase family,
together with a pentapeptide QACRG, containing the active cysteine (with the
exception of caspase 8, caspase 9 and caspase 10 which have an R to Q substitution in
the QACRG pentapeptide active site motif (Duan et al, 1996; Fernandes-Alnemri et
al, 1996A; Muzio et al, 1996; Vincenz et al, 1997)). This suggests that all caspases
members share the same catalytic mechanism and explains similar peptide preferences
for individual caspases. There is more diversity, however, in the amino acids that
putatively line the groove where the P2-P4 residues of the substrate lie, corresponding
in caspase 1 to Val338, Trp340, His342, Pro343, Arg383 and Gln385. These amino
acids are most likely responsible for the different macromolecular specificities and
different biological functions amongst the various family members.
1.6.3. Involvement of the caspases in apoptosis
Definite proof that a particular protein contributes to the effector pathway of
apoptosis requires that it is expressed in cells competent to activate the pathway, that
overexpression initiates death and that downregulation or specific inhibition block cell
death. At present only a few of the caspases fulfil all these requirements. Caspase
genes are present in both vertebrates and invertebrates, and expression of many
procaspase appears to be a feature of cells of most if not all lineages. Furthermore
apoptosis has been induced in a variety of mammalian and insect cells following
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overexpression of caspase 1 and most of the other members of the caspase family
(Miura et al, 1993; Ahmad et al, 1997B; Song et al, 1997; Fraser et al, 1997A). This
evidence alone is insufficient proof of a specific role of those caspases in cell death,
however, as introduction of other known proteases of entirely different specificities
has been claimed to induce death with many of the characteristic morphological
features of apoptosis including membrane blebbing, chromatin condensation and DNA
fragmentation (Williams et al, 1994). Evidence for the physiological role of caspases
in apoptosis derives from the efficacy of specific protease inhibitors (natural or
synthetic), the biology of genetically altered ('knock-out') mice, and protease activity
in apoptotic cell extracts. In brief, the inhibitors, which can be shown to interfere with
caspase protease function, when applied to cultured cells, produce retardation or in
some cases complete abrogation of apoptosis. The mice lacking caspases as a result of
germ-line gene knock-out sometimes lack apoptosis in certain lineages or in response
to particular stimuli. And the cell-free extracts engage caspase activity which
reproduces the effects of apoptosis on critical intracellular structures, such as the
nuclear envelope, nuclear chromatin, and cytosolic, nuclear and cytoskeletal proteins.
Some detail is given in the following paragraphs of these three strands of evidence for
the physiological role of caspases in apoptosis.
1.6.3.1. Natural inhibitors
Naturally occurring inhibitors of caspases have been identified in both the
mammalian and viral genome and functionally equivalent molecules are most likely to
be encoded in the genome of insects. Viral inhibitors of caspases include the cowpox
virus serpin CrmA, baculovirus proteins p35 and IAP and the recently discovered six
viral FLICE inhibitory proteins (vFLIPs) including human molluscum contagiosum
poxvirus (MCV) proteins MCI59 and MCI60, the equine herpesvirus-2 (EHV-2)
protein E8, Kaposi's-sarcoma-associated human herpesvirus-8 protein K13, bovine-
herpesvirus-4-encoded protein El l and herpesvirus saimiri (HVS) protein.
The cowpox virus serpin gene, which encodes a 38kDa protein, known as the
cytokine response modifier CrmA, has been shown to suppress caspase 1 induced
apoptosis in vitro and inhibit the cleavage of IL-1J3 (Miura et al, 1993; Ray el al,
1992; Komiyama et al, 1994; Howard et al, 1995). CrmA cDNA transfected into cells
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can inhibit apoptosis by nerve growth factor depletion (Gagliardini et al, 1994),
isolation from contact with extracellular matrix (Bourdeau et al, 1995), Fas ligation
(Tewari et al, 1995A; Tewari et al, 1995B; Enari et al, 1995A; Enari et al, 1995B;
Los et al, 1995) and activation of the tumour necrosis factor receptor (Miura et al,
1995; Tewari et al, 1995C; Tewari et al, 1995D). In cell free extracts (see 1.6.3.4.)
CrmA has been shown to inhibit the nuclear structural changes of apoptosis and the
cleavage of the caspase substrate lamin A (Takahashi et al, 1996A). Hence the death
pathway in all these systems converges onto a CrmA-inhibitable step. Successful
inhibition of certain caspases appears, however, to require high levels of expression of
the CrmA gene, not necessarily achieved during viral infection. Comparison of the
kinetics ofCrmA interaction with caspase 1, 3, 6, 7 and 8 have shown that these five
caspases are inhibited with rates and affinities ranging over five orders of magnitude.
CrmA shows the highest affinity for caspase 1 and the second highest for caspase 8,
whereas caspase 7 is not inhibited by CrmA (Zhou et al, 1997).
Two baculovirus proteins, IAP and p35, can prevent insect cells from dying in
response to infection. P35 blocks apoptosis in baculovirus infected insect cells,
resulting in increased virus production (Crook et al, 1993; Clem et al, 1994) and can
block cell death in several species including nematode, insect and mammalian cells
(White et al, 1996B; Sugimoto et al, 1994; Hay et al, 1994). In mammalian cells
overexpression of p35 inhibits proteolytic activity of caspase 1, blocks neuronal cell
death induced by nerve growth factor depletion (Martinou et al, 1995; Rabizadeh et
al, 1993) and blocks both TNF and FasL induced apoptosis (Beidler et al, 1995).
Purified p35 has been shown to be a potent inhibitor of various other caspases
including caspase 2, 3 and 4, and C. elegans CED3 (Bump et al, 1995). This
antiapoptotic activity involves both cleavage by and inhibition of caspase family
members (Bertin et al, 1996). Both p35 and CrmA possess internal cleavage sites for
caspase family members. Cleavage at these sites results in a conformational change
and a stable complex formation between p35 and the protease. Exchanging the
cleavage site of CrmA to that of p35 confers the ability of p35 to arrest apoptosis in
C. elegans embryos upon CrmA (Xue et al, 1995). Further clues to the caspase
target(s) in mammals come from the recently identified Spodoptera frugiperda
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caspase 1. This insect caspase has a similar sequence to mammalian caspase 3 and 7,
has been shown to be capable of cleaving p35 and is potently inhibited by p35 (Ahmad
el a/, 1997B). Another baculovirus protein IAP (inhibitor-of-apoptosis) inhibits
apoptosis induced by caspase 1 and caspase 2 overexpression (Hawkins et a/, 1996)
and directly inhibits at least two caspase family members, caspase 3 and caspase 7
(Deveraux et al, 1997).
A new group a viral inhibitors include the vFLIPs (Hu et al, 1997; Thome et al, 1997;
Bertin et al, 1997). These viral inhibitors are members of the death domain family and
may represent a new class of viral proteins, able to inhibit Fas and TNFR induced
apoptosis by blocking FADD and TRADD killing but unable to inhibit caspase 8
induced apoptosis. This suggests an inhibitory function upstream of the caspases and
the presence of the death domains within the members of this viral protein family
suggests that these inhibitors might antagonise the FADD-caspase interaction and
thereby attenuate Fas- and TNFR-induced apoptosis.
The first mammalian inhibitor designated FLIP is currently investigated by a number
of different laboratories, hence the variety of names for the same protein (Hu et al,
1997; Srinivasa et al, 1997; Shu et al, 1997; Irmler et al, 1997B; Goltsev et al, 1997)
(see also chapter 1.5.3.1. and 1.5.3.2.). Its discovery firmly establishes the roles
caspases 8 and 10 in the Fas/TNF pathway and might represent the first of a number
of specific naturally occurring mammalian caspase inhibitors.
1.6.3.2. Synthetic inhibitors
Synthetic inhibitors have not only proved to be valuable tools in the
determination of the catalytic mechanism and the substrate specificities of the caspases
but have also given evidence for the direct involvement of caspases in the execution of
apoptosis (reviewed by Thornberry et al, 1995; Livingston, 1997). Peptide aldehydes,
nitriles and ketones are potent reversible inhibitors of the caspase family, while
compounds that form thiomethylketone adducts with the active site cysteine are
potent irreversible inhibitors (Thornberry et al, 1992; Thornberry et al, 1994;
Thornberry et al, 1995). A tetrapeptide corresponding to the substrate residues P4-P1
is sufficient for inhibition for both caspase 1 and caspase 3 and as a consequence has
formed the basis for inhibitor design. Peptide inhibitors have since been devised as
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reagents to block and thereby implicate the presence of certain caspases iif 'the
apoptotic pathway. The tetrapeptide aldehyde Ac-YVAD-CHO was designed to
mimic the YVHD caspase 1 recognition sequence within proIL-ip and has proved to
be a potent inhibitor of caspase 1. Coupled to a DEAE column, YVAD has been used
to purify active ICE to homogeneity from cytosolic extracts, demonstrating the
avidity and specificity of the peptide-enzyme binding (Thornberry et al, 1992). The
tetrapeptide aldehyde Ac-DEVD-CHO was designed to mimic the caspase recognition
site within poly(ADP-ribose)polymerase (PARP), a well-characterised caspase
substrate, and a biotinylated form of this tetrapeptide has been used as an affinity
ligand to purify caspase 3 from cytosolic extracts (Nicholson et al, 1995). Subsequent
kinetic analysis of a number of other caspase family members, some ofwhich are very
similar in sequence to caspase 1 or caspase 3, have shown, however, that neither
inhibitor is exclusively effective against those two caspases; both also inhibit other
caspase family members, albeit with different potency (Margolin et al, 1997).
Incubation of a variety of mammalian cells, induced to undergo apoptosis with
different stimuli, with both caspase inhibitors not only prevents the activation of
multiple caspases, but also prevents the cleavage of substrates and blocks all
morphological changes characteristic of apoptosis (McCarthy et al, 1997) (recent
publications include Kluck et al, 1997A; MacFarlane et al, 1997; Mariani et al, 1997;
Wolf et al, 1997; Hara et al, 1997; Polverino et al, 1997; Armstrong et al, 1996; Slee
et al, 1996). Studies with both inhibitors have thus firmly confirmed the status of
caspases as effectors of the apoptotic pathway but have left the question of the role of
specific caspases mostly unresolved.
Development of the biotinylated peptide YV(bio)KD-aomk, which is based on the
caspase 1 cleavage site in pro-IL-ip and only binds to the larger subunit of active
caspase 1 and other active caspases, including caspase 3 and caspase 6, allows direct
affinity labelling of active caspases (Thornberry et al, 1994). YV(bio)KD-aomk
applied to cell free extracts allowed visualisation of at least five distinctive
polypeptides which correspond to active caspases (Takahashi et al, 1996A; Takahashi
et al, 1996B). Another affinity labelling reagent Z-EK(bio)D-aomk designed to mimic
the EVD motif (Thornberry et al, 1994) covalently modifies the larger subunit of
27
caspase 1, 2, 3, 4, 5 and 6. On unidimensional SDS-PAGE the affinity label detects
four discrete bands in HL60 cells undergoing apoptosis in response to etoposide
treatment, with each band appearing at a characteristic time after the addition of the
apoptotic stimulus. Two-dimensional SDS-PAGE revealed that as many as eight
different subunits are involved in apoptosis of these cells. Multiple species of caspase
3 and caspase 6 have been identified as the major active caspases in apoptotic cells
(Martins et a!, 1997B; Faleiro et al, 1997) These inhibitor studies thus firmly suggest
the involvement of multiple caspases in apoptosis. More specific new peptide
inhibitors identified in recent specificity studies of caspases, which utilise a positional
scanning synthetic combinatorial library, may help to identify the majority of unknown
distinctive caspase subunits.
P4 P3 P2 Pf
Caspase 1 W E H D
WEHD Caspase 4 WorL E H D
Caspase 5 WorL E H D
C. elegans CED3 D E T D
DEXD Caspase 3 D E V D
Caspase 7 D E V D
Caspase 2 D E H D
Caspase 6 V E H D
(VL)EXD Caspase 8 L E T D
Caspase 9 L E H D
Figure 1.6. Peptide specificities of individual caspases (adapted from Thornberiy et al,
1997).
No inhibitor was found which was specific to a single caspase. However, based on
their inhibition profile the caspases have been classified into three caspase subclasses
which might give better clues to the identities of the enzymes involved in apoptosis
and their relationship to each other (Thornberry et al, 1997).
1.6.3.3. Knockout mice
Insights into both the importance and the potential redundancy of caspases has
been gained from observations in knockout mice. Caspase 1/ICE deficient mice
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develop normally, appear healthy and are fertile. The mice are, however, unable to
produce mature IL-1(3 and are highly resistant to the lethal effects of endotoxin by
surviving a high dose of lipopolysaccharides (LPS) that kills all wild type mice.
Additionally, their macrophages are defective in processing and release of IL-1(3 but
sensitive to ATP-induced apoptosis. Thymocytes from caspase 1 knockout mice have
been shown to be sensitive to apoptosis induction by dexamethasone and radiation but
are resistant to Fas-induced apoptosis measured by cell viability in vitro. The
physiological significance of this observation is, however, unclear as analysis of the
caspase 1 deficient mice revealed no phenotype resembling the MRL/lpr mice that are
defective in Fas-mediated apoptosis (Kuida et al, 1995; Li et al, 1995; Li et al, 1997).
Studies of the caspase 2/Nedd2 knockout mice show that these mice develop normally
and are healthy. Their B cells, however, show a partial resistance to apoptosis induced
by granzyme B and the mice at 4 days after birth possess twice the number of oocytes
of wild type litter mates (Bergeron et al, unpublished data). Various models can be
build around these results, e.g. caspases other than caspase 1 and 2 are essential for
physiological cell death, several proteases may function redundantly in apoptosis, or
caspase 2 itself plays little role in apoptosis in the majority of tissues, in which case
one would predict that mice deficient in one caspase would still be capable of normal
apoptosis. The fact that many caspases are coexpressed in many tissues and cell types
does suggest some redundancy of the cell death pathway. Evidence against complete
redundancy between several caspases comes from observations of caspase 3/CPP32
knockout mice. These are smaller than their littermates, die prematurely at about 1-3
weeks of age and frequently die in utero or perinatally. They show profound
abnormalities of the central nervous system development, with largely increased
number of neurones, a variety of hyperplasias and disorganised cell development. The
existence of these excess cells is most likely a result of decrease in the normal rate of
apoptosis of neuroepithelial cells (Kuida et al, 1996). This demonstrates that mutation
of a mammalian ced3 homologue leads to decreased cell death and a supernumerary
cell population during development, suggesting that the basic machinery of apoptosis
is evolutionarily conserved. The brain specificity of the caspase 3/CPP32 phenotype
also suggests that other caspases may have an important role during apoptosis in
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other tissues or cell types. Future knock-outs of various other caspase family
members will give a better understanding of the roles of individual caspases and may
reveal that the activity some individual caspases is more important in apoptosis than
others.
1.6.3.4. Cell free systems
Cell free systems provide another powerful approach for study of the effector
mechanisms of apoptosis. They allow dissection of the activation of the effector from
the target structure involved in the effector pathway itself. Proteases or their inhibitors
can be directly added to the system circumventing the permeability barrier that the
plasma membrane presents in intact cells. Cell free systems therefore permit the
analysis of the role of individual components of the pathway and provide information
about the identity and cellular localisation of the substrates of the effector. In the first
description of such a system extracts from chicken hepatoma cells induced in HeLa
nuclei all the nuclear morphological changes expected in apoptosis, including
chromatin condensation, dissociation of the nuclear membrane and DNA
fragmentation (Lazebnik et al, 1993). The active principle in these cell free extracts
turned out to be a cytoplasmic cysteine protease, named prICE (protease resembling
ICE) which provided first evidence for the existence of other caspases apart from
caspase 1/ICE. The same extracts also led to the identification of various nuclear
caspase substrates (Lazebnik et al, 1994; Lazebnik et al, 1995A; Lazebnik et al,
1995B; Takahashi et al, 1996B) (see chapter 1.6.4.). Several other cell free systems
have since been described, including extracts from human Jurkat and ITL60 cells
(Zhivotovsky et al, 1997; Muzio et al, 1997; Schlegel et al, 1996; Martins et al,
1997B) and mouse W4 lymphoma cells (Enari et al, 1996A) These have proved to be
valuable tools for the study of proteolytic activities involved in Fas-mediated
apoptosis. Cell free apoptosis inducing extracts from Xenopus eggs have revealed the
connection between mitochondria, the release of cytochrome c and the activation of
caspases (Newmeyer at al, 1994; Kluck et al, 1997A; Kluck et al, 1997B). Cell free
apoptotic extracts of HL60 cells have been used in conjunction with Z-EK(bioD)-
aomk, a peptide affinity labelling reagent for caspases which covalently binds to a
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variety of caspases (caspase 1, 2, 3, 4 and 6), to delineate the spectrum of caspases
activated in HL60 (Martins et al, 1997B).
1.6.4. Cellular substrates for caspases
Study of the proteolytically cleaved proteins that appear during apoptosis has
helped define the biology of the effector pathway and has provided intriguing if still
not definite information of the plurality of the apoptotic caspases themselves. If the
caspases are indeed in the final common path for apoptotic effector events then their
substrates should include cell components that are responsible for the structural
changes observed in apoptotic cell death. Candidate substrates known to undergo
proteolytic cleavage in apoptosis include PARP (Kauffnann et al, 1993; Lazebnik et
al, 1994, Schlegel et al, 1996), nuclear lamins (Lazebnik et al, 1995; Zhitovsky et al,
1997), fodrin (Martin et al, 1995), U1 small ribonuclear protein particle (Casciola-
Rosen et al, 1994B), growth arrest specific protein 2 (Gas 2) (Brancolini et al, 1995),
actin (Mashima et al, 1995A; Kayalar et al, 1996), sterol regulatory element-binding
protein (SREBP-1 and SREBP-2) (Wang et al, 1995; Wang et al, 1996; Pai et al,
1996), GDP dissociation inhibitor (D4-GDI) (Na et al, 1996), Retinoblastoma protein
(RB protein) (An et al, 1996); the catalytic subunit of the DNA dependant kinase
(Casciola-Rosen et al, 1995; Song et al, 1996; Han et al, 1996), protein kinase C5
(Emoto et al, 1995), PITSLRE kinases (Beyaert et al, 1997), histone HI,
topoisomerase I and II (Kaufmann et al, 1989; Voelkel-Johnson et al, 1995),
huntingtin (Goldberg et al, 1996), the cell membrane associated adenoma polyposis
coli protein (APC) (Browne et al, 1994, Browne et al, 1998), DNA replication
complex C (DSEB/RF-C140) (Ubeda et al, 1997), keratin 18 (Caulin et al, 1997),
Alzheimer-associated presenilins 1 and 2 (Kim et al, 1997), DNA fragmentation
factor (DFF) (Liu et al, 1997) and the related chaperone ICAD (caspase-activated
deoxyribonuclease inhibitor) that masks and inactivates a nuclear-seeking nuclease
responsible for chromatin cleavage (Sakahira et al, 1998). In addition, at least eight
proteins that are cleaved early in apoptosis remain unidentified, including proteins of
380, 320, 220, 190, 170, 130 and 80 kDa (Rosen et al, 1997). Although all of these
have been shown to be specifically cleaved early during apoptosis, with inhibition
characteristics typical for caspase family members, not all of these substrates have
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been shown to be directly cleaved by caspases in vitro. Caspase substrates include
PARP (Tewari et al, 1995C; Nicholson et al, 1995; Gu et al, 1995B), nuclear lamins
(Lazebnik et al, 1995; Takahashi et al, 1996B; Orth et al, 1996A), the catalytic
subunit of the DNA-dependant protein kinase (DNA-PKcs) (Casciola-Rosen et al,
1996), Ul-ribonucleoprotein (Casciola-Rosen et al, 1996), PITSLRE kinases
(Beyaert et al, 1997), actin (Mashima et al, 1997), huntingtin (Goldberg et al, 1996),
presenilins (Kim et al, 1997), DSEB/RF-C140 (Ubeda et al, 1997) and APC (Webb et
al, in publication).
Caspase Cleaved substrate
Caspase 1 pro-IL-ip, PITSLRE kinases, PARP (weakly), Ul-
70snRNP, pro-caspase 1, procaspase 3, procaspase 4
Caspase 2 PARP (weakly)
Caspase 3 PARP, actin, PITSLRE kinases, huntingtin, preselinins,
APC, Ul-70 snRPN, DNA/RF-C140, DNA-PKcS p460,
procaspase 6, procaspase 7, ICAD
Caspase 4 PARP (weakly), Ul-70 snRPN, procaspase 1 (weakly),
procaspase 3
Caspase 5 9
Caspase 6 PARP, lamin A, B1/B2, C, procaspase 3
Caspase 7 PARP, procaspase 1, procaspase 7, Ul-70snRNP
Caspase 8 PARP(weakly), procaspase 2, 3, 4, 6, 7 and 9
Caspase 9 PARP
Caspase 10 PARP, Ul-70snRNP, procaspase 3, procaspase 7,
procaspase 10
Figure 1.7. Human caspases and their substrates
Since the expression of different caspases in different cells and tissues may vary and
since recombinant protein levels in vitro might not necessarily represent physiological
caspase expression levels in vivo, the ascription of a particular substrate in apoptotic
cells to a particular caspase in vitro has to be seen with some caution and depends
heavily on comparison of catalytic cleavage efficiencies. Cleavage of PARP by
caspase family members is the best-characterised substrate cleavage event during
apoptosis. PARP is a nuclear chromatin associated protein with a molecular weight of
116kDa that catalyses covalent attachment of ADP-ribose units from its substrate
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NAD to numerous nuclear proteins including itself. PARP is inactivated during
apoptosis by cleavage into two fragments of about 25kDa and 85kDa, which results in
the isolation of the DNA binding domain from the catalytic domain. PARP cleavage
occurs at a DEVDG cleavage site (Lazebnik et al, 1994), which is strikingly similar to
DEVDN cleavage site of caspase 3 within DNA-PKcs (Casciola-Rosen et al, 1996)
and the DGPDG cleavage site of caspase 3 within the U1-ribonuclear protein
(Casciola-Rosen et al, 1996) and strongly supports that caspase 3 is responsible for
PARP cleavage. The exact physiological function of PARP and its cleavage in
apoptosis, however, is unclear as recent findings from PARP knock-out mice by three
different laboratories suggest that neither activation nor cleavage of PARP has a
causal role in apoptosis (Leist et al, 1997; Wang et al, 1997; Eliasson et al, 1997).
PARP may play an important role in the maintenance of genomic integrity and
activation of PARP is a key mediator of excitotoxic and ischemic neuronal and non-
neuronal cell death rendering PARP knock-out mice resistant to cerebral ischemia.
Cleavage of structural proteins such as fodrin, actin and keratin as well as the nuclear
lamins by caspases could all contribute to the altered cell shape and rearrangements
during apoptosis. Apoptosis is, however, also accompanied by the internucleosomal
degradation of chromosomal DNA (see chapter 1.2.). Recent findings by S. Nagata's
group in mice show that chromatin is cleaved by a nuclease that is specifically
activated by caspase 3 during apoptosis, and has thus been named CAD (caspase-
activated DNase) (Enari et al, 1998; Sakahira et al, 1998). CAD is present in the
cytoplasm in its inactive form bound to and stabilised by its cytoplasmic inhibitor
ICAD (inhibitor ofCAD). Upon caspase 3 activation Triggered by different apoptotic
stimuli, ICAD is cleaved by caspase 3, releases CAD, which enters the nucleus and
cleaves DNA. The caspases thus may not only directly cleave critical elements of the
cell in the ordered process of apotosis, but also trigger, through cleavage of specific
inhibitors, downstream events like DNA degradation. While some events appear to be
triggered in parallel (e.g. Ul-70 and PARP cleavage) others may be in series, possibly
because of a cascade-like central organisation of the caspases. The caspases, thus
have the capacity to contribute to multiple near-synchronous events in the nucleus and
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in the cytoplasm that underlie the long-known characteristic structural events of
apoptosis. How this activity of the caspases is regulated is poorly understood.
1.6.5. Regulation of the caspases
As described above, application of both cell-permeable synthetic peptide and
natural, macromolecular inhibitors, generation of knockout mice as well as the
identification of several potential downstream targets have established the role of
caspases as the effector molecules of apoptosis. How this protease activity is activated
and regulated and where the caspases act in the pathway in relation to other important
regulatory molecules is beginning to be resolved. Multiple levels of control probably
exist for the regulation of caspase activity within the cell. In theory control could be
achieved at the mRNA level through transcriptional regulation and alternative splicing
and at the protein level through posttranslational modification, proteolytic cleavage
and interaction with other components of the cell death pathway.
Northern blot analysis demonstrates that mRNA expression of all caspases can be
detected in most human tissues. Caspase 1 mRNA has been shown to be induced by
loss of adhesion to extracellular matrix and by transcription factor IRF-1 (Boudreau et
a/, 1995). De novo synthesis of procaspase is, however, not required for the existence
of caspase activity during apoptosis as treatment of cells with cycloheximide or
puromycin does not inhibit cellular caspase activity (Weil et al, 1996; Martins et al,
1997B).
Northern blotting further reveals the presence of splice variants of some of the family
members. Four isoforms of Caspase 1/ICE have been cloned P, x, 8 and s (Alnemri et
al, 1995). Isoforms of other caspases, including caspase 2/ICH-l (termed ICH-1L and
ICH-ls), caspase 3/CPP32 (CPP32a and p), caspase 4/Mih4 (a, P, x, 5), caspase
6/Mch2 (Mch2a and Mch2P), caspase 7/Mch3 (a and P) and caspase
10/Mch4/FLICE2 (a and P) have also been identified (see chapter 1.6.1. for original
references). These isoforms arise by the usage of alternative splice donor/acceptor
sites and result in a full-length isoform of the enzyme and truncated forms. Some of
these caspase isoforms have opposing functions acting as inducers or inhibitors,
including caspase 1, 2, 6 and 7, whereas isoforms of caspase 3, 4 and 10 are all
inducers of apoptosis. The presence of some caspase isoforms in apoptotic cells,
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including caspase 3 and 6, has been shown by the use of biotinylated peptide affinity
labels (see chapter 1.6.3.2.). The biological role of certain isoforms, particularly
caspase 2 (ICH-1S), is, however, controversial as transfection of FDC-pl cells with
NEDD2S, the mouse equivalent of ICH-1S, has no effect on cell survival and therefore
does not suggest a major role in the regulation of apoptosis, at least in that cell type
(Kumar, 1995). Potentially enzymatically inactive, alternatively spliced isoforms could
regulate the enzyme activity by acting as dominant negative inhibitors of the enzyme,
perhaps through interference with the heterodimerisation of the active full length form
of the enzyme. Proof of this principle is provided by a synthetic active site mutant of
caspase 10 which has a dominant negative effect and effectively inhibits apoptosis
(Vincenz et al, 1997). The mammalian caspase inhibitor FLIP also exists in several
isoforms (see also chapter 1.5.3.1.). Itself catalytically inactive, it could be processed
to inactive subunits which then, on the basis of high sequence identity, heterodimerise
with either of the caspases thus serving as a dominant inhibitor (Hu et al, 1997). The
exact nature of the inhibitory mechanism of alternatively spliced caspase and caspase
inhibitor isoforms still needs to be investigated. Alternatively to acting as dominant
negative inhibitors, isoforms with potentially different structure could interact with
activators of the caspases and prevent activation of the full length caspase
proenzymes.
So far no information is available on posttranslational modification, including
glycosylation or phosphorylation of the caspases. However, the presence of multiple
caspase subunits in apoptosis, detected with biotinylated affinity labels on two-
dimensional SDS-PAGE could indicate differences in posttranslational modifications.
Ubiquitination has been shown to regulate the turnover of several proteins that might
be involved in apoptosis, including cyclins, c-myc and p53 (Ciechanover, 1994).
Although the role of the ubiquitin/proteasome pathway in apoptosis is unclear, recent
evidence links proteasome inhibition to caspase 3 activation (Drexler, 1997).
Post-translational activation by proteolytic cleavage is a general feature of the caspase
family as described earlier (see chapter 1.6.2.). Most members of the caspase family
exhibit autocatalytic cleavage and activation when overexpressed in bacteria as
proenzymes. The extent to which this autoactivation occurs in authentic apoptosis is
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still uncertain, but the process could be critical for the initiation of activity of "apical
caspases", activated by their local high concentration on recruitment to the cytosolic
face of receptors such as Fas and their associated binding proteins.
A variety of studies have now confirmed that caspases of differing specificities are
required for the complete execution of apoptosis as different inhibitors with a variety
of specificities inhibit the apoptotic process and the cleavage of certain substrates at
various points during the apoptotic process (Fearnhead et al, 1995; Zhitovsky et al,
1995; Takahashi et al, 1996A; Takahashi et al, 1996B; Zhou et al, 1997; Longthorne
et al, 1997). Several lines of evidence suggest that this activation occurs as a protease
cascade. Thus various caspases have been shown to have protease activity against
other procaspases (listed in Figure 1.7.). Caspase 4/TX when overexpressed in COS
cells has protease activity against procaspase 1 (Faucheu et al, 1995). Caspase
7/Mch3a has a potential cleavage site (amino acids 20-23, DSVD) which is very
similar to the caspase 3 tetrapeptide substrate DEVD, making caspase 7 a potential
substrate for caspase 3 (Alnemri et al, 1995). Purified caspase 3 can cleave and
activate procaspase 2 (Nedd2), 6 and 7 and can in turn be cleaved by purified caspase
1, caspase 6 and caspase 8 (FLICE) (Fernandes-Alnemri et al, 1995; Tewari et al,
1995D; Harvey et al, 1996). Also fine data on time course studies shows that caspase
8 (FLICE) is capable of processing the majority of procaspases in a sequential order.
It can directly or in the presence of cell free extracts activate caspase 2, 3, 4, 6, 7 and
9 (Muzio et al, 1997). Thus activation of one caspase could lead to an amplifiable
protease cascade with caspase 8 and 10 being potentially the most apical members
(see below). The prodomain of individual caspases might play an important role in
caspase activation. Generally proapoptotic caspases can be divided into two groups:
those with a large prodomain such as caspase 2, 8, 9 and 10 and those with small
prodomains such as caspase 3, 6 and 7. Caspases with large prodomains are probably
the most upstream caspases (Srinivasula et al, 1996A, Srinivasula et al, 1996B;
Ahmad et al, 1997A) recruited directly by the Fas/TNF pathway. In the case of
caspase 2, caspase 8 and caspase 10 the prodomain containing death effector domain
motifs can interact with specific regulatory molecules and allow differential activation
by different death inducing signals (see chapter 1.5.3.).
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Caspases can also be activated by other proteases. Granzyme B gave the first
indication that other non-caspases interact and are part of this protease cascade. Thus,
the serine protease granzyme B from the granules of cytotoxic T lymphocytes
activates caspase 3 and cleaves caspase 1, caspase 2 (ICH-1/Nedd2) and caspase 8.
Other caspases including caspase 6, 7 and 10 might also be activated by granzyme B
(Darmon et al, 1995; Quan et al, 1996; Harvey et al, 1996; Muzio et al, 1996;
Vincenz et al, 1997; Alnemri, 1997).
Further control of enzyme activity might be achieved through heterooligomerisation.
Genetic complementation experiments have shown that several members of the
caspase family can heterodimerise with one another and form functional
intermolecular heterocomplexes that can also compensate for mutational inactivation
of individual subunits (Fernandes-Alnemri et al, 1995B; Faucheu et al, 1995; Gu et al,
1995). The two closely related caspases 3 and 7 can form functional intermolecular
heterocomplexes and caspase 1 and 4 form heterooligomers.
Dramatic advances have been made in the last two years regarding the order of the
cell death pathway components and the upstream regulation of caspase activity (see
also chapter 1.4.1). Biochemical studies investigating caspase activation, PARP
cleavage and apoptotic morphology have placed Bcl-2, Bcl-xl and the adenovirus E1B
19kDa protein, a viral homologue of Bcl-2, clearly upstream of the caspases
(Chinnaiyan et al, 1996A; Boulakai et al, 1996; Ibrado et al, 1996; Shimuzu et al,
1996). Clues to how Bcl-2 family members regulate the activation of caspases comes
from studies on the role of mitochondria in apoptosis and links caspase activation to
cytochrome c release (Newmeyer et al, 1994; Kluck et al, 1997A; Kluck et al,
1997B). Cytochrome c has been shown to be released from the mitochondria of
staurosporine induced HL-60 cells and Jurkat cells induced by Fas ligation and leads
to the induction of apoptosis characterised by lamin Bi and fodrin cleavage and
activation of caspases (Yang et al, 1997; Adachi et al, 1997).
1.6.6. Caspases: Some remaining questions
Major advances in apoptosis research in the last three years have firmly
established the role of caspases as the effector molecules of apoptosis. Unresolved is
whether all the caspases identified take part in the apoptotic pathway and whether the
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caspases may have other physiological functions in addition to effector molecules in
apoptosis. Whether caspase participation is stimulus or tissue specific is also only
partially resolved. Nor is it clear whether caspases have preferred intracellular
localisations (before and after activation), and if so whether this is lineage dependent.
The experimental work in this thesis was a step towards answering some of these
questions with reference to a caspase discovered early, but as yet with little firmly
established physiological function, caspase 2.
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2.0 AIMS
My ultimate goal was to define the role of caspase 2 in apoptosis. Specifically,
I wished to analyse its subcellular localisation, subunit configuration, expression and
tissue distribution in both normal and diseased tissue and its activation during
apoptosis. To address this, tools were needed for immunohistochemical,
immunocytochemical and Western blotting analysis. At the onset of this work no
commercially suitable antibodies were available or even reported in the literature. My
aims in this study therefore were a) to generate three different polyclonal antibodies,
specific to the zymogen and the subunits of the active enzyme, using as immunogens
bacterially expressed recombinant polypeptides, specific to functional regions of
caspase 2; b) to establish the specificity of those antibodies and c) to use those
antibodies to delineate caspase 2 in cells and tissues and to investigate the relationship
of caspase 2 to the initiation of apoptosis. To examine this, apoptotic cell culture
systems of two mammalian cell lines were developed and caspase 2 levels were
studied in response to a variety of different apoptotic stimuli, including a nuclear
(topoisomerase II inhibition), a cytoplasmic (protein kinase inhibition) and a cell
surface (Fas receptor coupling) stimulus.
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3.0 RESULTS
3.1 CASPASE 2 RECOMBINANT POLYPEPTIDES AS RABBITANTIGENS
3.1.1. Design ofprocaspase, large and small subunit specific caspase 2 antigens
In order to raise antibodies to caspase 2 which do not cross-react with other
caspase family members, amino acid regions within caspase 2 with low homology to
other known caspases had to be identified. These less conserved and caspase 2
specific amino acid regions would then be subsequently expressed in bacteria and
would be used as antigens for immunisation to obtain specific rabbit anti-caspase 2
polyclonal antibodies. A protein sequence alignment of the identified caspases at that
time was carried out. This included human caspase 1, caspase 2 and caspase 3 as well
as the C. elegans CED3 protein (Figure 3 .1).
Alignment of these four caspase sequences indicated that all four caspases contain a
number of highly conserved key amino acids necessary for enzyme activity. Regions
of highest identity between the four caspases were found in the small and large
subunit, particularly around the active site cysteine and histidine with the pentapeptide
QACRG conserved between the individual caspases. A lower region of similarity was
apparent in the prodomains of the caspases.
Parts of the caspase 2 prodomain sequence thus seemed particularly promising
caspase 2 specific epitopes, whereas the active site pentapeptide and adjacent amino
acids were found to be so highly conserved that the risk of cross-reactivity between
individual caspases would be high. Lesser conserved amino acid stretches at the
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Figure 3.1. Sequence alignment of multiple caspase family members. Sequence
alignment of caspases 1 (ICE), 2 (ICH-ll/s), 3 (CPP32) and CED3. Identical amino
acid residues are marked in blue and yellow within the sequence. Amino acid residues
required for enzyme catalysis are marked in yellow. Amino acid residues at positions,
which tend to be of conservative character, are printed in bold. Aspartic acid
proteolytic cleavage sites giving rise to the active enzyme (undetermined for caspase 2
and CED3 at the time of the original analysis) are highlighted in green for each
individual caspase sequence. Caspase 2 polypeptide antigen sequences are shown as
underlined amino acid residues.
One further important factor to be considered in the choice of caspase 2 antigen is the
position of the post-translational processing sites. Alignment of the caspase 2
sequence with that of caspase 1 permitted prediction of the processing sites of caspase
2 and hence identification of the prodomain, the large p 18 and the small p 12 subunit
(Figure 3.2.). Peptide sequences were selected to lie within these regions.
Subsequently published microsequencing data on caspase 2 confirmed the validity of
these choices, with the exception of an additional 20 amino acids in the NH2-terminal
region of fragment 2, which lie within the linker region that is cleaved off upon
enzyme activation. The remaining 86 amino acids of fragment 2 do, however, all lie
within the p 12 subunit.
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15 109 151 281 307 422
Figure 3.2. Subunit specific caspase 2 antigens. A schematic representation of
caspase 2/ICH-lL. The prodomain and linker regions are indicated as solid black
boxes. The size and the position of the protease subunits is depicted within the
precursor protein, the predicted active site pentapeptide is indicated by a solid dark
grey box. Vertical lines above the diagram indicate the potential precursor aspartic
acid cleavage sites to form the active enzyme subunits and are numbered according to
their position in the protease precursor. The actual cleavage sites are indicated in bold
underneath the diagram. The chosen three recombinant caspase 2 polypeptide
sequences (fragment I-III) and their relative positions within procaspase 2 are
indicated as light grey boxes.
Three polypeptide sequences within caspase 2 were thus chosen as antigens (see also
Figure 3.1. for underlined caspase 2 amino acid sequence). The predicted molecular
weight of the three caspase 2 fragments is 11.9kDa for the NH2-terminal prodomain
fragment (polypeptide/fragment 1), 13.7kDa for the COOFI-terminal small subunit
fragment (polypeptide/fragment 2) and 15.4kDa for the large subunit fragment
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(polypeptide/fragment 3). The resulting anti-fragment 2 and anti-fragment 3
antibodies will recognise either of the active enzyme subunits and the proenzyme
containing the uncut subunits, whereas the anti-fragment 1 antibody will only bind to
the proenzyme. These antibodies will thus allow the study of caspase 2 activation in
apoptosis, analysing the appearance of both subunits, and will also allow comparative
immunohisto- and immunocytochemical studies of protein levels of caspase 2
proenzyme versus active enzyme.
3.1.2. Construction ofexpression vectorsfor caspase 2 fragments in bacteria
In order to amplify the caspase 2 coding region, total mRNA was isolated
from HeLa cells. The polynucleotide sequences corresponding to the three caspase 2
polypeptide fragments and the whole sequence were amplified with specific primers
by RT-PCR and analysed by agarose gel electrophoresis (Figure 3.3 ).
Figure 3.3. RT-PCR amplification of three caspase 2 (ICH-1L) oligonucleotide
fragments. M: marker in base pairs; A) lane 1. whole caspase 2 cDNA; B) lane 1.
fragment 1; lane 2: fragment 2; C) lane 1: fragment 3.
The predicted open reading frame of caspase 2 cDNA consists of 1308 bp and
encodes the 435 amino acid caspase 2 (ICH-li) protein product. The first caspase 2
fragment (prodomain fragment) is encoded by 282 bp, the second fragment (small
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subunit fragment) is encoded by 348 bp and the third fragment (large subunit
fragment) is encoded by 408 bp. All three fragments and the entire coding region,
with the correct size, were amplified from the cDNA (Figure 3 .3 ). The position of the
amplified caspase 2 fragments 1-3 within the caspase 2 cDNA sequence is indicated
in Figure 3.4.
44
i GCACAAGGAGCTG ATG GCC GCT GAC AGtj GGA CGC AGG ATA TTG GGA GTG TGT GGC ATG CAT CCT















































































































































305 GAG GAT ATG T^TG CTC ACC ACC CTT TCT GGG CTT CAG CAT GTA CTC CCA CCG TTG AGC TGT











































425 CGC CTG TCG ACA GAT ACT GTG GAA CAC TCC CTA GAC AAT AAA GAT GGT CCT GTC TGC CTT











































































































































































































































845 GAG GTT TTT CAG CTC TTT GAC AAC GCC AAC TGC CCA AGC CTA CAG AAC AAA CCA AAA ATG
278=> 2 F Q L F D N A N C P S L Q N K P K M
905 TTC TTC ATC CAG GCC TGC CGT GGA GAT GAG ATC GAT CGT GGG GTT GAC CAA CAA GAT GGA
2 98=> F F I Q A C R G D E T D R G V D Q Q D G
965 AAG AAC CAC GGA GGA TCC CCT GGG TGC GAG GAG AGT GAT GCC GGT AAA GAA AAG TTG CCG
318=> KNHAGSPGCEESDAG'KEKLP
1025 AAG ATG AGA CTG CCC ACG CGC TCA GAC ATG ATA TGC GGC TAT GCC TGC CTC AAA GGG ACT
338=> KMRLPTRSDMICGYACLKGT
1085 GCC GCC ATG CGG AAC ACC AAA CGA GGT TCC TGG TAC ATC GAG GCT CTT GCT CAA GTG TTG
358=>AAMRNTKRGSWYIEALAQVF
114 5 TCT GAG CGG GCT TGT GAT ATG CAC GTG GCC GAC ATG CTG GTT AAG GTG AAC GCA CTT ATC
378=>SERACDMHVADMLVKVNALI
1205 AAG GAT CGG GAA GGT TAT GCT CCT GGC ACA GAA TTC CAC CGG TGC AAG GAA ATG T]CT GAA
398=> KDREGYAPGTEFHRCKEMSE
1265 TAC TGC AGC ACT CTG TGC CGC CAC CTC TAC CTG TTC CCA GGA CAC CCT CCC ACA TGA
420=> YCSTLCRHLYLFPGHPPT OC
Figure 3.4. Nucleotide and deduced amino acid sequence of caspase 2 (ICH-1L)
Nucleotides are numbered 5' to 3'. The termination codon is designated OC. The
primers are denoted by bold arrows, PCR amplified polynucleotide sequences are in
bold print. The active enzyme subunit composition is underlined.
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In order to construct caspase 2 expression vectors, PCR-amplified caspase 2-
polynucleotide fragments 1-3 were digested with Xhol and Ncol and were ligated
with linearised pET23d bacterial expression vector. The ligated vectors were
transformed into competent cells and analysed by a single restriction digest with the
restriction endonuclease Pvul, which cuts the pET23d vector at a single site resulting
in vector linearisation or a double digest with the restriction endonucleases Dralll and
Bglll, which each cut the vector at a single site (see Appendix 2, Figure 1. pET23d
vector diagram).
Figure 3.5. Restriction endonuclease analysis of recombinant pET23d vectors 1,
2 and 3. M: kilobase marker in base pairs. A) incomplete Pvul digest; lane 1. top
band (very faint), nicked circular recombinant vector; middle band, linearised
recombinant vector pET23dl (insert: fragment 1) 3865bp, lower band supercoiled
recombinant vector. B) incomplete Pvul digest; lane 1-2. top band, nicked circular
vector; middle band, linear pET23d without insert 3583bp; lower band, supercoiled
vector; lane 3: recombinant vector pET23d2 (insert: fragment 2) 393lbp. C) Dralll
and Bglll digest; lane 1-2. linear recombinant vector pET23d3 (insert: fragment 3)
3090bp and 90lbp
The restriction digest gel analysis of clones showed the presence of predicted DNA
fragments of the appropriate size corresponding to recombinant vectors pET23dl-3
(Figure 3.5 ). The correct cloning of the caspase 2 polynucleotide fragments 1-3 in
the recombinant vectors pET23dl-3 was further confirmed in a restriction
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endonuclease digest with Ncol and Xhol, the original cloning sites for all three
polynucleotide fragments, resulting in the excision of the cloned caspase 2 fragments
(data not shown).
In order to exclude any mutations and to confirm correct insertion of the fragment
into the vector in frame with the six COOH-terminal histidine residues, all three
plasmids (pET23dl-3) were subsequently sequenced. Correct in frame insertion of the
target DNA into the linearised vector is of critical importance to ensure translation of
the COOH-terminal histidine residues which allow the purification of the recombinant
protein from bacterial lysates on nickel columns by affinity chromatography (see also
chapter 3.1.3 ). No mutations within caspase 2 polynucleotide sequences were found
and the correct reading frame was confirmed (sequencing data not shown).
3.1.3. Preparation andpurification ofbacterial lysates expressing caspase 2
polypeptides
To obtain recombinant caspase 2 polypeptide fragments as antigens for the
immunisation of rabbits, the three recombinant plasmids were transformed into the
E.co/i bacterial expression strain BL2I (DE3) pLysS. This bacterial expression strain
is a lambda derivative that has the immunity region of phage 21 and carries a DNA
fragment containing the lacl gene, the lacU\r5 promotor and the gene for T7 RNA
polymerase. The only promotor known to direct transcription of the T7 RNA
polymerase gene is the lacUV5 promotor, which is inducible by the nonmetabolisable
analog of lactose, IPTG. Addition of IPTG to a growing bacterial culture induces T7
RNA polymerase, which in turn transcribes the target DNA in the pET23d vector.
The E.coli bacterial expression strain BL21 (DE3) pLysS is thus particularly suitable
for potentially toxic target gene expression (see Appendix 2, Figure 2. Control
elements of the pET system). Target gene expression in the bacterial culture was
monitored by SDS-PAGE. Optimal expression was achieved when the growing
culture was induced by the addition of IPTG to the culture medium at an optical
density (OD6oo) around 0.6. Overgrowth of the culture to OD> 0.8 resulted in very
low yields of recombinant protein.
Initial column chromatography was carried out with each culture extract prepared
under native and denaturing conditions. Attempted purification of prodomain caspase
2 fragment 1 and small subunit fragment 2 under native conditions resulted in very
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low amounts of recombinant protein (>0.5mg from a 400ml culture). This suggested
that both of the recombinant caspase 2 fragments were expressed mainly in insoluble,
aggregated form in the bacterial expression strain and were most likely contained
within bacterial exclusion bodies. Caspase 2 fragments 1 and 2 were thus subsequently
purified from a membrane fraction under highly denaturing conditions in the presence
of 6M urea in the binding buffer. In contrast the large subunit fragment 3 appeared to
be mainly expressed as a soluble form and was purified under native conditions from
the cytoplasmic fraction without further incubation with 6M urea.
To assess recombinant protein yield from induced bacterial cultures, protein
concentrations of column purified recombinant protein and soluble and insoluble
whole protein fractions were determined at all stages of the lysate preparations.
Individual standard curves were prepared each time and Table 3.1. shows the average
protein amounts obtained in five separate experiments.
Culture pET23dl Culture pET23d2 Culture pET23d3
Fraction 1 104.32mg 116.83mg 98.65mg
Fraction 2 7.65mg 6.81mg 15.83mg
Fraction 2A 18.99mg 13.19mg
Fraction 3 6.09mg 3.06mg 1.47mg
Table 3.1. Protein concentrations of protein fractions obtained from 400ml
induced bacterial culture. The OD595 values were read from individual standard
curves. Protein concentrations represent the average of five independent experiments.
Fraction 1 is the whole cell extract after freeze/thaw cycles. Fraction 2 is the soluble
protein fraction for culture pET23d3 (discarded for culture pET23dl and 2) after
ultracentrifugation and prior to column chromatography. Fraction 2A is the 6M urea
solubilised protein fraction of culture pET23dl and 2 after ultracentrifugation and
prior to column chromatography. Fraction 3 is the column purified eluate fraction,
consisting of the purified recombinant protein.
On average substantially less column purified recombinant protein than claimed by the
manufacturer was obtained from each induced culture, with particularly low recovery
obtained with fragment 3, and the experiment was accordingly scaled up from a
recommended 100ml culture volume to 400ml culture. Reasons for the
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disappointingly low expression are obscure, but the recombinant caspase 2 fragments
could interfere with the integrity of the cell and could be potentially toxic.
In order to monitor target gene expression and purity of the column-eluted caspase 2
fragments samples of total cell protein and column eluted caspase 2 fragments from
induced cultures were subjected to protein electrophoresis followed by Coomassie
blue staining (Figure 3 .6.A). The efficiency of the cell extract preparation for column
chromatography by freeze/thaw cycles was assessed by additional analysis of the
solubilised final cell pellet (the pellet obtained by ultracentrifiagation of lysates prior to
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Figure 3.6. SDS-PAGE analysis of recombinant caspase 2 fragment expression.
Expression analysis of recombinant caspase 2 fragments 1, 2 and 3 bacterial cultures
lysates and purity analysis of purified recombinant protein. Approximately 50pg/lane
of samples protein were run on 15% SDS-PAGE large gel; M: molecular weight
standards in kDa. A) Culture pET23dl (fragment 1) lanes 1- 5; culture 23pETd2
(fragment 2) lane 6-10 and culture 23pETd3 (fragment 3) lane 11- 15. Lane 1:
uninduced total cell lysate; lane 2: lh induced total cell lysate; lane 3: 2h induced
total cell lysate; lane 4: 3h induced total cell lysate; lane 5: column purified eluate
fraction (fragment 1); lane 6: uninduced total cell lysate; lane 7: lh induced total cell
lysate; lane 8: 2h induced total cell lysate; lane 9: 3h induced total cell lysate; lane
10: column purified eluate fraction (fragment 2); lane 11: uninduced total cell lysate;
lane 12: lh induced total cell lysate; lane 13: 2h induced total cell lysate; lane 14: 3h
induced total cell lysate; lane 15: column purified eluate fraction (fragment 3). B)
Culture pET23dl lanes 1-6; lane 1: uninduced total cell lysate; lane 2: lh induced
total cell lysate; lane 3: 2h induced total cell lysate; lane 4: 3h induced total cell
lysate; lane 5: column purified eluate fraction (fragment 1); lane 6: solubilised pellet
after ultracentrifugation. Culture 23pETd2 lanes 7-12; lane 7: uninduced total cell
lysate; lane 8: lh induced total cell lysate; lane 9: 2h induced total cell lysate; lane
10: 3h induced total cell lysate; lane 11: column purified eluate fraction (fragment 2);
lane 12: solubilised pellet after ultracentrifugation.
The recombinant caspase 2 fragments expressed in the bacterial cultures were visible
on the Coomassie stained polyacrylamide gel by the appearance of a new protein band
in the total cell lysate at 1 hour after the induction with IPTG. The intensity of bands
and the relative amounts of the protein of all three bands corresponding to the
recombinant caspase 2 fragments increased over the three hour time period following
induction with IPTG.
The prodomain fragment 1 with a predicted molecular weight of 11.9kDa appeared as
band of a similar apparent molecular weight in the total cell lysate on a 15% SDS-
PAGE gel. In the total cell lysates of the induced cultures expressing fragments 2 and
3, however, the apparent molecular weight of the expressed proteins differed from the
expected size.
The small subunit fragment 2 had an apparent molecular weight of 16.5kDa instead of
the predicted molecular weight of 13.7kDa. The reason for this apparent discrepancy
in molecular weight are obscure.
In several cultures transformed with the pET23d3 vector for the expression of
fragment 3, a protein of approximate molecular weight of 22kDa appeared to be
strongly induced and was assumed to be caspase 2 fragment 3, which has a predicted
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molecular weight of 15.4kDa. Later examination showed, however, that a protein
band of similar molecular weight (22kDa) also appeared in the cell lysate of the
induced cultures transformed with pET23dl and pET23d2 and in the column purified
fraction of recombinant fragment 2 (Figure 3.6.A, lane 10). However, lysates of
bacterial cultures transformed with nonrecombinant pET23d as a negative induction
control, also showed a prominent protein band of about 22kda, but no change in
expression levels was apparent over a three hour time period, following induction
with IPTG (data not shown). In contrast with this prominent band, a weakly induced
smaller protein is apparent as a band of approximately 15.5kD in the total cell lysate
of pET 23d3 transfected bacteria following 1 and 2 hours after the induction with
IPTG, corresponding to the predicted molecular weight of caspase 2 fragment 3. This
protein also elutes off the Nickel column, even though in much smaller amounts, and,
as later confirmed by amino acid sequencing and mass spectrophotometry (see
below), is the recombinant caspase 2 fragment 3.
All three recombinant caspase 2 fragment eluate fractions, purified by metal chelating
affinity chromatography (see Figure 3.8. A, lanes 5, 10 and 15), contained some
higher molecular weight contaminating proteins. The presence of higher molecular
weight proteins is most likely an indication of insufficient washing of the columns
prior to elution of Nickel bound histidine-tagged proteins, resulting in retention of
unbound larger molecular weight proteins. Due to the relative insensitivity with which
Coomassie stain binds to and therefore detects less abundant proteins on fixed
polyacrylamide gels, however, no definite answer to the purity of the recombinant
protein following column chromatography could be obtained by this method alone.
The inefficiency of bacterial cell lysis by freeze/thaw cycles became apparent (Figure
3 .8. B, lane 6 and 10) when the final cell pellet, obtained by ultracentrifugation of the
cell extracts prior to purification on the affinity columns, was solubilised in SDS-
sample buffer and analysed by SDS-PAGE for the presence of recombinant protein. A
substantial amount of recombinant protein was still contained within the pellet, giving
further explanation for the relatively low yield of purified recombinant protein.
To confirm that the three bacterially expressed and column purified proteins were
indeed fragments of caspase 2, a column purified sample of each recombinant caspase
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fragment was further purified and separated from bacterial proteins by reverse-phase
HPLC (High performance liquid chromatography) (HPLC chromatograms not
shown). Column purified recombinant caspase 2 fragments 1 and 2 provided a distinct
elution profile and the protein fractions, corresponding in elution time to the predicted
molecular weight of fragments 1 and 2, were collected and subjected to NH2-terminal
amino acid sequencing (chromatogram reports not shown). The HPLC profile of
column purified recombinant caspase 2 samples further established the presence of
both low and high molecular weight contaminating proteins, probably of bacterial
origin, in the affinity column purified recombinant caspase 2 preparations.
In the case of the large subunit fragment 3, proteins, most likely of bacterial origin,
coeluted of the HPLC column at approximately the same time at which the predicted
size recombinant fragment 3 should have eluted and no single prominent fragment 3
protein peak was initially obtained. The HPLC elution profile of larger molecular
weight proteins, particularly the 22kDa protein, contained within the fragment 3
protein preparation, which would have eluted later off the HPLC column were not
analysed. HPLC fractions from two additional runs were pooled and the amino acid
sequencing reaction was repeated in order to determine the NH2-terminal fragment 3
sequence. This showed that the recombinant caspase 2 fragment 3 band was present in
very small quantities within the fragment 3 column purified sample and corresponded
to the weak 15.5kDa protein band and not the prominent 22kDa protein.
The NH2-terminal 10 amino acids of all three recombinant proteins, corresponding in
HPLC elution profile to the predicted molecular weight of the three caspase
fragments, were thus identified as the correct NH2-terminal amino acids sequences of
caspase 2 (Table 3.2.).
Table 3.2. NH2-terminal amino acid sequencing of three recombinant caspase 2
polypeptides
10 NH2-terminaI amino acids(single letter code)
fragment 1 (prodomain)
fragment 2 (small subunit)





In order to determine the exact molecular weight and thus confirm the identity of the
three recombinant polypeptides, each column purified recombinant caspase 2 fragment
was analysed by mass spectrum photometry. Initial mass spectrum photometry results
with the recombinant polypeptides showed non-quantitatively the presence of a
variety of unidentified proteins present in the Ni2 affinity column eluate fraction and
thus further confirmed the impurity of the recombinant polypeptides eluted of the
column. Recombinant caspase 2 fragments were thus column purified twice prior to
analysis by mass spectrophotometry (Figure 3 .7 ).
Caspase 2 fragment 1 with a predicted molecular weight of 11974 Dalton most likely
corresponded to one of the four proteins found with a molecular mass range of
10187-10838 Dalton, most likely reduced in molecular mass due to decomposition
(Figure 3.7.A). Other smaller proteins were found to be present in the sample, and
may represent further fragments of the recombinant protein or contaminating bacterial
proteins.
Caspase 2 fragment 2 with a predicted molecular weight of 13710.5 Dalton most
likely corresponded to the detected protein of 13997.7 Dalton (Figure 3.7.B). The
difference between predicted and detected molecular weight was most likely due to
inaccurate calibration of the mass spectrum photometer. Similar to the fragment 1
sample, a variety of other unidentified proteins were detected in the fragment 2
sample.
Caspase 2 fragment 3, however, with a predicted molecular weight of 15400 Dalton
could not be identified in any of the scans. Instead a protein of 23329.4 Dalton,
detected also with a double charge as 11673.6 Dalton protein, was most prominent.
This protein most likely corresponded to the 22kDa protein detected by SDS-PAGE.
Larger amounts and a less contaminated sample of recombinant fragment 3 would be
required to confirm the exact molecular mass and the identity of fragment 3.
The mass spectrometry thus confirmed the presence of fragment 1 and 2 polypeptides
of the predicted molecular weight, whereas fragment 3 was undetectable and thus
appeared not to be contained within the protein sample analysed.
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Figure 3.7. Mass spectrum of the column purified recombinant caspasc 2 fragments 1-3. A)
Mass spectrum column purified fragment 1 Accelerating Voltage: 26250; Low Mass Gate: on;
Negative Ions: off; Laser: 905; Scans Averaged: 3; Pressure: 1.88c-07. B) Mass spectrum column
purified fragment 2. Accelerating Voltage: 26250; Low Mass Gate: on: Negative Ions: off; Laser:
800; Scans Averaged: 2; Pressure: 1.3 le-07. C) Mass spectrum column purified fragment 3.
Accelerating Voltage: 26250; Low Mass Gate: on: Negative Ions: off: Laser: 608; Scans Averaged:
4: Pressure: 1.19e-07.
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In summary, all three methods, SDS-PAGE analysis, HPLC, amino acid sequencing
and mass spectrometry established the identity of recombinant fragment 1 and 2 as
caspase 2 fragments present in high amounts in the eluate fraction, albeit with some
additional contaminating proteins. The eluate fraction of cultures expressing fragment
3, however, contained only minimal amounts of the recombinant caspase 2 protein
with the majority of protein being contaminating bacterial proteins.
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3.2. CHARACTERISA TION OF POLYCLONAL ANTIBODIES
The preceding results indicated that recombinant caspase 2 protein fragments
1 and 2 were obtained from bacterial cultures successfully and in sufficient quantities
The successful purification of fragment 3 was in substantial doubt and much smaller
quantities of the protein were obtained. All three preparations of recombinant proteins
were used as antigens, however, for the immunisation of six rabbits and three different
polyclonal antisera were generated. The six rabbits (two for each recombinant caspase
2 fragment) were immunised with single column-purified protein fractions according
to the following the rabbit immunisation scheme (Table 3.3.).
Caspase 2 fragment 1
Rabbits 16AB + 68AB
Caspase 2 fragment 2
Rabbits BX03 + BX08
Caspase 2 fragment 3
Rabbits 32AB + 90AB
prebleed 1 prebleed 1 prebleed 1
prebleed 2 prebleed 2 prebleed 2
immunisation 1 (time 0) immunisation 1 (time 0) immunisation 1 (time 0)
testbleed 1 (2 wks) testbleed 1 (2 wks) testbleed 1 (2 wks)
testbleed 2 (4 wks) testbleed 2 (4 wks) testbleed 2 (4 wks)
testbleed 3 (6 wks) testbleed 3 (6 wks) testbleed 3 (6 wks)
immunisation 2 (8 wks) immunisation 2 (8 wks) immunisation 2 (8 wks)
testbleed 4 (10 wks) testbleed 4 (10 wks) testbleed 4 (10 wks)
testbleed 5 (12 wks) testbleed 5 (12 wks) testbleed 5 (12 wks)
testbleed 6 (14 wks) testbleed 6 (14 wks) testbleed 6 (14 wks)
immunisation 3 (9 month) immunisation 3 (9 month)
testbleed 7 (4 wks) testbleed 7 (4 wks)
Table 3.3. Rabbit immunisation scheme for polyclonal anti-caspase 2 antibodies.
Immunisation 3 at indicated month after initial immunisation for rabbits 68AB and
BX08 only; wks = weeks.
Following the first and second immunisation with recombinant column purified
polypeptides 1, 2 and 3, the six rabbits were testbled every two weeks and the
testbleed sera, initially only of the rabbits immunised with caspase 2 fragment 1 and 2,
were analysed for anti-recombinant caspase 2 immuneresponse by Western blotting.
Antisera to the caspase 2 fragment 3 preparations were obtained 3 months after those
initial experiments.
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3.2.1. Determination ofwhole serum antibody titre against recombinant caspase 2
fragments
In order to analyse whether the rabbits had shown an immuneresponse to the
recombinant caspase 2 fragments and to determine the polyclonal antibody binding
affinity for the recombinant polypeptides a series of whole testbleed sera dilutions
were tested against a constant amount of recombinant polypeptide using a multi-well
blotter (Figure 3.8 ).
Testbleed sera from rabbits 68AB and 16AB (Figure 3.8.A) showed a strong immune
response to the caspase 2 polypeptide fragment 1 and were able to bind to fragment 1
at 1:1000 dilution, whereas prebleed sera showed no immunoreactivity against the
caspase 2 polypeptide. Testbleed antisera from rabbits BX03 and BX08 (Figure
3.8.B) were equally able to detect recombinant fragment 2 at 1:1000 dilution while
prebleed sera were unable to detect the recombinant polypeptide. Testbleed sera
16AB, 68AB and BX08 further detected multiple higher molecular weight bands on
the Western blots, which correspond in size to dimer- and multimer-formations of the
recombinant polypeptides. These dimers and multimers appear to be formed at high
recombinant protein concentrations. When substantially less recombinant protein
(50pg in comparison to 500pg) was run on SDS-PAGE and subsequently analysed by
Western blotting no higher molecular weight bands were detected, indicating that the
recombinant protein was fully denatured (data not shown).
In view of these results sera from rabbits 32AB and 90AB, immunised with the
attempted fragment 3 preparation, were analysed on ten times less recombinant
polypeptide (50pg). At 1:500 dilution the testbleed sera bound to many proteins, but
in particular a 22kDa protein band (Figure 3.8.C). Both rabbits showed, in
comparison to rabbits immunised with fragment 1 and 2, a later immune response to
the antigen. These results suggest that the poor quality of the immunogen did not give
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Figure 3.8. Immunoblot analysis of polyclonal antibody affinity to recombinant
caspase 2 fragments. 15% SDS-PAGE ininigel. transferred to nitrocellulose and probed with
serial dilutions of non-purified polyclonal anti-caspase 2 testbleed sera (TB) and prcbleed sera (PB).
Molecular weight standards in kDa. The position of each recombinant pohpeptide is indicated by an
arrow. A) 500pg of fragment 1 detected w ith serial dilutions of fragment 1 polyclonal antisera. rabbit
16AB and 68AB (dilutions from left to right: 1:30; 1:100; 1:500; 1:1000). B) 500pg of fragment 2
detected with serial dilutions of fragment 2 polyclonal antisera. rabbit BX03 and BX08 (dilutions
from left to right: 1:30; 1:100; 1:1000); visible bands in the prebleed wells of rabbit BX08 were due
to leakage of tcstblecd sera after disassembly of the multi-well blotter. C) 50pg of fragment 3
detected with serial dilutions of fragment 3 polyclonal antisera. rabbit 32AB and 90AB (dilutions
from left to right: 1:100; 1:250; 1.500).
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The antibody affinity to the recombinant fragment 1 and 2 antigen was further
characterised by testing the antibody at the previously determined optimal dilution on
varying amounts of recombinant immunogen. These experiments aimed to give an
indication of the minimum level of detection of endogenous caspase 2 in whole cell
lysates by these antibodies, as both the expression level and stability of caspase 2 in
cells is unknown. (Figure 3.9.)
Figure 3.9. Immunoblot analysis of antibody affinity to recombinant caspase 2
fragments. Whole polyclonal antiserum at 1:1000 dilution tested against various
concentrations of recombinant polypeptide; 15-175ng/lane run on 15% SDS-PAGE
minigel. M: molecular mass marker in kDa. A) caspase 2 fragment 1, whole testbleed
serum 68AB; B) caspase 2 fragment 2, whole testbleed serum BX08.
Anti- fragment 1 antibody 68AB detected down to 15ng of recombinant polypeptide
fragment 1 at a 1:1000 dilution. 25ng was optimal for detection at the given dilution.
Anti-fragment 2 antibody BX08 was able to detect 25ng of recombinant fragment 2 at
1:1000 dilution, although,. 50ng was optimal. Both anti- fragment 1 and 2 antibodies
thus seemed to be promising tools in the detection of endogenous caspase 2.
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3.2.2. Determination ofpurified antibody titre against recombinant caspase 2
fragments
The initial Western blots were carried out with whole serum and confirmed a
strong immune response of the rabbits to recombinant caspase 2 antigens (fragment 1
and 2). To determine both the immunoglobulin class and the actual amounts of the
anti-caspase 2 polyclonal antibodies within the whole serum, testbleed antisera from
individual rabbits were pooled (T2-T6 for fragment 1 and 2 antisera; T4-T6 for
fragment 3 antisera) and the IgG fractions were purified by Protein A and G column
affinity purification. Polyclonal antibody affinity against recombinant polypeptide was
subsequently determined with purified IgG antibodies from rabbits 68AB (fragment 1)
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Figure 3.10. Antibody affinity determination of purified antisera by Western
blotting analysis. 7pg of recombinant caspase 2 fragments were run on an analytical
comb on 15% SDS-PAGE minigel, probed on a multi-well blotter with serial dilutions
of purified (IgG fraction) polyclonal antiserum (total protein in pg). M: molecular
weight markers in kDa. A) varying amounts of purified 68AB polyclonal antiserum
tested against recombinant fragment 1; lane I: lOOgg; lane 2: 75gg; lane 3: 50gg,
lane 4: 25gg B) varying amounts of purified BX08 polyclonal
antiserum tested against recombinant fragment 2. lane 1: lOOgg; lane 2: 75gg; lane
3: 50gg; lane 4. 25gg; lane 5: 15gg.
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Purified IgG fractions of antisera 68AB and BX08 maintained a very high affinity
towards the recombinant polypeptide antigen and were able to bind to the
recombinant protein when blots were probed with 20pg of 68AB (Figure 3.10. A,
lane 4) and lOpg of BX08 (Figure 3.10. B, lane 5). This suggests that both polyclonal
anti-caspase 2 antibodies are IgG class molecules.
3.2.3. Antibody specificity testing by Western blotting and ELISA
In experiments to define specificity of the polyclonal antibodies two questions
were addressed. First can cross-reactivity between anti-fragment 1 and anti-fragment
2 antibodies be excluded? This is important as the antibodies were designed to
discriminate between proenzyme (fragment 1 antibody) and the small subunit
(fragment 2 antibody) (see also chapter 3.1.1.) and cross-reactivity, particularly of
anti-fragment 1 antibody with other areas of caspase 2, would have destroyed this.
Second, the antibodies were tested for reactivity against recombinant subunits from a
variety of other caspases. The intention here was to determine the usefulness of the
anti-caspase 2 antibodies to distinguish caspase 2 from other members of the caspase
family. The first question was approached by Western blotting, using unpurified
antisera. Antibodies to fragment 1 were tested for their ability to detect and therefore
cross-react with recombinant fragment 2 and antibodies to fragment 2 were tested for
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Figure 3.11. Immunoblot analysis of whole serum antibody cross reactivity
Indicated amounts of recombinant caspase 2 fragments were run on 15% SDS-PAGE
minigel. M: molecular weight markers are indicated in kDa on the left of each blot. A)
Fragment 1 antiserum 68 AB (testbleed 5) at 1:1000 dilution. Lane I: 25ng; lane 2:
50ng; lane 3: 75ng; lane 4: 25ng; lane 5: 50ng; lane 6: 75ng. B) Fragment 2
antiserum BX08 (testbleed 6) at 1:1000 dilution. Lane I: 25ng; lane 2: 50ng; lane 3:
75ng ; lane 4: 25ng; lane 5: 50ng; lane 6: 75ng .
Both antibodies bound to the recombinant polypeptide fragment they were raised
against but failed to detect the other recombinant polypeptide thus showing no cross
reactivity within caspase 2.
The second question of cross-reactivity of the antibodies with other recombinant
caspase family members was tested by ELISA. Recombinant caspase subunits were a
kind gift from D.W. Nicholson and include large and small subunits of caspase 1
(ICE), caspase 2 (ICH-1), caspase 3 (CPP32), caspase 4 (ICErci-II) and caspase 5
(ICErei-III). Each polyclonal antibody was expected to bind specifically with high
affinity to its recombinant fragment antigen, whereas prebleed sera at the same
dilution should have no affinity towards the same amount of recombinant polypeptide
fragment. Additionally the antibodies to fragment 2 were expected to bind to the
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recombinant caspase 2 small subunit and antibodies to fragment 3 were expected to
bind to the recombinant caspase 2 large subunit.
In initial ELISAs the affinity of the antibodies for recombinant caspase 2 fragment
preparations was established by testing various dilutions of 68AB (fragment 1), BX08
(fragment 2), 32AB (fragment 3) prebleed and testbleed sera against serial dilutions of
the immunogen (data not shown). Preliminary ELISA results for fragment 1 antibody
68AB determined the optimal dilution of 1:100 detecting 75ng of bound fragment 1.
The binding affinity of 68AB towards the recombinant polypeptide fragment 1 was,
however, very low with similar OD values reached when tested for binding to
fragment 2. ELISAs for the fragment 2 antibody BX08 suggested an optimal dilution
of 1:250 binding to 300-500ng of fragment 2 and fragment 3 antibody 32AB showed
an optimal dilution of 1:500 detecting 50ng. At those dilutions the testbleed sera
specifically bound to the recombinant protein samples with no cross-reactivity to
other caspase 2 fragments and the OD values of prebleed sera were similar to the
blank OD values. The antibodies were then tested at the determined optimal
concentrations for their affinity for the entire recombinant small subunit of caspase 2
and for other recombinant caspases (Figure 3.12.).
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Figure 3.12. ELISA antibody cross-reactivity testing. A) 68AB polyclonal
antiserum at a dilution of 1:100 (purified stock lmg/ml), ELISA plate coated with
75ng recombinant protein; B) BX08 at 1:250 dilution (purified stock lmg/ml), plate
coated with 300ng recombinant protein; C) 32AB at 1:500 dilution (purified stock
lmg/ml), plate coated with lOOng recombinant protein.
Polyclonal antibody 68AB bound to recombinant fragment 1 with very low affinity
with OD values similar to fragment 2 and was also able to detect caspase 1 (ICE)
large and small subunit and caspase 3 (CPP32) large subunit (Figure 3.12.A). Binding
of 68AB to both fragment 1 and fragment 2 was abolished when the antibody was
pre-incubated with recombinant caspase 2 fragment 2 (data not shown), confirming
that the observed binding of the antibody was most likely background binding to
bacterial proteins. ELISA analysis with purified 68AB fragment 1 antibody thus
showed that the antibody is unsuitable for ELISA. A potential explanation for this
unsuitability of the antibody 68AB could reside in the epitope that the antiserum
recognises. ELISA is carried out under non-denaturing conditions allowing the
reformation of some secondary structures including disulphide-bridges. Should the
antiserum mainly recognise a linear epitope, fully denatured in SDS-PAGE, the very
low binding of the antibody in ELISA could be explained.
Purified 32AB polyclonal antibody bound with high affinity to all caspase subunits
tested, particularly caspase 1 large and small subunit, caspase 4 large and small
subunit and caspase 3 small subunit (Figure 3.12.C), further confirming the
unsuitability of the antibody for further experiments. Like the antigen to which 32AB
was raised, the caspase subunits tested for cross-reactivity are also bacterially
expressed recombinant proteins of unknown purity and are, therefore, likely to
contain some bacterial proteins. What appeared to be wide cross-reactivity of the
32AB antibody with other caspase subunits is thus most likely antibody binding to
bacterial proteins rather than actual caspase subunits.
Purified BX08 antibody raised against fragment 2 showed high specificity towards
caspase 2 small subunit and caspase 2 fragment 2 with an almost identical signal
strength (Figure 3.12.B). The antibody showed no significantly cross-reactivity with
caspase 2 large subunit or any of the other four caspase subunits tested, with the
exception of the small subunit of caspase 4 to which it showed a low affinity. When
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this antibody was pre-absorbed with recombinant caspase 2 fragment 1, the binding to
recombinant fragment 1 was reduced to background values, while a high affinity was
retained towards the immunogen fragment 2 (Figure 3.13.). Preabsorption thus
further confirmed the specificity of the COOH-terminal anti-caspase 2 antibody to

























Figure 3.13. Comparative ELISA of absorbed and non-absorbed BX08
antiserum. ELISA plate coated with 300ng recombinant caspase fragment, antibody
at 1:250 dilution. OD measured at 450nm.
3.2.4. Endogenous caspase 2 detection in whole cell extracts of three human cell
lines
Following the demonstration of antibody affinity and specificity, partly by
Western blotting analysis and ELISA, for recombinant subunits and fragments of
caspase 2, the polyclonal antisera were tested for their ability to detect endogenous
procaspase 2 in whole cell extracts of three human cell lines. Fragment 1 and 2
antisera (both purified IgG fractions and unpurified whole sera) together with the
preimmune sera as negative controls were tested at various concentration (1:1000;
1:500; 1:250; 1:200; 1:100; 1:50) for their ability to detect caspase 2 in whole cell
protein extracts ofHeLa and Jurkat cells, reported to express high levels of caspase 2
(Wangefa/, 1994).
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In Western blotting analysis preimmune and testbleed sera of rabbits 16AB and 68AB
(prodomain/fragment 1 antibodies) and rabbits BX03 and BX08 (small
subunit/fragment 2 antibodies) at all concentrations tested failed to detect a protein of
48kDa corresponding to the predicted molecular weight of procaspase 2 (data not
shown). Prebleed and testbleed sera of rabbits 16AB and 68AB, however, strongly
bound to two proteins of approximately 29kDa and 18kDa while prebleed and
testbleed sera from rabbits rabbits BX03 and BX08 detected an 18kDa protein band.
Upon long exposure of the film to the membrane at 1:100 and 1:50 dilution prebleed
and testbleed sera of both antibodies detected a variety of high (>50kDa) and low
(<50kDa) molecular weight additional protein bands and a band with similar mobility
to caspase 2 in HeLa and Jurkat cell extracts. Comparison of preimmune and testbleed
antibody binding to a 48Kda protein corresponding to caspase 2 showed no clear
difference in binding due to the presence of additional nonspecific bands, which
migrated close to the that of full-length caspase 2. A commercial anti-caspase 2
monoclonal antibody at 1:1000 dilution used as a positive control, however, bound
specifically with no nonspecific background binding to a protein of about 46kDa,
approximately corresponding to the predicted molecular weight of caspase 2 (see
chapter 3.3.1.).
These Western blotting results showing high cross-reactivity with binding of the
polyclonal anti-caspase 2 antibodies to non-specific bands and low affinity to caspase
2 to caspase 2 contrasted so sharply with the previously obtained specific binding to
recombinant peptide in Western blots, that it seemed possible that the antibody
preparations had lost their activity. Accordingly the Western blotting was repeated
with the HeLa extract "spiked" with 500pg recombinant polypeptides, run on a large
SDS-PAGE gel with an analytical comb (data not shown). Purified and non-purified
fragment 1 antibodies 16AB and 68AB at 1:50 dilution were able to detect the
monomers and multimers of recombinant fragment 1 polypeptide (500pg) amongst
HeLa proteins and also detected other nonspecific protein bands. In contrast, negative
control purified and non-purified 68AB prebleed sera bound to the same HeLa
proteins but were unable to detect recombinant fragment 1 added to HeLa extracts.
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This experiment confirmed that the disappointing initial failure to detect caspase 2 in
protein extracts by Western blotting was not due merely to inactivation of the
antibodies on storage. Accordingly Western blotting was repeated under altered
conditions chosen to optimise binding of lower-affinity antibodies to caspase 2. Thus
the primary antibody incubation time was extended, longer washes and an
immunopure secondary antibody were applied. Titrations of both prodomain and
small subunit antibodies were tested for their ability to detect caspase 2 in HeLa and
Jurkat whole cell extracts (Figures 3.14. and 3.15.). In contrast to earlier results, this
altered protocol produced dramatically different results.
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Figure 3.14. Immunoblot analysis of caspase 2 detection in HeLa whole cell
extract. 12.5% SDS-PAGE minigel, 200|ig whole cell extract run on analytical comb,
purified 68AB and BX08 prebleed and testbleed sera at lmg/ml, titration as indicated;
M: molecular weight standards in kDa. A and B, lane 1: 1:50; lane 2: 1:100; lane 3:
1:200; lane 4: 1:300; lane 5: 1:400; lane 6: 1:500; lane 7: 1:750; lane 8: 1:1000;
lane 9: 1:2000; lane 10: no primary antibody; lane 11: 1:50; lane 12: 1:100; lane 13:
1:200; lane 14: 1:300; lane 15: 1:400; lane 16: 1:500; lane 17: 1:750; lane 18:
1:1000; lane 19: 1:2000.
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Figure 3.15. Immunoblot analysis of caspase 2 detection in Jurkat whole cell
extract. 12.5% SDS-PAGE minigel, 200pg whole cell extract run on analytical comb,
purified 68AB and BX08 prebleed and testbleed sera at lmg/ml, titration as indicated;
M: molecular weight standards in kDa. A and B, lam I: 1:50; lam 2: 1:100; lane 3\
1:200; lam 4: 1:300; lane 5: 1:400; lane 6: 1:500; lane 7: 1:750; lane 8 1:1000; lane
9: 1:2000; lane 10: no primary antibody; lane 11: 1:50; lane 12: 1:100; lane 13:
1:200; lam 14: 1:300; lam 15: 1:400; lane 16: 1:500; lane 17: 1:750; lane 18:
1:1000; lane 19: 1:2000.
Both polyclonal anti-caspase 2 antibodies were able to detect endogenous caspase 2
with similar affinity in human Hela and Jurkat cell extracts. 68AB and BX08 testbleed
sera detected a 48kDa protein in HeLa cell extracts at 1:50; 1:100; 1:200 and 1:300
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dilution, while prebleed sera at the same dilutions failed to detect a protein of the
same molecular weight (Figure 3.14 A and B). 68AB and BX08 testbleed and
prebleed sera both detected an additional four lower molecular weight proteins of
approximately 35kDa, 29kDa, 23kDa and 18kDa. Both anti-caspase 2 antisera
detected caspase 2 in Jurkat extracts in up to 1:2000 dilution, indicating higher
expression levels of caspase 2 in Jurkat cells. Prebleed and testbleed sera of antibody
68AB, however, also bound to two lower molecular weight proteins in Jurkat extracts
of approximately 29kDa and 18kDa, whereas prebleed and testbleed sera of anti-
caspase 2 antibody BX08 detected only the lower molecular weight 18kDa bands.
Binding to these nonspecific bands decreased at higher dilutions and was undetectable
at the 1:2000 for prodomain antibody 68Ab and 1:500 dilution for small subunit
antibody BX08, dilutions at which caspase 2 was still weakly detected by both
testbleed sera. Extended incubation with the primary antibody, a higher purified
secondary antibody, increased protein amounts in the blocking buffer and carefully
timed washing steps thus proved to be a requirement to decrease background binding
and ensure caspase 2 detection with both antibodies.
3.2.5. Endogenous caspase 2 detection in human tissue extracts
Additional to the reported expression of caspase 2 in a variety of human cell
lines, Northern blotting data has shown expression of a caspase 2 mRNA in a variety
of human tissues (Wang et al, 1994). In order to characterise the function of caspase
2, soluble tissue extracts were prepared of 11 human tissues, including three different
lung cases and the caspase 2 protein expression pattern was analysed by Western
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Figure 3.16. Immunoblot analysis of caspase 2 expression in 11 human tissues
30(ig sample/lane run on 12.5% SDS-PAGE minigel, transferred to nitrocellulose and
probed with purified polyclonal antisera at 1:100 dilution. M: molecular weight
standards in kDa. A) antibody 68AB; lane 1: cerebrum, lane 2: heart, lane 3: kidney,
lane 4: liver, lane 5: lung (case 387), lane 6: lung (case 388), lane 7: lung (case 396),
lane 8: pancreas, lane 9: prostate, lane 10: skeletal muscle, lane 11: spleen, lane 12:
small intestine, lane 13: testes. B) antibody BX08; lane 1: cerebrum, lane 2: heart,
lane 3: kidney, lane 4: liver, lane 5: lung (case 387), lane 6: lung (case 388), lane 7:
lung (case 396), lane 8: pancreas, lane 9 prostate, lane 10: skeletal muscle, lane 11:
spleen, lane 12: testes, lane 13: small intestine
At antibody dilutions of 1:400 -1:1000, which in previous Western blotting results of
human cell lines showed clear binding to caspase 2, both polyclonal caspase 2
antibodies failed to detect a protein of the correct molecular weight (48kDa) while
antibody 68AB in particular strongly bound to an approximately 18kDa protein which
most likely corresponds to the previously identified protein band in HeLa and Jurkat
cells. At a dilution of 1:300 with variability in binding between different blots and very
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low affinity, detectable only after long exposure of the film to the blot (approximately
40 min), antibody 68AB bound to a protein of about 48kDa in cerebrum, lung and
small intestine protein extracts (Figure 3.16.A), while antibody BX08 detected very
faintly a protein of about 48kDa in cerebrum and lung (Figure 3.16.B). Both
antibodies detected a nonspecific band at 18kDa. Similar results were obtained with
antibodies 16AB and BX03 (data not shown).
The required antibody dilution of 1:300 points to the low affinity of the antibodies, an
observation also found in later experiments with other noncommercial anti-caspase 2
polyclonal antibodies (see chapter 3.6.7.). The data, however, also suggests that
protein expression levels of procaspase 2 are very low in the human tissues analysed
and suggest a potential role of caspase 2 in the brain, lung and small intestine,
although it is impossible to infer function merely from protein expression patterns.
3.2.6. Immunocytochemical detection ofcaspase 2
The ability of the caspase 2 polyclonal antibodies to detect caspase 2 in
immunocytochemistry was tested. Cytospins of exponentially growing non-apoptotic
human Jurkat, HeLa and H9 were prepared and various concentrations (1:10; 1:20;
1:30; 1:50 and 1:100) of both purified IgG antisera, whole sera and preimmune sera
were used in the immunocytochemical detection of cytoplasmic procaspase 2 (Figure
3.17.). Negative control cytospins incubated with secondary antibody only were















Figure 3.17. Immunocytochemical analysis of caspase 2 expression in H9 cells
with polyclonal anti-caspase 2 antibodies. Cytospins H9 cells were incubated with
purified polyclonal anti-caspase 2 fragment 1-3 antisera and pre-immune sera at
indicated dilutions, secondary swine anti-rabbit HRP coupled antibody (1:100
dilution), visualisation with DAB; magnification 400x. PB = prebleed, TB = testbleed.
Panel A : TB BX08 1:100; panel B.PB BX08 1:100; panel C. TB BX08 1:200; panel
D: PB BX08 1:200; panelE.TB68AB 1:100; PB 68AB 1:100.
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No specific staining relative to the prebleed control was observed with any of the
antibodies. H9 cytospins probed with purified BX08 testbleed serum at 1:100 dilution
showed cytoplasmic immunostaining (Figure 3.17., panel A) with identical staining
pattern at the same dilution purified BX08 prebleed sera (Figure 3.17, panel B). This
cytoplasmic prebleed staining was much reduced at 1:200 dilution (Figure 3.17. panel
D) but testbleed sera at the same dilution also showed no staining (Figure 3.17. panel
C). 68AB testbleed/prebleed (panels E and F) gave similar results with further serum
dilutions resulting in loss of staining of both test- and prebleeds (data not shown).
Immunocytochemical analysis of HeLa and Jurkat cells gave identical results. Both
polyclonal antibodies from all four rabbits thus failed to detect caspase 2 in cytospins
of all three cell lines which suggests that either both antibodies require a linear
denatured epitotope or that the binding to caspase 2 is overshadowed by the
nonspecific binding of the antibodies to the 29kDa and 18kDa protein bands. In
contrast immunocytochemical experiments with commercial anti-caspase 2 antibodies
demonstrated high levels of a cytoplasmic protein in all three human cell lines (see
chapter 3.3.3., Figure 3.19.). The polyclonal anti-caspase 2 antibodies were,
nevertheless, tested for their ability to detect a product in tissue sections.
3.2. 7. Immunohistochemical detection ofcaspase 2
Immunohistochemical analysis of paraffin embedded human tissues, including
colon, liver, pancreas, tonsil and thymus was carried out with both anti-caspase 2
polyclonal antibodies (data not shown). Comparison of both purified and non-purified
prebleed and testbleed sera staining showed identical results: none of the polyclonal
sera was able to detect caspase 2. These results confirmed the unsuitability of all
polyclonal antisera raised against recombinant caspase 2 polypeptides in both the
immunohistochemical and immunocytochemical detection of caspase 2. Other non¬
commercial anti-caspase 2 antibodies do, however, also give very poor results in
immunohistochemistry (J.Yuan, personal communication).
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In summary, the attempt to raise antibodies to fragment 3 produced no satisfactory
reagents, probably because the immunogen was poor in concentration of the
appropriate caspase 2 peptide and was heavily contaminated with bacterial proteins.
In contrast two antisera, were raised against successfully purified recombinant caspase
2 polypeptides to which the rabbits showed a strong immuneresponse. Using a
standard Western blotting protocol both antibodies bound non-specifically to a variety
of protein bands potentially including procaspase 2. Under altered conditions designed
to enhance binding of low affinity antibodies, both fragment 1 (prodomain) and
fragment 2 (small subunit) antibodies successfully detected procaspase 2 in
nonapoptotic HeLa and Jurkat cell extracts and bound specifically to procaspase 2,
albeit with weak affinity in Western blotting of tissue extracts. Both polyclonal anti-
caspase 2 antibodies failed in immmunohistochemical- and immunocytochemical
detection of caspase 2 and thus could not be used to investigate its subcellular
localisation, relative levels of expression and distribution in tissues. Despite these
limitations, the usefulness in Western blotting of the antibodies raised against
fragments 1 and 2 permitted their application to the analysis of caspase 2 activation in
apoptosis (chapter 3.6.7.).
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3.3. CHARACTERISATION OF COMMERCIAL ANTI-CASPASE 2
MONOCLONAL ANTIBODY
3.3.1. Determination ofcommercial antibody specificity
Whilst the experiments with the fragment 1, 2 and 3 antibodies were
proceeding, two anti-caspase 2 antibodies became available commercially, an anti-
peptide polyclonal anti-caspase 2 antibody (Santa Cruz Biotechnology) and a
recombinant polypeptide anti-caspase 2 monoclonal antibody (Transduction
Laboratories) (see Appendix 2, Figure 3. Antigen for caspase 2 polyclonal and
monoclonal antibodies). The availability of the commercial antibodies suggested an
alternative route to meet the initial aims of this thesis. In order to test these
commercial antibodies for their affinity and specificity both antibodies were applied in
Western blotting analysis of HeLa extracts for their ability to detect caspase 2
proenzyme (Figure 3.18 ).
M 1 2
Figure 3.18. Immunoblot analysis of caspase 2 expression in HeLa cells. HeLa
whole cell protein extracts (1 OOpg/lane) run on 12.5% SDS-PAGE (large gel). M:
position of prestained molecular weight markers indicated in kDa. Lane 1: strip of
membrane probed with caspase 2/ICH-li,/s polyclonal antibody at 1:100 dilution, lane
2: strip of membrane incubated with caspase 2 monoclonal antibody at 1:1000
dilution
The two anti-caspase 2 antibodies, both claimed to be caspase 2 specific, tested on the
same Western blot detected two different protein bands in HeLa protein extracts with
a molecular weight difference of approximately 3-4kDa. The Transduction
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Laboratories monoclonal anti-caspase 2 antibody at 1:1000 dilution bound to a
protein with an apparent molecular weight of approximately 45-46kDa, whereas the
Santa Cruz anti-caspase 2 at 1:100 dilution bound to a larger protein of approximately
46-49kDa. A spokesperson from Transduction Laboratories indicated that a variety of
unspecified further tests had been carried out and confirmed that the monoclonal anti-
caspase 2 antibody was caspase 2 specific, whereas the polyclonal Santa Cruz
Biotechnology antibody was subsequently temporarily withdrawn from the market. In
subsequent immunoblot analysis of caspase 2 expression the commercial anti-caspase
2 monoclonal antibody supplied by Transduction Laboratories was thus used.
Raised against a large proportion of the caspase 2 protein (see Appendix 2, Figure
3.A) the antibody might in theory recognise either the large or the small subunit
present in both pro- and active enzyme or it could bind to the linker region lost upon
procaspase 2 activation. In order to determine whether the antibody recognised active
caspase 2 large or small subunits, it was tested in Western blotting analysis for its
ability to bind to any of the three recombinant caspase 2 fragments described in
chapter 3.1 or the recombinant caspase 2 large and small subunits (provided by D.W.
Nicholson from Merck Frosst) (data not shown). The commercial antibody failed to
detect any of the three recombinant caspase 2 fragments and both the large and the
small recombinant caspase 2. This surprising result might have two explanations.
First, as the Transduction Laboratories antibody was raised against a recombinant
polypeptide extending from amino acid 225-401, it is possible that the epitope
detected lies in a region not included in any of the tested polypeptides. This would
locate this epitope to the linker region between the large and the small subunit (amino
acids 316-336). Alternatively, the Transduction Laboratories antibody might itself
have an inappropriate specificity.
3.3.2. Caspase 2 expression in four human cell lines
Non-apoptotic whole cell extracts of four human cell lines, including Jurkat
and H9 (human T leukaemia cell lines), HeLa (cervical carcinoma) and Priess (a DR4
homozygous EBV transformed B cell line), were prepared in order to analyse levels
of caspase 2 expression by Western blotting (Figure 3.19.). Jurkat, HeLa and H9 cells
were chosen because of their reported high expression of various caspases (see
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chapter 1.6.1), whereas human Priess B cells are of particular interest because of the
potential role of caspase 2 in B cell apoptosis (Bergeron, unpublished data).
Figure 3.19. Immunoblot analysis of caspase 2 expression in four human cell
lines. Whole cell protein extracts were prepared, quantitated, were subjected to SDS-
PAGE (12.5% minigel) and blotted onto nitrocellulose membranes. All membranes
were probed with anti-caspase 2 monoclonal antibody at 1:750 dilution. M: prestained
molecular weight markers indicated in kDa. A-D). Lane 1 15pg; lane 2: lOpg; lane
3: 5pg; lane 4. lpg ofwhole cell protein extract was run. A) titration of Jurkat whole
cell protein extract, B) titration of H9 whole cell protein extract, C) titration of HeLa
whole cell protein extract; D) titration of Priess whole cell protein extract.
In all four cell lines a protein band of an apparent molecular weight of 46kDa was
detected by the monoclonal anti-caspase 2 antibody, corresponding approximately to
the predicted size of caspase 2 of 48kDa High expression of the detected protein was
found in all four cell lines. The monoclonal antibody appeared to have a high affinity
for this protein, being able to detect it in as little as lpg whole cell extract.
3.3.3. Immunocytochemical caspase 2 detection in three human cell lines
In order to analyse the subcellular localisation of caspase 2, cytospins of
exponentially growing non-apoptotic Jurkat, HeLa and H9 were prepared and
analysed by immunohistochemical staining (Figure 3.20 ).
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The anti-caspase 2 monoclonal antibody showed exclusively cytoplasmic staining in
all three cell lines (Figure 3.20., panels A, C and E). Staining intensity varied
depending on the cell density of the cytospin and was strongest in the H9 cytospin
(Figure 3.20. panel E).
In summary, a commercially available monoclonal antibody raised against caspase 2
(Transduction Laboratories) was shown to bind strongly to a 45-46kDa protein in
FleLa, Jurkat, H9 and Priess cell lines, and detected a cytoplasmic protein in
immunocytochemical preparations of these cells. Although this suggested the
monoclonal antibody could be a useful reagent, there remains some concern about its
specificity: unlike the polyclonal antibodies described in section 3.2., it does not bind
in Western blots to purified peptides covering all but 20 amino acid in recombinant
caspase 2 of the monoclonal antibody immunogen. Moreover, the polyclonal
antibodies and another commercial antibody to caspase 2 identify a protein in human
cell extracts of perceptibly larger molecular weight (46-48kDa) in comparison with
the Transduction Laboratories monoclonal antibody
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Figure 3.20. Caspase 2 immunocytochemical staining in three human cell lines.
Cytospins incubated with anti-caspase 2 antibody at 1:30 dilution, secondary rabbit
anti-mouse HRP coupled at 1:100 dilution, detection with DAB. Negative control
slides were incubated with secondary antibody only. Phase contrast microscopy,
magnification 400x. Panel A: Jurkat cells incubated with anti-caspase 2 antibody;
panel B Jurkat negative control cytospin; panel C. HeLa cells incubated with anti-
caspase 2 antibody; panel D. Hela negative control; panel E. H9 cells incubated with
anti-caspase 2 antibody; panel F H9 negative control.
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3.4. USE OF COMMERCIAL ANTIBODIES TO STUDY THE DISTRIBUTION
OF CASPASE 2 INHUMAN TISSUES
3.4.1. Analysis ofcaspase 2 expression in human tissue extracts
Despite the reservations over specificity, the strong reactivity of the
Transduction Laboratories antibody in Western blotting and immunocytochemical
preparations made it an attractive reagent with which to study caspase 2 distribution
in healthy and diseased human tissues. Accordingly, the antibody the antibody was
applied to Western blotting of extracts prepared from a variety of normal human
tissues and to paraffin embedded sections of human tissues. Soluble protein extracts
were prepared, including three different lung tissue extracts, and were analysed by
Western blotting for levels of caspase 2 expression (Figure 3.20 ). In parallel, all 13
tissues extracts were analysed in Coomassie stained SDS-PAGE gels to confirm equal
protein loading and lack of obvious protein degradation (Figure 3 .21.)
Ml 2 3 4 5 6 7 8 9 10 11 12 13
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Figure 3.21. SDS-PAGE analysis of human tissue extracts. Soluble protein
extracts of 13 human tissues were prepared, normalised for protein content
(15|ig/lane), subjected to SDS-PAGE (12.5% minigel), fixed and stained with
Coomassie blue. M. molecular weight standards in kDa. Lane 1. cerebrum; lane 2:
heart; lane 3: kidney; lane 4. liver; lane 5. lung (case 387); lane 6: lung (case 388);
lane 7: lung (case 396), lane 8. pancreas; lane 9: prostate; lane 10. skeletal muscle;
lane IT. small intestine; lane 12: spleen; lane 13: testes.
The Coomassie stained SDS-PAGE gel of the 13 human tissue protein extracts
showed that equal amounts of total protein were loaded on the gel and samples were





Figure 3.22. Immunoblot analysis of human tissues using the Transduction
Laboratories monoclonal antibody to caspase 2. Soluble protein extracts were
prepared from human tissues, normalised for protein content (15pg/lane) and
subjected to SDS-PAGE (12.5% minigel), transferred to nitrocellulose and incubated
with 1:750 dilution of anti-caspase 2 monoclonal antiserum. M: molecular weight
markers in kDa. Jurkat whole cell extract (15|ig) was run as a positive control on
each blot. A) Immunoblot of 13 human tissue protein extracts. Lane 1: Jurkat extract;
lane 2: cerebrum; lane 3: heart; lane 4. kidney; lane 5: liver; lane 6: lung (case 387);
lane 7: lung (case 388), lane 8: lung (case 396); lane 9: pancreas; lane 10: prostate;
lane 11: skeletal muscle; lane 12: small intestine; lane 13: spleen; lane 14: testes. B)
Immunoblot of pancreatic protein extract at various concentrations. Lane 1: 15pg
Jurkat extract; lane 2: 20pg; lane 3. 15|ig; lane 4: 10pg; lane 5: 5pg pancreatic
extract
A protein with a molecular weight of around 46kDa was identified in all tissues
analysed, although the relative levels varied between tissues (Figure 3.22.A). The
highest levels were found in cerebrum, kidney, liver, lung (case 386), prostate,
skeletal muscle, small intestine, spleen and testes, whereas expression was slightly
lower in heart, pancreas and other lung cases. Titration of pancreatic tissue protein
extract confirmed that the detected protein was present in the pancreas at slightly
lower concentration (Figure 3.22.B).
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3.4.2. Immunohistochemical analysis ofnormal human tissues
The Transduction Laboratories antibody was applied to human tissue sections
from the same human source as the samples of the immunoblot analysis. Various
antigen retrieval methods were explored (data not shown). Optimal staining results
were obtained with microwaved sections; staining was little or absent using untreated
or trypsinised sections. Figure 3.23. shows selected examples of the results achieved
using the anti-caspase 2 monoclonal antibody and Table 3.4. summarises the results.
Negative controls (secondary antibody only) produced negligible staining (data not
shown).
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Figure 3.23. Representative examples of immunostaining in normal human
tissue sections using the Transduction Laboratory antibody to caspase 2.
Microwaved sections incubated with primary anti-caspase 2 monoclonal antibody at
1:30 dilution and secondary rabbit anti-mouse HRP-coupled antibody at 1:100
dilution, visualisation with DAB. Analysis by phase contrast microscopy,
magnification indicated in brackets. Panel A: kidney anti-caspase 2 (200x); panel B
kidney negative control (200x); panel C. spleen anti-caspase 2 (400x); panel D.
spleen negative control (200x).
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Table 3.4. "Caspase 2" immunoreactivity in normal human tissues
Organ/Tissue Structure/Cell type Caspase 2 intensity
Pituitary gland






Collecting tubules Proximal convoluted tubules 3








Bile duct epithelium 1
Lymph nodes/tonsil
Germinal centre Follicular dendritic cells 1
Mantle zone Lymphocytes 1
Squamous epithelium 1
Nervous system
Brain hemispheres and basal ganglia 0
Spinal cord 0
Pancreas
Exocrine Centri-Acinar ducts 1-2
Ductal epithelium 1-2
Endocrine Islets of Langerhans 2




Spleen Marginal zone lymphocytes 2
Thymus Hasselli Corpusdes thymocytes 0
The immunostaining was scored according to the intensity as 0 negative; 1 trace/weak; 2 definite; 3
intense.
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Immunostaining was absent or weak in most tissues, but strong immunoreactivity was
identified in selected cell types - notably the ductular and acinar cells of pancreas,
renal tubular epithelium, and marginal zone lymphocytes in spleen.
3.4.3. Immunohistochemical analysis of chronically inflamed and neoplastic
human pancreas
Following the observations of immunoreactivity in normal pancreas,
immunostaining with the Transduction Laboratory antibody was studied in chronic
pancreatitis and pancreatic carcinoma in order to analyse whether the expression is
modulated by the tissue disease status (Figure 3.24 ). Results presented for normal,
chronically inflamed and cancerous human pancreas was based on multiple
immunohistochemical analysis (7 different cases each) of multiple immunostained
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Figure 3.24. Representative examples of immunostaining in normal, inflamed
and cancerous human pancreatic tissue sections using the Transduction
Laboratory antibody to caspase 2. Microwaved sections incubated with primary
anti-caspase 2 monoclonal antibody at 1:30 dilution and secondary rabbit anti-mouse
HRP-coupled antibody at 1:100 dilution, visualisation by DAB; magnification 200x.
For all tissues examined, the immunostaining procedure was performed in parallel.
Panels A-B: normal pancreas; panels C-D. chronic pancreatis; panel E- F: pancreatic
cancer
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Ductal epithelium 0to 1 OJ
The immnostaining was arbitrarily scored according to the intensity as 0 negative; 1
trace/weak; 2 definite; 3 intense.
In normal pancreas the exocrine cells of the small ducts and centri-acinar ducts
showed cytosolic staining, whereas the epithelial cells lining the pancreatic ducts were
either unstained or contained only weak immunoreactivity. Both the a- and (3-
endocrine cells of the islets of Langerhans stained positive. Expression appeared
enhanced in ductal epithelium in cases of chronic pancreatitis in comparison to normal
and de novo expression was identified in areas of acinar-ductal transformation. In
ductal carcinoma there was widespread but heterogenous expression in malignant
epithelium. Particularly intense staining was evident in malignant glands in
pseudopapillary projections into the gland lumen. In the malignant tumours, apoptotic
cells were identified, and they were either unstained or weakly immunoreactive.
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In summary, the Transduction anti-caspase 2 monoclonal antibody clearly detected a
46kDa protein in Western blotting, immunocytochemistry and immunohistochemistry,
with an apparent tissue specific staining pattern, whereas the anti-fragment 1 and 2
antibodies only very weakly bound to a protein of the predicted molecular weight of
caspase 2 in Western blotting analysis of human tissues extracts and were
nonfunctional in immunohistochemistry. Nonetheless the Transduction Laboratories
monoclonal antibody leaves some confusion about its specificity as the antibody failed
to detect any of the recombinant fragments and recombinant caspase 2 subunits and
bound to a protein of approximately 46kDa, varying from the predicted molecular
weight of 48kDa for procaspase 2.
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3.5. INDUCTION OFAPOPTOSIS INHUMAN CELL LINES
Hitherto in this thesis, the emphasis has been to establish reagents specific for
caspase 2, in order to study the presumptive role of this enzyme in apoptosis. In the
experiments to follow the aim is rather to initiate bona fide apoptosis in cell systems
of interest and observe the impact of this process on the proteins detected by these
reagents. Two lymphoid cell lines are studied, Jurkat T cells and Priess B cells. Jurkat
cells were chosen because the initiation of apoptosis in these cells has been
particularly well-studied by other laboratories and they are known to express the
majority of caspases. Priess B cells were chosen because of the suggested role of
caspase 2 in B cell apoptosis from caspase 2 knock-out studies (see chapter 1.6.3.3).
Three very different stimuli were applied arising in the cytoplasm (staurosporine),
nucleus (etoposide) and the cell surface (Fas). Apoptosis was assessed by
morphological analysis and by immunoblotting analysis of cleavage of PARP, a well
characterised caspase substrate cleaved during apoptosis. Involvement of caspase 2
and 3 was sought from evidence of their proteolysis during apoptosis.
3.5.1. Detection ofapoptosis in Jurkat and Priess cells
To establish the time course of development of apoptosis in Jurkat and Priess
cells, the cells were harvested, following the application of the lethal stimulus, for the
study of apoptotic morphology (Figure 3.25., data shown for Fas-induced cells only).
Morphological confirmation and quantification of apoptosis was assessed by studying
cells, stained with acridine orange, under a fluorescence microscope. Cells with
condensed or fragmented nuclei surrounded by cell membrane, exhibiting bright
fluorescent green nuclear staining were scored as apoptotic. Cells showing shrinkage
but no chromatin condensation, therefore showing a more diffuse fluorescent green
nuclear staining, were scored as normal. Jurkat and Priess cells treated with each of
the apoptotic inducing agents showed the same characteristic changes of apoptosis.
Jurkat and Priess cells with normal cell morphology showed a characteristic opaque
green staining of the nucleus (Figure 3.25., panels A and B), early apoptotic cells
showed cell shrinkage with nuclear condensation visible as fluorescing bright green
nuclei and late apoptotic cells were further condensed in cell size and showed the




Figure 3.24. Fluorescence microscopic analysis of Fas-induced Jurkat and Priess
cells. Cells induced with 200ng/106cell anti-Fas antibody. Photographs of cells were
taken at a 6 hour time point on a fluorescence microscope at 400x magnification.
Panel A : Jurkat cells; panel B Priess cells.
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3.5.2. Concentration dependent induction ofJurkat cell apoptosis by staurosporine
In order to determine the optimal concentration of staurosporine sufficient to
induce apoptosis in Jurkat cells, Jurkat cells were treated with concentrations of
staurosporine up to 5p.M and apoptosis was assessed by fluorescence microscopy
over a 22 hour time course. Figure 3.26. shows the effect of different staurosporine
concentrations on the rate of Jurkat cell apoptosis.
Figure 3.25. Concentration dependent induction of apoptosis by staurosporine.
Jurkat cells were incubated with lpM, 2uM and 5pM staurosporine and were
analysed at the indicated time points for apoptotic morphology, controls received no
treatment.
At all three concentrations staurosporine potently induced apoptosis in Jurkat cells
resulting in about 85-95% apoptotic cells at 6 hours. At a concentration of lpM,
however, a later and more gradual onset of apoptosis was observed with less
apoptotic cells at 2 hours. In order to analyse early apoptotic events with only a small
percentage of the cell population undergoing apoptosis and to be able to compare
those with later time points with mainly apoptotic cell population 1 pM concentration
of staurosporine was chosen for future experiments.
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3.5.3. Time course of induction ofapoptosis in Jurkat and Priess cells with three
different stimuli
Jurkat and Priess cells were induced to undergo apoptosis with etoposide,
anti-Fas antibody and staurosporine. At each time point protein extracts for
immunoblotting were prepared and cell extracts were analysed under a fluorescence
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Figure 3.27. Time course of apoptosis in Jurkat and Priess cells following
incubation with etoposide, anti-Fas antibody and staurosporine. Jurkat and
Priess cells were incubated for up to 12 hours either in medium alone (control) or in
the presence of 50pM etoposide, 200ng/106 cells anti-Fas antibody or lpM
staurosporine (induced). At indicated time points after the addition of the stimulus
aliquots of cell were taken and scored for apoptotic morphology. A) Jurkat cells; B)
Priess cells.
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All three agents induced apoptosis in both cell lines, although with different kinetics
and overall efficiency. Anti-Fas treatment resulted in the rapid induction of apoptosis
(20% apoptotic cells at 1 hour), whereas etoposide and staurosporine treatment only
reached similar values between two and four hours. At the given concentration
staurosporine was the most effective inducing agent rendering about 90% cells
apoptotic at 12 hours in both cell lines, whereas etoposide treatment was much less
effective in inducing apoptosis, particularly, in the case of Priess cells. This indicated
that Priess cells might be more resistant to DNA damage and might require a higher
etoposide dose to reach similar apoptotic values. Control cells for both lines showed
less than 2% apoptosis throughout the study period of 12 hours. All three agents thus
proved to be suitable to study caspase 2 and 3 activation in potentially different
apoptotic signalling pathways.
3.5.4. Analysis ofapoptotic cell morphology by electron microscopy
In order to analyse the detailed apoptotic morphology of apoptotic Jurkat and
Priess cells and to compare morphological changes induced by different apoptotic
stimuli, samples of apoptotic cells were prepared for electron microscopy and
analysed in a transmission electron microscope (Figure 3.28 ).
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Figure 3.28. Electron microscopic analysis of Jurkat and Priess cells. Cells
induced with 200ng/106cell anti-Fas antibody, lpM staurosporine or 50pM etoposide.
Panels A, B and C. apoptotic Jurkat cells, panels D, E and F. apoptotic Priess cells.
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Detailed morphological analysis by electron microscopy of Jurkat and Priess cells
treated with each of the reagents showed the characteristic structural changes of
apoptosis (Figure 3.28., panels A-F). In particular the nuclear changes appeared
identical regardless of the lethal stimulus, including chromatin condensation, usually in
a circumferential orientation. Nuclear pore complexes were degraded only adjacent to
decondensed chromatin and nuclear splitting to multiple fragments was observed with
all stimuli. Cytoplasmic shrinkage with dilation of the endoplasmic reticulum was also
observed with all stimuli. Mitochondrial morphology in early apoptosis was normal.
Occasional cells, however, showed changes more akin to necrosis, with cytoplasmic
changes including degenerate organelles and a distorted nucleus without the extensive
condensation of apoptosis.
3.6.6. Analysis ofPARP cleavage in apoptotic Jurkat and Priess cell extracts
Cleavage of caspase 3, caspase 2 and PARP, the classical caspase 3 substrate
were studied by Western blotting of extracts harvested from Jurkat and Priess cells,
following application of the three lethal stimuli in phase with the morphological
changes. Western blots were probed with a human PARP antibody, which recognises
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Figure 3.29. Immunoblot analysis of PARP cleavage in etoposide, anti-Fas and
staurosporine treated Jurkat and Priess cells. Both human cell lines were treated
continuously with either 50pM etposide, 200ng anti-Fas antibody or lpM
staurosporine and whole cell extracts were prepared at the indicated time points
(hours). 15|ig/lane was subjected to SDS-PAGE (7.5% minigel), transferred to
nitrocellulose and incubated with human anti-PARP monoclonal antibody at 1:750
dilution. The position of the full length PARP (116kDa) and the cleaved large
fragment (89kDa) is indicated by arrows.. Panel A: Jurkat whole cell lysate; panel Ii
Priess cell whole cell lysate.
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PARP was cleaved in both cell lines during apoptosis induced with all three stimuli.
This cleavage correlated closely with the kinetics of appearance of morphology of
apoptosis for all three stimuli (see Figure 2.27.). PARP cleavage was first visible in
both cell lines, at the 0.5h hour time point in Fas-induced apoptosis, corresponding to
approximately 10% morphologically assessed apoptotic cells in culture. PARP
cleavage was longest delayed in etoposide-induced apoptosis, in particular of the
Priess cells, where a faint band corresponding to the cleaved product became,
apparent at 4 hours, again at about 10% apoptosis. This became clearly visible only
after 10 hour treatment corresponding, to approximately 25% apoptotic cells. In
staurosporine-induced apoptosis, PARP cleavage was visible after 3 hour (Jurkat) and
4 hour (Priess) treatment, when approximately 40% of the cells were already
undergoing apoptosis. At no time point following induction with any of the three
stimuli was PARP cleaved to completion corresponding with the fact that throughout
the entire studied treatment period both cell lines retained some non-apoptotic cells.
3.5. 7. Analysis ofcaspase 3 status in apoptotic Jurkat and Priess cell extracts
The kinetics of caspase 3 activation were examined by analysis of procaspase
3 in immunoblots of extracts from Jurkat and Priess cells during the induction of
apoptosis (Figure 3.30 ).
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Figure 3.30. Immunoblot analysis of procaspase 3 in etoposide, anti-Fas and
staurosporine treated Jurkat and Priess cells. Both human cell lines were treated
continuously with 50pM etposide, 200ng anti-Fas antibody or lpM staurosporine and
whole cell extracts were prepared at the indicated time points. 15pg/lane whole cell
extract was subjected to SDS-PAGE (12.5% minigel), transferred to nitrocellulose
and incubated with human anti-caspase 3/CPP32 monoclonal antibody at 1:750
dilution. The position of the proenzyme form of caspase 3 (32kDa) is indicated by an
arrow. The time of preparation of lysates is indicated at the top of each panel. Panel
A: Jurkat whole cell lysate, pane/ B: Priess cell whole cell lysate
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In control cell lysates of both cell lines the anti-caspase 3/CPP32 monoclonal antibody
reacted with a single band of approximately 32kDa corresponding to the predicted
molecular weight of procaspase 3. During induction of apoptosis in both cell lines and
with all three stimuli procaspase 3 levels decreased to low or undetectable amounts: at
30 min in Fas induced apoptosis, at 3 hours in staurosporine treated cells and 5 hours
in etoposide treated cells. For each stimulus and in both cell lines this marked
decrease in procaspase 3 level correlated closely with the percentage of total
apoptosis induced by each stimulus (see Figure 3.27.) and the occurrence of the
PARP cleavage (see Figure 3.29.). The results therefore suggest activation of caspase
3 by cleavage in both cell types by all three stimuli. Lower molecular weight
fragments, corresponding to expected cleaved caspase 3 subunits of 17kDa and
12kDa, were not identified, even after prolonged exposure of the blots. Failure to
detect this cleavage product may result from differential stability of proenzyme and
cleaved subunits within the apoptotic cell. It should be also noted, however, that many
low molecular weight proteins are poorly retained on nitrocellulose filters (due to a
faster transfer than higher molecular weight proteins), which could contribute to the
inability to detect the 17kDa and 12kDa caspase 3 subunits by immunoblotting and
this also could contribute to the difficulty in their detection. However, it is also
possible that the epitope detected by this monoclonal antibody lies within the
prodomain: Transduction Laboratories are unable to provide any information
regarding the antibody epitope (see Appendix 2, Figure 4. Antigen for caspase 3
monoclonal antibody).
3.5.8. Analysis ofcaspase 2 status in apoptotic Jurkat and Priess cell extracts
The previous results have demonstrated evolution of apoptosis in terms of
caspase 3 activation and caspase substrate cleavage. To assess the status of caspase 2,
and at the same time examine the credentials of several antibodies raised against it, the
same extracts were therefore used in Western blotting analysis with the Transduction
Laboratories anti-caspase 2 monoclonal antibody (Figure 3.31), two further
polyclonal anti-caspase 2 antibodies obtained from the laboratories of J. Yuan and
D.N. Nicholson (Figures 3.32. and 3.33.) and the two polyclonal antibodies (to
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caspase 2 fragment 1 and 2) described in sections 3 .1. and 3 .2. of this thesis (Figures
3.34. and 3.35 ).
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Figure 3.31. Immunoblot analysis of procaspase 2 in etoposide, anti-Fas and
staurosporine treated Jurkat and Priess cells (monoclonal anti-caspase 2
antibody). Both human cell lines were treated continuously with either 50pM
etoposide, 200ng anti-Fas antibody or 1 pM staurosporine and whole cell extracts
were prepared at the indicated time points. 15pg/lane whole cell extract was subjected
to SDS-PAGE (12.5% minigel), transferred to nitrocellulose and incubated with
human anti-caspase 2 monoclonal antibody at 1:750 dilution. The position of the
proenzyme form of caspase 2 is indicated by an arrow. The time of preparation of
lysates is indicated at the top of each panel. Panel A: Jurkat whole cell lysate, paneI
B. Priess cell whole cell lysate.
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With all three stimuli and in both cell lines the 46kDa protein detected with the
Transduction Laboratories anti-caspase 2 monoclonal antibody remained unchanged
in quantity or molecular weight during the time course of apoptosis. No consumption
of the detected protein band occurred during apoptosis with any of the three stimuli
under conditions in which caspase 3 was clearly activated, PARP cleavage occurred
and the molecular changes of apoptosis were evident (see Figures 3.27., 3.29. and
3.30.).
In contrast when the same cell lysates were analysed by immunoblotting for levels of
procaspase 2 and caspase 2 subunits with two polyclonal anti-caspase 2 antibodies
supplied by J. Juan and D.W. Nicholson (Figure 3.32., results shown for Fas induced
apoptosis only) substantially different results were obtained which were further
confirmed by new data obtained with the original 68AB/fragment 1 (prodomain) and
BX08/fragment 2 (small subunit ) anti-caspase 2 polyclonal antibodies (Figures 3.33.
and 3.34 ).
The polyclonal anti-caspase 2 antibodies provided by J.Yuan and D.W. Nicholson
have been shown to bind to the full length procaspase 2, the large pi8 subunit and 32-
33kDa cleavage intermediate which either consists of the prodomain plus the large
p 18 subunit or the large subunit together with the small p 12 subunit and the linker

















Figure 3.32. Immunoblot analysis of caspase 2 levels in anti-Fas treated Priess
cells with two polyclonal anti-caspase 2 antibodies. Priess cells were induced with
200ng anti-Fas antibody or 1 pM staurosporine, whole cell extracts were prepared at
the indicated time points. 15pg/lane whole cell extract was subjected to SDS-PAGE
(12.5% minigel), transferred to nitrocellulose and incubated with A) human anti-
caspase 2 polyclonal antibody at 1:2000 dilution (D.W Nicholson) and B) human
anti-caspase 2 polyclonal antibody at 1:3000 dilution (J. Yuan). The positions of the
proenzyme form of caspase 2 (48kDa) and activated enzyme are indicated by arrows.
The time of preparation of lysates is indicated at the top of each panel. M: prestained
molecular weight standards indicated in kDa.
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Both polyclonal anti-caspase 2 antibodies proved to have a very low affinity towards
caspase 2 and the recommended protocols reflected this. In Fas induced Priess B cells
both antibodies were able to detect a protein band of approximately 48kDa
corresponding to the predicted molecular weight of procaspase 2. During the ten hour
time course this band decreased in intensity correlating with the appearance of two
lower molecular weight bands of approximately 32kDa and 17kDa, which
approximately correspond to caspase 2 large subunit (18kDa) and to a caspase 2
cleavage intermediate of 32kDa. These potential caspase 2 subunits were detected by
the anti-caspase polyclonal antibody (D.W. Nicholson) at the 1 hour time point
(Figure 3 .32.A) at which the level of procaspase 2 band was reduced. These findings
were confirmed in immunoblot analysis with the other anti-caspase 2 polyclonal
antibody (J. Yuan) (Figure 3 .32.B). A slight decrease of procaspase level is detectable
from the 2 hour time point onwards, with potential caspase 2 cleavage intermediate
and large subunit weakly detected in the 1 hour Fas extract and a stronger band visible
in the 2, 4 and 6 hour extracts.
Western blotting analysis of staurosporine induced Jurkat and Priess cell extracts with
both non-commercial anti-caspase 2 antibodies also suggests caspase 2 activation and
proenzyme consumption (data not shown). Binding of both antibodies to procaspase 2
was much reduced in Jurkat and Priess whole cell protein extracts, which had
previously been thawed and refrozen (2-4 times) and no binding to the active enzyme
subunits was detectable in those extracts, pointing to the instability of the caspase 2
subunits.
These two polyclonal antibodies were subsequently tested by Western blotting
analysis for their ability to detect any of the three recombinant caspase 2 fragments
and the caspase 2 subunits provided by D.W. Nicholson (data not shown). Both anti-
caspase 2 polyclonal antibodies bound to the large (pi8) caspase 2 subunit but failed
to recognise the prodomain or the small subunit. On the basis that both antibodies do
not bind to the small subunit of caspase the 32-33kDa intermediate processing
product of caspase 2 was believed to be the prodomain plus the large subunit,
confirming previously published procaspase 2 processing (Li et a/, 1997).
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To further examine whether caspase 2 is activated in Jurkat cells induced to undergo
apoptosis with etoposide (50g.M) and staurosporine (1 pM), whole cell lysates were
prepared over an eight hour time course and subjected to Western blotting analysis
using the two polyclonal antibodies raised against fragment 1/prodomain (68AB)
(Figure 3.34.) and fragment 2/small subunit (BX08) (Figure 3.35.).
In this experiment Jurkat cells induced with staurosporine were approximately 85%
apoptotic at the 8 hour time point, a figure closely similar to that obtained earlier (see
Figure 3.31), while the Jurkat cells induced with etoposide were only 55% apoptotic
at the 8 hour time point, showing about 25% less apoptosis than a previously
established 8 hour average in Jurkat cells (see Figure 3.31). Control cells in both
experiments showed less than 2% apoptosis. Whole cell extracts from both
experiments were analysed for caspase 3 cleavage (Figure 3.33.) In staurosporine
treated Jurkat cells a reduction in procaspase 3 levels corresponding to caspase 3
activation was visible at the 4 hour time point, was further reduced at 6 hours and
nondetectable at the 8 hour time point (Figure 3.33.A). In Jurkat cells treated with
etoposide a slight reduction in procaspase 3 levels was apparent at 8 hours




Figure 3.33. Immunoblot analysis of caspase 3 activation in staurosporine and
etoposide treated Jurkat cells. Jurkat cells were induced with lpM staurosporine
(A) or 50|4M etoposide (B), whole cell extracts were prepared at the indicated time
points. 30|ig/lane whole cell extract was subjected to SDS-PAGE (12.5% minigel),
transferred to nitrocellulose and incubated with anti-caspase 3 monoclonal antibody at
1:750 dilution (Transduction Laboratories) The positions of the proenzyme form of
caspase 3 (32kDa) indicated by an arrow. The time of preparation (in hours) of lysates














Figure 3.34. Immunoblot analysis of caspase 2 levels in staurosporine and
etoposide treated Jurkat cells. Jurkat cells were induced with lpM staurosporine
(A) or 50p.M etoposide (B), whole cell extracts were prepared at the indicated time
points. 30|ig/lane whole cell extract was subjected to SDS-PAGE (12.5% minigel),
transferred to nitrocellulose and incubated with 68AB/fragment 1 anti-caspase 2
polyclonal antibody at 1:300 dilution The positions of the proenzyme form of caspase
2 (48kDa) and activated enzyme are indicated by arrows. The time of preparation (in
hours) of lysates is indicated at the top of each panel. M: prestained molecular weight
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Figure 3.35. Immunoblot analysis of caspase 2 levels in staurosporine and
etoposide treated Jurkat cells. Jurkat cells were induced with lpM staurosporine
(A) or 50(j.M etoposide (B), whole cell extracts were prepared at the indicated time
points. 30pg/lane whole cell extract was subjected to SDS-PAGE (12.5% minigel),
transferred to nitrocellulose and incubated with BX08/fragment 2 anti-caspase 2
polyclonal antibody at 1:300 dilution The positions of the proenzyme form of caspase
2 (48kDa) and activated enzyme are indicated by arrows. The time of preparation (in
hours) of lysates is indicated at the top of each panel. M: prestained molecular weight
standards indicated in kDa.
Western blotting analysis with the prodomain/fragment 1 anti-caspase 2 antibody
68AB shows clear consumption of procaspase 2 in staurosporine induced Jurkat cells
at the 4 hour time point (Figure 3.33.A). Procaspase 2 levels are further reduced at
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the 6 and 8 hour time points and this reduction in procaspase 2 levels closely
correlated with the appearance of an additional band at approximately 32kDa, which
was already visible at 2 hours and most likely represents a caspase 2 cleavage
intermediate. This 32kDa band probably consists of the prodomain and the large
subunit since previous results have shown that this antibody does not cross-react with
the large or the small subunit (see Figure 3.11.) but only detected the prodomain. In
etoposide treated Jurkat cells the antibody also detects this 32kDa processing
intermediate of caspase 2 at 4 hours even though procaspase 2 levels, similarly to
procaspase 3 levels, are not markedly reduced (Figure 3.34.B). The antibody also
detected two additional protein bands at approximately 29kDa and 18kDa, which are
previously identified non-specific bands and are not part of the caspase 2 locus (see
Figure 3.15).
Western blotting analysis with the small subunit/fFagment 2 anti-caspase 2 antibody
BX08 also showed clear consumption of procaspase 2 in staurosporine induced Jurkat
cells at the 4 hour time point and further reduction of procaspase 2 levels at 6 and 8
hours (Figure 3.35.A). In etoposide treated Jurkat cells no clear consumption of
procaspase 2 was visible (Figure 3.35.B), however, induction of apoptosis with both
inducing agents led to the appearance of a faint 32kDa band which is most likely an
intermediate caspase 2 processing product. Since this polyclonal antibody was raised
against the small subunit of caspase 2 and was shown to not cross-react with other
parts of the caspase 2 molecule and four other caspases (Figures 3.11. and 3.12.) this
32kDa processing intermediate of caspase 2 is likely to consist of the large and the
small subunit. In both etoposide and staurosporine treated Jurkat cells the antibody
failed to detect the small subunit of caspase 2. The antibody also detected an
additional protein band of 18kDa in Jurkat extracts which was previously detected by
both prebleed and testbleed sera and is thus most likely not related to caspase 2 (see
Figure 3.15.).
Two conclusions can be drawn from these results. First, all four non-commercial anti-
caspase 2 antibodies gave different results from the Transduction Laboratories
monoclonal anti-caspase 2 antibody, clearly indicating consumption of the caspase 2
proenzyme, the appearance of processing intermediates and in some cases, the
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appearance of active enzyme subunits. Second, processing of procaspase 2 occurred
in distinct steps with kinetics similar to that of procaspase 3 consumption and the
cleavage of PARP (see Figure 2.29.). All of these antibodies were raised against
recombinant caspase 2 fragments and detected protein bands of the correct size. In
contrast, the Transduction Laboratories antibody failed in all of these aspects, binding
to a protein of lower molecular weight (46kDa instead of the predicted 48kDa)
(Figure 3.18) and failing to detect active enzyme subunits and proenzyme
consumption (Figure 3.31).
In summary, the experiments in this section have shown that caspase 2 is cleaved
during apoptosis of Jurkat and Priess cells induced by three different stimuli. The
kinetics of cleavage are close to those of caspase 3 activation and cleavage of the
caspase 3 substrate PARP. In contrast, the protein recognised by the 'anti-caspase 2'
antibody marketed by Transduction Laboratories is not proteolytically cleaved.
Previous reports that caspase 2 remains inactivated during apoptosis of these and
other cell types derive exclusively from experiments using this monoclonal antibody.
These earlier reports might have suggested the need that caspase 2 operates within
selective apoptotic pathways only, or is sequestered within cells so that it is generally
inaccessible to cleavage during the caspase-driven effector phase of apoptosis.
Although this postulate was interesting, the experiments described here show that it is
unnecessary: caspase 2 is cleaved with other caspases and their substrates in apoptosis
induced by a variety of stimuli.
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4. DISCUSSION
The aim of this thesis was to explore the role of caspase 2 in apoptosis by
using specific anti-caspase 2 polyclonal antibodies and to determine the distribution of
caspase 2 expression using an immunohistochemical approach. Using bacterially
expressed recombinant caspase 2 polypeptides two anti-caspase 2 polyclonal
antibodies were successfully raised and the specificity of those antibodies to the
prodomain and the small subunit of caspase 2 was confirmed. Both antibodies proved
unsuitable for use as immunohistochemical and immunocytochemical reagents and cell
type- and differentiation-specific patterns of caspase 2 expression were therefore not
established. The antibodies, however, proved to be valuable tools in Western blotting
and established that caspase 2 is activated relatively early in apoptosis induced by
etoposide, Fas activation and staurosporine. Information obtained from
immunohistochemistry or Western blotting using the Transduction Laboratories anti-
caspase 2 monoclonal antibody was proved irrelevant to the study of caspase 2, as the
protein detected by this antibody, although showing interesting cytological
associations, was shown not to be caspase 2.
4.1. PRODUCTION OF CASPASE 2 ANTIBODIES
The data presented above show that of the three polypeptides used as
immunogens two led to the production of satisfactory antibodies. Fragment 3 from
the large caspase 2 subunit was produced in inadequate quantities and was heavily
contaminated by bacterial proteins. Fragment 1/68AB (prodomain) and fragment
2/BX08 (small subunit) were satisfactorily induced and gave rise to caspase 2 specific
polyclonal antibodies suitable for use in Western blotting. The fragment 2 antibody
BX08 is also suitable for use in ELISA analysis, however, the potential cross-
reactivity to the small subunit of caspase 4 needs to be considered. The rabbits
immunised with caspase 2 fragment 1 and fragment 2, showed a strong immune
response to the recombinant caspase 2 immunogen. The resulting antibodies appear to
have a relatively low affinity to endogenous caspase 2, but using an adapted Western
blotting protocol, both antibodies successfully detected procaspase 2 and two
different processing intermediates of 32kDa. Fragment 2/small subunit antibody BX08
failed to detect the small subunit of the active enzyme. This may be attributed to the
e■ T
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low affinity of the antibody and to low levels of active enzyme due to short half live in
cells or to technical factors that modulate effective transfer of small fragments in the
semi-dry transfer system used.
Both antisera bound non-specifically to one (BX08) or two (68AB) additional cellular
proteins. These non-specifically bound proteins are evident using preimmune sera and
may contribute to the unsuitability of the antisera for immunocytochemistry and
immunohistochemistry. Other reported caspase 2 polyclonal antibodies, raised against
histidine tagged recombinant caspase 2 fragments, also show non-specific binding (Li
et al, 1997) and their application in Western blotting demonstrate similar weak
antibody affinity to endogenous caspase 2. The two non-commercial anti-caspase 2
polyclonal antibodies provided by D.W. Nicholson and J. Yuan were unable to detect
endogenous caspase 2 in immunohistochemical analysis (Yuan) or had been not tested
(Nicholson). Both antibodies showed, similar to the fragment 1 and 2 anti-caspase 2
antibodies, a high affinity to recombinant caspase 2 polypeptides in particular to the
immunogen. In contrast, affinity of both of these antibodies to endogenous caspase 2
was relatively weak and was further dramatically reduced after freeze/thawing of the
antibodies.
Recombinant bacterial proteins are, however, widely used as antigens in non¬
commercial and commercial anti-caspase antibodies, including antibodies to caspase 1
and 3. One way to increase the affinity of antibodies for an antigen and to reach higher
titers of antibody are multiple rounds of injections. Repeated injections of rabbits
(New Zealand white females) with bacterially expressed recombinant caspase 3
protein resulted in a non-commercial polyclonal anti-caspase 3 antibody with high
affinity to endogenous caspase 3, suitable for both immunoblot and
immuhistochemical analysis (Krajewska et al, 1997). The rabbits were injected with
200(iig recombinant protein and then boosted seven times. The anti-caspase 2
polyclonal antibodies (fragment 1 and 2) were, however, boosted only three times
after the initial immunisation. Repeated injections of the rabbits with recombinant
caspase 2 fragments might have increased the affinity of the anti-caspase 2 antibodies
which in turn could have affected the sensitivity in both immunoblot and
immunohistochemical analysis. Additionally purification of the recombinant proteins
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to homogeneity resulting in an immuneresponse only to recombinant caspase 2
polypeptides, could have potentially increased affinity the to endogenous caspase 2.
Multiple runs of the eluate fractions over the affinity columns together with increased
washing of the columns prior to protein elution could have led to purer recombinant
proteins.
Alternatively some properties of the caspases themselves could influence the affinity
of antibodies to members of the caspase family. The caspase family is a group of
enzymes highly conserved across species with a variety of homologues identified in
mouse, hamster, rat, guinea pig, nematode and insects (Kumar et al, 1994; Casano et
al, 1994; Wang et al, 1997; Ni et al, 1997; VandeCraen et al, 1997; Yuan et al, 1993;
Song et al, 1997; Fraser et al, 1997; Ahmad et al, 1997). Caspases from other species
share approximately 30% amino acid identity and up to 60% amino acid similarity
with the human caspases, with highest region of homology in the amino acid
sequences that form the active enzyme and complete conservation of the active site.
Recent two-dimensional affinity blot analysis of active caspases present in apoptotic
cell extracts of various human cell lines demonstrated that multiple caspase species are
present in apoptotic cells with as many as five different caspase 3 species identified in
apoptotic Jurkat extract (Faleiro et al, 1997; Martins et al, 1997). Some of the
caspase 3 species found are cleaved at distinct sites and differ in their molecular
weight, suggesting multiple or alternative processing of these caspases and/or post-
translational modifications of the processed subunits. However, other species differed
only in their isoelectric points, suggesting post-translational modifications. Potential
covalent modifications include acetylation, glycosylation, hydroxylations,
methylations, phosphorylations, and ADP-ribosylations. Some of these modifications
could modulate the activity and alter structural properties of the caspases. No
published data about the status of post-translational modifications of individual
caspase family members is currently available, two-dimensional analysis does,
however, suggests the presence of side chain modifications. Expressicfn of
recombinant proteins in bacteria will result in unmodified recombinant proteins
lacking post-translational modifications, whereas expression of recombinant proteins
in insect cells, able to carry out side chain modifications, could result in recombinant
r #■
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proteins with higher resemblance to the endogenous protein, thereby potentially
increasing immunodetection of the endogenous protein by the antibody.
4.2. SPECIFICITYOF THE TRANSDUCTION LABORA TOR YMONOCLONAL
ANTIBODY
The Transduction Laboratories anti-caspase 2 monoclonal antibody was raised
against a 19.5kDa recombinant caspase 2 fragment, although, no information on the
identity of the fragment, the immunisation scheme, the antibody epitope or specificity
were available on request. The evidence from several independent experiments carried
out as part of this thesis with this antibody clearly shows that this antibody does not
bind to caspase 2. In immunoblot analysis of seven human cell lines the antibody
detected a protein band of approximately 45-46kDa, a protein with an approximately
2kDa lower molecular weight than the predicted molecular weight of procaspase 2 of
48kDa (Yuan et al, 1994; Xue et al, 1996). Comparative immunoblot analysis with
the Santa Cruz Biotechnology commercial polyclonal anti-caspase 2 antibody, which
detected a protein band of approximately 48-50kDa further questions the claimed
specificity of the Transduction Laboratories antibody.
Western blotting analysis of recombinant caspase 2 large and small subunit and the
recombinant caspase 2 fragments with the Transduction Laboratory antibody further
seriously warrants re-evaluation of the antibody specificity, as the antibody failed to
detect any of the recombinant proteins analysed, whexeas the two non-commercial
polyclonal antibodies (D.W. Nicholson and J. Yuan) and the fragment 1 and fragment
2 antibodies detected recombinant caspase 2 fragments and subunits.
Immunoblot analysis with the Transduction Laboratory monoclonal anti-caspase 2
antibody further revealed no significant change of quantity or molecular weight of the
protein detected during apoptosis in Jurkat and Priess cells in response to three
different stimuli under conditions of activation of apoptosis. Under the same
conditions the two non-commercial polyclonal anti-caspase 2 antibodies (D.W.
Nicholson and J. Yuan) show consumption of procaspase 2 in both cell lines to a
32kDa band and an approximately 18kDa band and polyclonal antibodies 68AB and
BX08 show clear consumption of procaspase 2 and the appearance of the cleavage
intermediate. These observations with all four polyclonal anti-caspase 2 antibodies
thus firmly establish that caspase 2 is activated during apoptosis in Jurkat and Priess
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cells and contradict the conclusion from previous immunoblotting results of the same
extracts with the monoclonal Transduction Laboratory antibody. Other laboratories
using the Transduction Laboratories monoclonal anti-caspase 2 antibody also failed to
show consumption of the detected protein and were also unable to detect any lower
molecular weight proteins corresponding to the active enzyme subunits in HL60 cells
(a human promyelocyte cell line) induced with etoposide (Martins et al, 1997), with
staurosporine (Han et al, 1996), or treated with anisomycin or geranylgeraniol
(Polverino et al, 1997). When blots of the same HL60 apoptotic lysates treated with
either anisomycin or geranylgeraniol were, however, subsequently probed with a goat
polyclonal anti-caspase 2 antibody from Santa Cruz Biotechnology, a band with
similar mobility to caspase 2 decreased in intensity over time with a concomitant
increase in intensity of a band of approximately 12kDa, corresponding to the
predicted molecular weight of the small subunit of caspase 2. Similar results were
obtained using a Santa Cruz Biotechnology rabbit polyclonal antibody against caspase
2, although additional non-specific bands were observed. Following stimulation with
anti-Fas antibody caspase 2 activation was also detected in HL60 cells with the goat
anti-caspase 2 polyclonal antibody (Polverino et al, 1997).
Published data using the Transduction Laboratory monoclonal antibody suggest that
caspase 2 is uncleaved during apoptosis with a variety of stimuli and a time when
other caspases are activated and their substrates are cleaved. This result would have
been of great interest suggesting a complex biology for caspase 2 with potentially
stimulus specific activation. The data presented here, however, show that these results
have a different interpretation: The Transduction Laboratories antibody does not
detect caspase 2. Paradoxically it binds to protein, apparently abundant in the
cytoplasm, which remains stable late in apoptosis.
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4.3. BIOLOGICAL FUNCTION OF CASPASE 2
Caspase 2 is a member of the caspase protease family, the effector proteases in
the apoptotic pathway. It shares a high sequence similarity with other caspase family
members and contains three caspase specific aspartic acid cleavage sites at which the
proform of caspase 2 is cleaved to form the active enzyme, consisting of 12 and
18kDa subunits (Xue et al, 1996). It is present in several cell types, including T-cells,
B-cells and monocytes (Tamura et al, 1995; Han et al, 1996). Structurally caspase 2
has, similar to caspase 9, a long prodomain. This prodomain of caspase 2 contains
protein motifs that mediate association with similar motifs in the NH2-terminus of the
linker molecule CRADD/RAIDD, which shares significant sequence identity with
caspase 2, caspase 9 and CED-3, and also binds to the death domain of RIP. This
suggests that CRADD/RAIDD and caspase 2 may play a role in the transduction of
Fas- and TNF-receptor apoptotic signaling pathway and that caspase 2 might be
activated in response to Fas- and TNF mediated apoptosis (Ahmad et al, 1997; Duan
et al, 1997). The inability ofmutant caspase 2 or various putative dominant-negative
versions of RAIDD to block TNFR-1 induced apoptosis, however, points to an
alternative TRADD-FADD-FLICE (caspase 8) pathway (Duan et al, 1997).
It has been argued that long prodomain caspases, based on their interaction with
signal transduction molecules via their prodomain, may be the first caspases to be
activated which in turn activate other short prodomain caspases (Harvey et al, 1997).
Unlike other caspase family members, including 3, 8 and 10, procaspase 2 has,
however, been shown to be unable to activate any procaspases other than its own
precursor proenzyme (Ahmad et al, 1997). In vitro caspase 2 has been shown to be
cleaved by caspase 3 (Li et al, 1997) and recombinant caspase 8, which directly
cleaves various recombinant caspases, was found to cleave caspase 2 efficiently only
at a relatively late stage (1-2 hours) in the presence of cytosolic extract, suggesting
the requirement for an additional cytosolic component to mediate the activation of
caspase 2 by caspase 8 (Muzio et al, 1997). The observation that caspase 2 is
activated in CTL-mediated apoptosis, but is not activated by granzyme B directly,
also suggests that other factors are required for caspase 2 activation in perforin-
granzyme B killing (Li et al, 1997). Currently unpublished reports of caspase 2/Nedd2
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knock-out mice show that these mice have no apparent phenotype suggesting either
redundancy in the apoptotic pathway or no central role in the initiation of apoptosis
for caspase 2.
Immunological studies of this thesis show that procaspase 2 is activated in Jurkat and
Priess cell apoptosis induced by etoposide, anti-Fas and staurosporine, detectable by a
reduction in procaspase levels, and the appearance of 32kDa cleavage intermediates
and the large subunit. This cleavage and activation of procaspase 2 occur in distinct
steps through a processing intermediate which appears at around the same time as
caspase 3 activation and cleavage of the well characterised caspase substrate PARP.
Activation of caspase 2 has been reported in other cell lines including Jurkat and
HeLa cells induced with anti-Fas antibody, staurosporine and TNFa (Li et al, 1997)
and TF1P.1 cells induced with etoposide (MacFarlane el al, 1997), in which
procaspase 2 is processed in distinct steps. A 32-33kDa doublet, which consists of the
large and the small subunit and the linker of caspase 2, appears simultaneously to
caspase 3 activation and PARP cleavage, but caspase 2 cleavage to the active subunits
occurs only 2-3 hours later than caspase 3 activation (Li et al, 1997). Data from this
thesis, however, suggest that two different processing intermediates are formed, one
consisting of the prodomain plus the large subunit while the other one is formed by
the large and the small subunit and the linker region. Taken together, these results
suggest that the cleavage events that reduce procaspase 2 to its two active subunits
can occur in any order.
The mouse homolog of caspase 2, Nedd2, has also been shown to be activated in
three mouse cell lines (NIH-3T3, Mo7e and BL30A cells) following induction of
apoptosis by interleukin 3 and serum withdrawal, etoposide treatment and y-
irradiation (Harvey et al, 1996; Harvey et al, 1997). Studies of caspase 2 activation in
THP.l cells induced with etoposide give no indication to the time of activation of
procaspase 2 in respect to other caspases or cleavage of caspase substrates
(MacFarlane et al, 1997). Studies of Nedd2 activation in two mouse cell lines,
however, suggest that Nedd2 is activated in response to a variety of apoptotic stimuli
and that this activation occurs earlier than caspase 3 activation. Recent reports from
immunoblot and affinity labeling experiments, which indicate that as many as nine
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caspase genes are simultaneously expressed in certain leukaemia cell lines and that at
least four caspases, including caspase 2, are activated during apoptosis, (MacFarlane
et al, 1997; Martins et al, 1997) leave unclear whether all caspases participate in
apoptotic events.
Observations in different cell lines induced to undergo apoptosis by a variety of
different stimuli thus all demonstrate activation of caspase 2 in apoptosis. Both the
mechanism of caspase 2 activation, the exact identity of the upstream molecule
leading to active caspase 2 and the kinetics of this activation in relation to other
caspases remains unclear. Identification/development of natural or synthetic substrates
is required to further elucidate the role of caspase 2 activation in apoptosis.
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5. MATERIALS AND METHODS
5.1. DESIGNING CASPASE 2 SPECIFIC POLYPEPTIDESAS ANTIGENS
5.1.1.Sequence alignment of caspase family members
The protein sequence of four caspases, human caspase 1/ICE, 2/ICH-l,
3/CPP32/Yama/apopain and C. elegans CED3 were retrieved from the Swiss-Prot
protein databank. The four protein sequences are entered into the protein database
under the following accession numbers caspasel/ICE: P42573, caspase 2/ICH-
1L/S:P42575; caspase 3: P42574. Multiple sequence alignment of the four protein
sequences was carried out by ClustlalW multiple sequence alignment programme
applying the incorporated default setting options. ClustalW is accessible for registered
users through HGMP, Hinxton.
5.1.2. Caspase 2 antibody strategy
Amino acid sequences of four caspases were compared and conserved amino
acid sequences between the four proteases were identified. Stretches of amino acid
sequence of least homology to other known caspases and specific for caspase 2
proenzyme, the large pl8kDa and the small pl2kDa subunit were chosen as antigens
to raise caspase 2 specific polyclonal antibodies.
5.2. RNA EXTRACTION
5.2.1. Treatment ofwater and equipmentfor use with RNA
Diethyl pyrocarbonate (DEPC) treated water for RNA work was prepared by
adding DEPC at a final concentration of 0.1% v/v to deionised double distilled water
(ddH20) in a fume hood and small batches were autoclaved. DEPC treated ddH20
was used for the making of all solutions.
A separate set of pipettes designated 'RNA work only' was used for all RNA work,
other items of equipment were either guaranteed 'RNAse-free' by the manufacturer or
immersed over night in DEPC treated water and autoclaved to prevent RNA
degradation by contaminating RNAse.
5.2.2. Isolation of total RNA from HeLa cells
TRIzol Reagent (Life Technologies) was used for the preparation of RNA
from HeLa cells according to the manufacture's instructions. TRIzol is a mono-phasic
solution of phenol and guanidine isothiocynate, and is based on the method developed
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by Chomczynski and Sacchi (1987). Briefly, 6 x 106 HeLa cells were washed twice in
5ml of phoshate buffered saline (PBS) (Appendix 1) and were mixed with 1ml of
TRIzol reagent, lysed by repetitive pipetting and incubated at room temperature for 5
min. 0.2ml of chloroform was added, the mixture inverted several times and then
incubated at room temperature for 2-3 min. The sample was centrifiiged at 13000rpm
in a bench top microfuge (Micro Centaur, MSE) for 15 min at 4°C and the aqueous
phase was recovered. 0.5ml propan-2-ol was added to precipitate the RNA and RNA
was recovered by centrifiigation at 1300rpm for 10 min at 4°C. The supernatant was
discarded and the pellet was washed with 1ml of 75% ethanol in DEPC ddH20, and
centrifuged at 6500rpm for 5 min at 4°C. The ethanol was discarded and the RNA
pellet was dried under the vacuum (Edwards, High voltage vacuum pump) for 3-4
min, prior to resuspension in 50pl of DEPC ddH20. The concentration of total RNA
was estimated by ultraviolet spectrophotometry at 260nm using a Genequant II
RNA/DNA Calculator (Pharmacia).
5.3. REVERSE TRANSCRIPTASE POLYMERASE CHAINREACTION (RT-
PCR)
5.3.1. Reverse transcription
First strand complementary DNA (cDNA) was synthesised from total RNA
using an RNAse H- Moloney Murine Leukaemia Virus Reverse Transcriptase
(Superscript II, Life Technologies) and an oligo (dT) primer (Boehringer). A reaction
mixture of l-2pg of total RNA, lOOng primer (dT)t5 and llpl DEPC ddH20, was
overlayed with 19pl paraffin oil (Boots), heated to 70°C for 5 min and quickly chilled
on ice for 5 min. The reaction mixture was then made up to 20ptl by adding 4pl of 5x
first strand buffer, 2pi 0.1M dithiothreitol (DTT), lpl of lOx mixed dNTP stock
solution (Appendix 1) and 200 units RNAse H- Superscipt, was briefly microfuged,
incubated on ice for 10 min before being placed on a thermal heating block (Ommni-
gene, Hybaid) on the following programme:
37°C for 10 min
42°C for 60 min
50°C for 10 min
94°C for 10 min
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Reactions were placed on ice, diluted with DEPC ddH20 to a final volume of lOOpl
and stored at -20°C. Control reactions were carried out to which no RNA was added.
5.3.2.RT-PCRfor human caspase 2
Total RNA from HeLa, a human cervix epitheloid carcinoma cell line, was
isolated and reverse transcribed as described above and subjected to PCR with
custom-manufactured and cartridge-purified oligonucleotide primers (Cruachem).
Primers were designed to synthesise the whole sequence of caspase 2, oligonucleotide
sequence corresponding to a NH2-terminal protein prodomain fragment (fragment 1),
a COOH-terminal small subunit fragment (fragment 2) and large subunit fragment
(fragment 3). The primers are shown below:
Whole sequence
Forward: 5'> TATACCATGGCCGCTGACAGGGGA <3'
Reverse: 5'> ATACTCGAGAGGGTGTCCTGGGAACAG <3'
Fragment 1
Forward: 5'> GTAACCATGGATCCTCATCATCAGGAA <3'
Reverse: 5'> TATCTCGAGGCCAGAAAGGGTGGTGAGCAA <3'
Fragment 2
Forward: 5'> TATACCATGGAGACTGATCGTGGGGTT <3'
Reverse: 5'> ATACTCGAGAGTGCTGCAGTATTCAGA <3'
Fragment 3
Forward: 5'> ATTACCATGGAAGATGGTCCTGTCTGC <3'
Reverse: 5'> TAACTCGAGCTGAAAAACCTCTTGGAG <3'
All primers incorporate an Nco I (forward) and a Xho I (reverse) restriction
endonuclease site to permit easy cloning. The PCR reaction mixture contained the
following components:
1 0|lx1 of lOx Thermophilic buffer
3pi of 50mM magnesium chloride
2pl mixed dNTP stock solution (Appendix 1)
lpl (lOOng) of each primer
2.5 Units Taq (Thermus aquaticus) DNA polymerase (Life Technologies)
made up to a final volume of lOOpl with autoclaved ddH20
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The mixture was overlaid with 75p.l paraffin oil and amplification was carried out on a
thermal cycler (OmmniGene, Hybaid) according to the following programmes:
PCR programme for whole sequence of caspase 2:




Step 2, repeated 30 times 65°C, 20 sec
55°C, 30 sec
94°C, 30sec
Step 3, repeated once 70°C, 1 min
72°C, 5 min
25°C, 10 sec
PCR programme for caspase fragments 1-3:




Step 2, repeated 30 times 65°C, 20 sec
72°C, 30 sec
94°C, 30 sec
Step 3, repeated once 70°C, 1 min
72°C, 5 min
25°C, 10 sec
1 Opil of RT-PCR products were analysed on a 1% agarose gel in lx Tris-borate
EDTA (TBE) (Appendix 1) as described below. Products were stored promptly at -
20°C.
5.4. ANALYSIS AND PREPARA TION OF PLASMID DNA
5.4.1. DNA quantification
DNA was quantified by spectrophotometry measuring the optical density
(OD) of 1:100 diluted DNA solutions at a wavelength of 260 nm in a Genequant II
RNA/DNA Calculator (Pharmacia) in which an OD26o of 1 is equivalent to a
concentration of 50pg/ml of double stranded DNA. Alternatively DNA quantities
were determined by comparing the fluorescent intensity of DNA samples pipetted
onto ethidium bromide petri dish plates under ultraviolet (UV) light to known
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quantities ofDNA standards. DNA standards in the range of 10-250ng/ml were made
up with either Kilobase DNA ladder (Life Technologies) or Marker V (Boehringer)
diluted in ddH20. Petri dishes were prepared of 1% agarose gel containing 5pg/ml
ethidium bromide; samples pipetted onto the petri dish were left for 10-15 min for
absorption and then placed on an UV transilluminator (Herolab) for estimation of
DNA concentration. DNA purity was assessed on the Genequant by measurement of
the OD26o/28o ratio.
5.4.2 Restriction endonuclease digestion ofDNA
The DNA digestions were set up in sterile microfuge tubes (Eppendorf)
containing a mixture of ddH20, the appropriate restriction endonuclease and the
manufacturer's recommended buffer of the correct ionic strength. All restriction
enzymes were purchased from Boehringer, stored at -20°C and kept in a bench top
Stratacooler (Stratagene) while in use. The required amount of DNA was digested in
a reaction mix containing the restriction endonuclease to an excess of the
recommended activity for the amount ofDNA to be digested (1 unit of enzyme being
the amount required to digest lpg of DNA to completion in 1 hour) in ddH20
containing lOx stock buffer, diluted 1:10 in the final reaction volume. Digestion was
carried out for at least one hour at 37°C or as directed.
5.4.3. Agarose gel electrophoresis ofDNA
Agarose gel electrophoresis was carried out to analyse PCR products and
restriction digests, to characterise plasmids and to purify restriction fragments for
further cloning steps. Preparation of gels and electrophoresis was carried out in Bio-
Rad MiniSub Cells or Anachem Origo H3 gel tanks as described by Sambrook et al
(1989). 0.1 volume of gel loading buffer (Appendix 1) was added to samples and
loaded into wells submerged in TBE electrophoresis buffer. Kilobase DNA ladder
(Life Technologies) or Marker V (Boehringer) was run in parallel and used for sizing
DNA fragments.
5.4.4. Isolation ofDNA fragmentsfrom agarose gels: Gelpurification
Digested DNA fragments were run out on agarose gels, visualised by UV
transillumination and excised from the gels in the smallest possible volume. Fragments
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were purified using the GlassMAX DNA Isolation Spin Cartridge System (Life
Technologies) according to the manufacture's instructions.
5.4.5. Purification ofDNA fragments: Removal of oligonucleotides
To remove primer dimers formed in PCR reactions from PCR products,
reaction mixtures were purified on Quick Spin G-50 Sephadex Columns (Boehringer
Mannheim) according to the manufacture's instructions. Double stranded DNA
fragments of size up to 72 base pairs were retained in the column resulting in
purification of larger DNA fragments. All PCR products were designed with
incorporated restriction Xhol and Ncol endonuclease sites, which after a restriction
digest with the two enzymes, gave compatible ends with the cloning vector. To
remove oligonucleotides from restriction digests, in order to prevent religation of
digested oligonucleotides in ligation reactions, restriction digests of PCR products
were column purified.
5.4.6. Ethanol Precipitation ofDNA
The procedure was carried out as described in Sambrook et al, 1989. Plasmid
DNA was precipitated by the addition of 1/10 volume of 3M NaAc and 2 volumes of
ice-cold absolute ethanol (98% EtOH). If the DNA quantity was very small, i.e. less
then 50ng, lpg of glycogen was added as an inert carrier. The mixture was chilled on
dry ice until viscous or alternatively incubated at -70°C for 30 min. The DNA was
pelleted in a microfuge at 12000g at 4°C for 10 min, the EtOH was discarded and the
pellet was washed with ~0.5ml 70% EtOH. The supernatant was removed and the
DNA pellet was air dried and resuspended in TE, pH 8.0 (Appendix 1).
5.4. 7. Ligation ofcaspase 2 DNA fragments
Following fragment isolation appropriate amounts of fragment for a ligation
reaction were calculated by the following formula according to Sambrook et al, 1989:
x ng PCR product = (v bp PCR product) (50ng vector)
size in bp of vector
Generally 50ng of vector was ligated to approximately an equimolar or 1:2 amount of
insert DNA. RT-PCR products were cloned by direct insertion into pET23d vector
(3663 bp) (Novagen). Maxiprepped circularised vector DNA was linearised in a
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restriction enzyme digestion with Xhol and Ncol to provide compatible ends for the
cloning of the PCR caspase 2 fragments. Both restriction enzymes cut the vector at a
single site releasing a fragment of 80bp which was further cleaved at a single site by
treatment with the restriction enzyme EcoRl. In order to prevent religation in
subsequent ligation reactions, the linearised vector was purified from the cut out
fragments on G50 Sephadex column. The PCR amplified caspase 2 fragments were
also digested with the restriction enzymes Ncol and Xhol to provide compatible
cloning ends followed by G50 Sephadex column purification. lpL of pretreated PCR
product was added to 50ng of linearised pET23d in a 1 Optl ligation reaction containing
3 units T4 DNA ligase and l|iL lOx ligase buffer (Promega). A control ligation
containing no insert DNA was always included to assess the extent of self-ligation.
The reaction components were assembled fresh each time and the reaction was
incubated at 15°C for a minimum of 4 hours or left over night.
5.4.8. Transformation ofcompetent E.coli cells
Transformation reaction were carried out with commercially produced
competent E. coli cells. Competent cells were defrosted on ice and aliquoted into pre-
chilled 1.5ml microfuge tubes. Unused aliquots were snap frozen in a dry ice methanol
bath and stored at -70°C. For each transformation reaction lpL of the ligation
reaction was gently mixed with 20pL XLl-BlueMRF' competent cells (Stratagene)
and incubated on ice for 30 min. Cells were then heat shocked for 45 sec in a 42°C
water bath and placed back on ice for 2 min. 80pL of S O C. medium (Appendix 1),
pre-warmed to room temperature was added to each vial and cells were incubated in a
shaking incubator at 225 rpm at 37°C for 1 hour to allow expression of (3-lactamase
and to confer antibiotic resistance. Controls were provided by parallel transformation
with no DNA (negative control) or with pUC19 DNA (positive control). Transformed
cells which conferred ampicillin and chloramphenicol resistance were then spread onto
selective medium plates (disposable 100mm bacterial culture dish, containing L-broth
(LB) supplemented with 1.2% Bactoagar, containing 34ug/ml chloramphenicol and
50pg/ml ampicillin (Appendix 1). If, in the case of XLl-BlueMRF' cells, blue white
selection was to be used, L-Amp/Choramp plates were spread with lOOpl 20mM
1PTG (isopropyl-(3-D-thio-galactopyranoside, Stratgene) and lOOpl 0.5% X-Gal (5-
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bromo-4-chloro-3-indoyl-(3-D-galactopyranoside, Boehringer) and incubated at 37°C
for 30 min prior to spreading of the transformed cells.
Plates were incubated over night at 37°C. In case of blue white selection plates were
placed at 4°C for a minimum of 2 hours to allow the blue color development. White
(or light blue) colonies were picked as they were an indication of the disruption of the
lacZ a-peptide reading frame in most cases by insertion of the PCR product and
therefore contained recombinant plasmid.
For protein expression the recombinant pET23d plasmid with the correctly inserted
caspase 2 fragment was transformed into E. coli protein expression strain BL21
(DE3) pLysS as described above. Plates with colonies for protein expression were
stored up to 10 days at 4°C after which new transformations had to be set up. Stocks
of transformed cells could not be frozen due to lysozyme expression in BL21pLysS
cells.
5.4.9. Small scalepreparation ofplasmid DNA (Mini-preps)
Plasmid DNA was purified form bacterial cultures for restriction digest
analysis using the Wizard Minipreps DNA purification systems (Promega). Single
colonies were picked from L-Amp and inoculated into 5ml of LB medium containing
the appropriate antibiotic in Falcon 2059 tubes (Becton Dickinson) and were
incubated over night at 37°C in an orbital shaker at 225rpm. In brief, 1.5ml of cells
were transferred into a microfuge tube and the bacteria were pelleted at 13000g for 2
min. The culture medium was discarded and the cell pellet was resuspended in 200|il
cell suspension solution. Cells were lysed by addition of 200pl cell lysis solution,
resulting in denaturation of bacterial protein and chromosomal and plasmid DNA, and
the solution was neutralised from strong alkaline conditions by addition of 200pl
neutralising solution. Addition of neutralising solution results in rapid renaturation of
circular plasmid DNA which is separated from the bulk of denatured proteins,
chromosomal DNA and the SDS by centrifugation at 13000g for 5 min. The cleared
lysate was transferred into a clean microfuge tube and the plasmid DNA was purified
on Wizard minicolumns using a vacuum manifold according to the manufacture's
instructions. Purified plasmid DNA was resuspended in 50pl of TE, pH 8.0 (Appendix
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1). 2-3(J.L of this was used for one restriction digest and was analysed by gel
electrophoresis.
5.4.10. Large scalepreparation ofplasmid DNA (Maxi-preps)
For large scale preparation of plasmid DNA, 500ml of LB medium (Appendix
1), containing the appropriate antibiotic was inoculated with 20pl of miniprep culture
and incubated at 37°C over night (no longer than 16 hours) in a shaking incubator at
225 rpm. Plasmid DNA was purified by anion exchange column chromatography
supplied in kit form by Qiagen according to the manufacture's instructions (Tip-
2500). The concentration and purity of the DNA was estimated as described above.
5.4.11. DNA sequencing
Maxi-prepped plasmid DNA was sequenced according to Sanger et al, 1977,
using a Sequenase Version 2.0 DNA sequencing kit (United States Biochemical) in
order to confirm correctness of the oligonucleotide sequence and an in frame insertion
of the cloned fragment. 5pg of double stranded DNA was diluted in 45ptl ddH20 and
denatured with 5pl of 2M NaOH, 2mM EDTA and incubated for 5 min at room
temperature. The solution was neutralised with 5pi NH4Ac, pH 4.6 and the DNA was
precipitated at -70°C for 30 min with 185pl of absolute ethanol. DNA was pelleted by
centrifugation in a bench top microcentrifuge at 13000g for 10 min at 4°C and the
pellet was washed once with 200pl of ice-cold 70% ethanol, centrifuged as above for
2 min and dried under vacuum for 5 min. The pellet was resuspended in 6pl ddH20
for immediate use or stored dry at -20°C for up to one week. The resuspended DNA
was annealed to 2pmol of primer (T7 upstream primer and Ml3 downstream primer)
in lx Sequenase buffer in a final volume of lOpl at 65°C for 2 min, slowly cooled to
<37°C in a water bath placed on the bench over 15-30 min, placed on ice for 30 sec,
centrifuged briefly and put back onto ice. The annealed template/primer mix was then
labelled at room temperature for 3-5 min with 5pCi (lOOOCi/mmol) of [a-35S]-dATP
in 3.5pl labeling mix plus 2pl of 1:8 diluted Sequenase. 2.5pl of the termination mix
for each of the four dideoxyribonucleotides was aliquoted into separate microfiige
tubes and heated up to 37°C. 3.5pi of the labelling reaction was added to each tube
and the reaction was terminated after 5 min by the addition of 4pi stop solution to
each tube. Samples were stored at -20°C. Prior to running on a sequencing gel
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samples were denatured by heating to 75°C for 5min. 3pl of each reaction was loaded
into wells and run at 70Watts in lx TDE on a pre-run (~1 hour to reach temperature
of 45°C) 6% denaturing polyacrylamide sequencing gel (Appendix 1) using a S2
sequencing apparatus (Life Technologies) and a model 300 microcomputer
electrophoresis power supply. At the end of the run the silicon coated (Gel-Slick)
small plate was lifted off and the sequencing gel was fixed twice with 10% acetic acid,
10% methanol for 5 min, transferred to a piece of 3MM Whatman paper, covered in
plastic film and dried on a model 583 vacuum gel drier (Bio-Rad) for 2 hours at 80°C.
The cling film was removed and the dried gel was incubated with Biomax MR film
(Kodak) in an autoradiography cassette for a minimum of 18 hours. The film was
developed in a Hyperprocessor (Amersham) and analysed on a white light box.
5.5. TARGET GENE EXPRESSION
5.5.1. Induction of target gene expression
For protein expression a single colony was picked from plates up to 10 days
old and inoculated 400ml of LB medium containing 50gg/ml ampicillin and 34pg/ml
chloramphenicol in a 11 Erlenmeyer flask to ensure sufficient aeration. The culture
was incubated with shaking at 37°C and 1ml samples were taken at lh intervals,
analysed on a spectrophotometer (Philips PU8620) at a wavelength of 600nm to
monitor the culture growth. Once an OD6oo between 0.4-1 (ideally 0.6) was reached,
on average after about 8 hours, target gene expression was induced by addition of
0.4mM IPTG (Appendix 1). The incubation was continued for 3 hours to allow
substantial accumulation of target protein followed by harvesting of the culture.
5.5.2. Detection of target gene expression: Analysis of total cellprotein
Immediately before induction a 5o0pl aliquot of control cell sample was taken.
To study the time course of target protein expression after induction, 500pl aliquots
of the culture were taken at 1 hour intervals. Cells were collected by centrifugation at
13000g for 2 min, the supernatant was removed and the cell pellet was resuspended in
lOmM Tris-HCL buffer, pH 8.0 (Appendix 1) and lysed by addition of 50pl of 2x
SDS sample buffer (Appendix 1). DNA was sheared by running the samples through a
syringe with a 25 gauge needle and samples were stored at -20°C. Roughly 50ug of
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protein (equivalent of ~15pl uninduced cells and ~10|_tl induced cells) were analysed
on 15% SDS-PAGE electrophoresis (see below).
5.5.3. Purification of targetproteins: Soluble and insolublefraction
All solutions including the chromatography resin were obtained in kit from
Novagen (pET system). 400ml of induced cell culture was transferred into 50ml blue
cap Falcon tubes and was harvested by centrifiigation at 3400rpm for 5 min in a
Sorvall RT 6000D centrifuge. The supernatant was decanted and the cell pellet was
drained and resuspended in 4ml ice-cold binding buffer in a Falcon tube. Cells were
lysed by 5 freeze/thaw cycles in a dry-ice methanol bath or liquid nitrogen and a water
bath of 16°C with in-between vortexing on a bench top vortexer (Scientific
Industries). At the end of the freeze thaw cycles, samples were homogenised with the
tight pestle in a Wheaton 15ml homogeniser. To purify soluble target proteins, which
remain soluble in the cytoplasm the cell lysate was centrifuged in SWT-60 swing
bucket rotor in a Sorvall ultracentrifuge at 39000rpm for 20 min. The supernatant was
put through a syringe with a 25 gauge needle and filtered through a 45 micron syringe
end filter (Sartorius) to break up any DNA and to prevent clogging of the resin. The
resin was prepared according to the manufacture's instructions (Novagen) and
column chromatography was carried out as described in the manufacture's manual
(Novagen) except twice the amount of all solutions was used due to the increased
culture volume. Insoluble proteins were purified under denaturing conditions by
addition of 6M urea to all solutions including the resin unless stated otherwise, as
described in the manual. Cells were centrifuged as above, the cell pellet was subjected
to 5 freeze/thaw cycles and resuspended in 40ml of ice-cold binding buffer without
urea. The solution was homogenised as above centrifuged at 13000rpm in a Sorvall
SS 34 centifuge for 15 min to collect inclusion bodies and cellular debris while leaving
other proteins in solution. The supernatant was discarded and the cell pellet was
resuspended in 20ml of binding buffer without urea and the homogenisation and
centrifugation was repeated. The pellet was resuspended in 5ml of binding buffer plus
6M urea and incubated on ice for 1 hour to completely dissolve the protein.
Remaining insoluble material was removed by centrifugation as described for soluble
protein purification. Recombinant proteins were then purified by nickel metal
r
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chelating chromatography as described in the manual. Columns were discarded after
five runs of protein purification. Protein concentrations were determined by Bio-Rad
protein assay (see below) and purified samples of known protein concentration were
concentrated using a plastic disposable ultrafiltration device, Vivaspin 15
(Vivascience) with an exclusion size of 5kDa, as described in the operating
instructions.
5.7. PROTEINANALYSIS
5. 7.1. Protein quantification: Bio-Rad assay
Protein concentration were determined using a Bio-Rad protein assay kit as
described in the manufacture's instructions (Bio-Rad) and both micro- and
macroassays were carried out. Bovine serum albumin (BSA), diluted to various
known concentrations was used as standards. Absorbance was read at 595nm on a
Philips PU8620 spectrophotometer using disposable 1ml plastic cuvettes (Bio-Rad)
and a standard curve was prepared each time the assay was performed by plotting the
OD595 reading versus the concentration of the standards. The absorbance of protein
samples of unknown concentration was measured and unknown protein
concentrations were determined by reading from the standard curve.
5.7.2. SDSpolyacrylamide gel electrophoresis (SDS-PAGE)
Discontinuous SDS-PAGE was carried out according to the Laemlli systems




Table 5.1. Running gel and stacking gels recipes
Running gel final concentration (60ml; for ~10 1mm thick minigels, for 2 1.5mm
thick SE600/400 gels)
5% 7.5% 10% 12.5% 15%
Monomer solution 10ml 15ml 20ml 25ml 30ml
4x running gel buffer 15ml 15ml 15ml 15ml 15ml
10% SDS 0.6ml 0.6ml 0.6ml 0.6ml 0.6ml
ddH20 34.1ml 29.1ml 24.1ml1 19.1ml 14.1ml
10% Ammonium persulphate 300pl 300pl 300pi 300pl 300pi
TEMED 20pl 20pl 20pl 20pl 20pl
Stacking gel solution (4% acrylamide; for 2 SE600/400 gels, 1.5mm SE600/400 gel
solution for -10 minigels)
0.75mm 1.5mm
Monomer solution 1.33ml 2.66ml
4x running gel buffer 2.5ml 5.0ml
10% SDS 0.1ml 0.2ml
ddH20 6.0ml 12.0ml
10% Ammonium persulphate 50pl lOOpl
TEMED 5p lOpl
All stock solutions were made up according to the Hoefer protein electrophoresis
guide (Appendix 1). Unstained protein standards were used for Coomassie stained
gels (Life Technologies). Pre-stained molecular weight markers in low and high range
were used for Western blotting transfer (Life Technologies). TEMED
(Tetramethylethylethyenediamine) and bis-acrylamide at a ratio of 29:1 were obtained
from Severn Biotechnology. Minigels were poured in a multicasting tank (Bio-Rad) in
sets of 10-15 and were stored, wrapped up in cling film, at 4°C up for up two weeks.
Large gels were run in a SE 600 Vertical Gel Electrophoresis Unit (Hoefer) and
minigels were run on a SE 250 Minigel Electrophoresis Unit (Hoefer). On average
10-20pg of total protein were run on minigels and 50-80pg were run on large gels.
Samples were typically boiled for 2 min on a heating block (Techne Dri-Block) and
placed on ice until ready for use. Gels were run at 30mAmps per 1.5mm thick gel
until the dye reached the bottom of the gel. Gels were removed from the glass plates,
the stacking gel was cut off and gels were placed in rapid stain fixing solutions
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(Appendix 1) for 10-15 min for a 0.75-1.0mm gel and 30-60 min for a 1.5mm thick
gel. Fixing solution was replaced with rapid Coomassie stain (Appendix 1) and was
shaken slowly for 2 hours to overnight until bands were visible. Staining solution was
replaced with destaining solution (Appendix 1), frequently replaced by fresh solution
until the background was clear. To avoid cracking of gels thicker than 0.75mm and
over 12.5% acrylamide 2% glycerol was added to the final destain solution. Gels (final
gel concentration lower than 12.5%) were dried on a vacuum gel drier (Bio-Rad 583
Gel Drier). Gels were placed onto a sheet of filter paper, the top of the gel was
covered with plastic wrap and the gel was dried for 2 hours at 80°C. Alternatively
gels were air dried in a drying frame using the Dry Ease Gel Drying System (Novex)
according to the manufacture's instructions.
5. 7.3. Preparation ofhuman tissueprotein extracts
Samples of approximately 50mg of frozen tissue were cut off with a
disposable scalpel, transferred to a sterile microfuge tube and thawed on ice in 4
volumes of ice-cold 0 1 M sodium phosphate lysis buffer (Appendix 1). Human
soluble tissue extracts were prepared by homogenisation using an Omni EZ Connect
homogeniser followed by centrifugation at 15000g in a bench top microfuge for 10
min at 4°C, to remove insoluble material. Protein concentrations were determined as
described above and samples were stored at -20°C.
5. 7.4. Whole eel/protein extract preparation
Protein extracts were prepared from 2 x 107 cells, pelleted by centrifugation at
lOOOrpm for 5min, washed once with PBS and lysed in 500pl cell lysis buffer
(Appendix 1). DNA was sheared by putting the extracts through a syringe with a 25
gauge needle. Protein concentrations were determined as described above and
samples were stored at 4°C for immediate use or at -20°C for long term storage.
5.8. WESTERN BLOTTING
5.8.1. Conventional tank blotting
Protein transfer from SDS-PAGE gels to membranes was carried out as
described in the Protein Electrophoresis Guide (Hoefer) (Protein Electrophoresis
Applications Guide, Hoefer Scientific Instruments). In brief, SDS-PAGE gels were
pre-equilibrated for 5-15 min in Towbin transfer buffer (Appendix 1). Nitrocellulose
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membrane (Hybond ECL, Amersham) and blotting paper were cut to size, were
wetted in dH20 and soaked in transfer buffer for 2-5 min. The transfer sandwich using
a Bio-Rad Trans-Blot transfer unit for large gels and a Bio-Rad Mini Protean II unit
for small gels was assembled under buffer to minimise air trapping in the following
order: Grey or clear site of cassette (facing positive electrode)/ prewet sponge/ 2
pieces bf blotting paper/ membrane/ gel/ 2 pieces of blotting paper/ sponge/ black side
of the cassette (facing negative electrode). Large gels were transferred at 400mAmps
for 4-5 hours in the cold room. Minigels were transferred at lOOVolts for 1 hour at
room temperature. Gels were stained in Coomassie blue stain to verify transfer. The
transferred proteins were visualised by staining the membrane for 5-10 min with
Ponceau S (Sigma) for 5-10 min. Excess stain was rinsed off in dH20 before blocking.
When handling nitrocellulose membranes powder-free gloves were worn at all times.
5.8.2. Semi-dry transfer
Semi-dry blotting was performed using a Biometra Fastblot (Biometra Ltd).
Gel, nitrocellulose and paper were treated as described above. Two sheets of blotting
paper (3MM Whatman paper) were placed on the anode (plate electrode on the body
of the Fast Blot), a nitrocellulose sheet was placed on the filter paper, the gel placed
on top of the membrane and one layer of blotting paper was placed on top of the
polyacrylamide gel. The lid (kathode plate) was connected with the body and gels
were transferred at a constant current of 5mAmps per cm2 for 20-25 min for proteins
of 30-50 kDa molecular weight at a gel thickness of 1.0 or 1,5mm. Proteins of 80-120
kDa molecular weight on 0.75mm thick gel were transferred for 30 min. Gels and
nitrocellulose membrane were processed as described above.
5.8.4. Immunodetection
Following Ponceau S staining, blots were placed in blocking buffer (Appendix
1) for 1 hour at room temperature or at 4°C over night, in order to block non-specific
binding sites. The blocking buffer was decanted and blots were placed in primary
antibody. For the initial characterisation of the polyclonal antibodies raised against
oligopeptides of caspase 2/ICH-l serial dilutions of antibody in TTBS plus 5% blotto
(Appendix 1) were made to determine the optimal antibody concentration (see
below). The incubation period was lh at room temperature with agitation.
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Commercial antibodies were diluted in blocking buffer as suggested in each product
description sheet. Anti-CPP32 and Anti-ICH-1 monoclonal antibodies (Transduction
Laboratories) were used at a 1:750 dilution in blocking buffer with 1 hour incubation
period at room temperature. Anti-PARP monoclonal antibody (Biomol) was used at a
1:1000 dilution in blocking buffer with a 2.5 hour incubation period at room
temperature. Alternatively blots were incubated over night at 4°C with all primary
antibodies used. Following primary antibody incubation blots were washed 3x5 min
in TTBS and incubated with the appropriate secondary antibody either swine-anti-
rabbit or rabbit anti-mouse horse radish peroxidase coupled (Dako) at 1:1000 dilution
in blocking buffer for 1 hour at room temperature or over night at 4°C. The antibody
was decanted and blots were washed for 30 min in TTBS with agitation and changes
of wash buffer every 10 min. Immunodetection was by enhanced chemi luminescense
(ECL) provided in kit form and was carried out according to the manufacture's
instruction (Amersham). For miniblots a total 4ml of substrate solution was used, for
large blots 8ml were used. The blots were placed on autoradiography film (Hyperfilm-
ECL, Amersham) in an autoradiography cassette and exposed for 15 sec up to 1 hour,
depending on the signal strength as determined by the amount of target protein
present on the membrane. Films were developed in a Flyperprocessor (Amersham).
Following the initial characrterisation of the polyclonal antibodies, Western blotting
with all polyclonal antibodies was carried out according to the following protocols
(see below).
Western blotting protocol for polyclonal anti-caspase 2 antibody:
• block nitrocellulose membrane 1 hour at room temperature in 10% blotto 0.1%
TTBS (or alternatively at 4°C over night)
• incubate membrane 2 hours in primary antibody 1:300 dilution (anti-fragment 1
and 2 antibodies) or 1:3000 dilution (J. Yuan) in 5% blotto 0.1% TTBS
• wash membrane 3x 10 min in 0.1% TTBS
• incubate membrane for for 1 hour (anti-fragment 1 and 2 antibodies) or 30 min (J.
Yuan) in secondary donkey anti-rabbit HHP coupled antibody at 1:10 000 dilution
in 5% blotto 0.1% TTBS (Pierce)
• wash membrane 3x 10 min in 0.1% TTBS, followed by ECL detection.
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Western blotting protocol for polyclonal anti-caspase 2 antibody:
• block nitrocellulose membrane 1 hour at room temperature in 5% blotto 0.1%
TTBS
• wash membrane in 0.1% TTBS 2x 5 min
• incubate membrane for 1 hour in primary antibody 1:2000 dilution in 5% blotto
0.05% TTBS (D.W. Nicholson)
• wash membrane 3x 5 min in 0.1% TTBS
• incubate membrane for 1 hour in secondary donkey anti-rabbit HRP coupled
antibody at 1:10 000 dilution in 1% blotto 0.05% TTBS (Pierce)
• wash membrane 3x 5 min in 0.3% TTBS
• wash membrane 3x 5min in 0.1% TTBS, followed by ECL detection.
5.8.6. Antibody titrations
To determine the optimal concentration of polyclonal antibodies raised against
caspase 2 oligopeptides, 500pg of HeLa protein extract were run on 12.5% SDS
using an analytical comb without separate wells. Transfer and blocking was carried
out as described above. Miniblots were transferred to a 15 or 21 well multiblotter
(Bio-Rad), wells were rinsed out with TTBS, 1ml of each antibody dilution was made
up and 750pl pipetted into separate wells and incubated for 1 hour. Primary antibody
dilutions were removed by tilting the multiblotter over and letting the solution run
out. Wells were washed separately with three changes of wash buffer, the multiblotter
was disassembled and the blot was washed 3x 5 min in changes of wash buffer.
Immunodetection was continued for the whole blot as described above.
5.8. 7. HPLC and N-terminal amino acid sequencing ofrecombinantpolypeptides
The final purification of the three recombinant proteins by HPLC and amino
acid sequencing was carried out in collaboration with the Welmet Protein
Characterisation Facility, University of Edinburgh. Recombinant caspase 2
oligopeptides were purified by Reverse-phase HPLC according to Hayes et al, 1989.
Fractions form the //Bondapak Cis HPLC column were checked for purity before
being sequenced by using an Applied Biosystems 130A Microbore Separation System
fitted with an Aquapore RP-300 column (7pm particle size; 2.1mm x 30mm) (Applied
Biosystems), that was developed with a linear 8-80% (v/v) gradient of acetonitrile in
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Biosystems), that was developed with a linear 8-80% (v/v) gradient of acetonitrile in
aq. 0.1% (v/v) trifluoroacetic acid and monitored at 220nm. The polypeptides were
subjected to automated sequencing on an Applied Biosystems 477A instrument with a
120A on-line phenylthiohydantoin analyser. Polybrene (2mg) was loaded on to glass-
fibre filter disc, which was then precycled three times before being loaded with
approximately 1.5nmol of the recombinant polypeptide. After Edman degradation the
anilinothiazoline derivatives cleaved from the polypeptide were converted
automatically into more stable phenylthiohadantoin forms and separated on an
Applied Biosystems PTH Ci8 (5pm particle size; 2.1mm x 220mm) column that was
developed with a 0-100% (v/v) linear gradient of acetonitrile. The gradient was
formed by using an aq. 5% (v/v) solution of tetrahydrofuran as solvent A and
acetonitrile as solvent B. Chromatograghy was performed at 55°C and the column
was monitored at 269nm.
5.8.8. Mass spectrometry ofrecombinant polypeptides
The mass spectrum of the three recombinant caspase 2 oligopepetides was
obtained by Matrix-assisted laser desorption/ionisation time of flight mass
spectrometry (MALDI-TOF) using a Voyager Biospectrometry workstation
(PerSeptive Biosystems) calibrated with cytochrome c (12360.5 Dalton).
Approximately 1 pg of recombinant polypeptide in 1 pL elution buffer was embedded
in lpl of liquid matrix consisting of small highly absorbing molecules (SIM (4,5
Dimethoxy-4 hydroxycinnamic acid) and aCyano (a-Cyan-4 Hydroxy cinnamic acid)
at 10 mg/ml in dH20). Matrix embedding was required for absorption of energy from
the laser light and isolation of biopolymers from each other. 1 pL of the sample mix
was then applied to a stainless steel sample probe, dried at room temperature for
about 15 min and loaded into the Mass spectrophotometer for analysis. Energy
transfer to the sample was at a laser wavelength of 337nm with a typical laser
width/duration in the l-100ns range at 26000 extrcation voltage in a 1.2m flight tube.
The transient signal produced was viewed directly on an analog oscilloscope and
stored in a transient two channel digital oscilloscope (bandwith >100Mhz). The




5.9. RAISING OF RABBIT POLYCLONAL ANTISERA
5.9.1. Antigen preparation
For the first and second immunisation 750pg of each recombinant caspase 2
polypeptide in column elution buffer (Appendix 1) was made up to a volume of 750pl
with PBS. This was added to 1.75ml of imject alumn (Pierce) to a total volume of
2.5ml, according to the manufacture's instructions. For the third immunisation (one
rabbit/fragment only) 450pig of each column purified large subunit fragment was run
in three lanes (~150pg/lane) on a 12.5% SDS-PAGE and transferred to nitrocellulose
as described above. Nitrocellulose was stained with Ponceau Red (Sigma) and the
band corresponding in molecular weight to the recombinant polypeptide was cut out,
destained in dH20 in a microfiige tube and dried in a 37°C incubator for 10 min. The
three nitrocellulose strips were dissolved in 300pl dimethyl ethylsulphoxide (DMSO)
to which 300pi PBS was added dropwise under vortexing on a benchtop vortexer.
5.9.2. Immunisation scheme
Four and two weeks prior to immunisation six female black and white Dutch
rabbits were prebleed. 15ml of blood was taken at each point. Two rabbits per
recombinant caspase 2 polypeptide were immunized with 2ml of the immunogen-
alumn mix, injected at two sites (1ml each) subcutaneously near the back of the neck.
10ml of testbleed was taken every two weeks. Eight weeks after the first
immunisation all prebleeds and testbleeds were analysed by Western blotting for
antibody expression. Rabbits were reimmunised as before and 10ml testbleeds were
taken every two weeks for six weeks after the second immunisation. Nine month after
the first immunisation for fragment 1 and 2, six month for fragment 3, one rabbit out
of the two previously immunized which had previously shown a strong immune
response to the recombinant polypeptide (rabbits 68AB, BX08 and 32AB) were
reinjected subcutaneously at one site with 600pl antigen solution and 10ml testbleeds
were obtained four weeks later.
5.9.3. Purification ofantisera
After collection pre- and testbleeds were allowed to clot at room temperature
for 30-60 min and were then kept at 4°C over night to allow the formed blood clot to
contract. The following day samples were spun at lOOOOg at 4°C for 10 min in a
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Sorvall RT600D centrifuge. Clear serum was taken off with a Pasteur pipette,
transferred into 15ml narrow mouth bottles (Nalgene) and stored at -20°C.
Immunoglobulin G fractions were isolated from total serum by Protein A or B
Sepharose Fast Flow chromatography (Pharmacia Biotech). The column was packed
according to the manufacturer's instructions and equilibrated with 20-3Oml 20mM
phosphate buffer (Appendix 1). About 10ml of serum was applied to the column and
allowed to run through. To remove unbound protein the column was washed with 40-
50ml 20mM phosphate buffer and the bound IgG fraction was eluted with
approximately 10 ml of 0.1M glycine pH 3.0 (Appendix 1). Ten eluate fractions of
~lml were collected in microfuge tubes to which 50-1 OOjiil of 1M Tris-HCL, pH 9.0
had been added to neutralise the eluted fractions. The column was regenerated
according to the manufacturer's instructions. Columns were stored at 4°C in 10ml
phosphate buffer containing 1% sodium azide. The amount of protein present in each
fraction was visualised by pipetting 5pL of each fraction onto dry nitrocellulose,
incubating at 37°C for 5 min, staining in rapid Coomassie staining solution (Appendix
1) for ~5 sec, destained in destaining solution (Appendix 1) for 1 min. The
nitrocellulose membrane was dried at 37°C for 5 min and fractions containing protein
(visible as blue dots) were pooled and the pH was adjusted to 6.5-7.5 with 1M Tris
buffer. The amount of protein was quantitated by a Bio-Rad protein assay (see above)
and antibody solutions were diluted to lmg/ml in TBS, pH 7.5 (Appendix 1) and
stored as 500(j.l aliquots at -20°C.
5.10. STANDARD IMMUNOLOGICAL TECHNIQUES
5.10.1. Preparation ofcytospins
Cytospins were prepared for immunocytochemistry from three human cell
lines Jurkat T cells, H9 cells and HeLa cells. Cells were counted on a haemocytometer
(improved Neubauer counting chamber) as described above and diluted in PBS to a
concentration of 3-5 x 105 cells/ml. Cytospin chambers were assembled and inserted
into the cytospin 2 rotor. 100pJL of the cell suspension was pipetted into each
chamber and cytospin chambers were spun for 3 min at 400g in a Cytospin 2 Shandon
centrifuge. The cytospin chambers were dissassembled and the cytospins were air
dried for 5 min, fixed in acetone for 5 min and air dried before storage. Cytospins for
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immediate use were stored at 4°C, for long term storage cytospins were kept at -
20°C.
5.10.2. Preparation offrozen andparraffin embedded tissues
Human tissues were collected at the time of operation for treatment of the
diagnosed disease. In addition human organs were collected from routine autopsy,
where the autopsy was performed less than 12 hours after death to establish cause of
death. Tissues were fixed in buffered formalin for 16 hours and then processed to
paraffin wax in VIP (vacuum impregnating processor). Paraffin embedded sections
were cut on a mycrotom to a thickness of 3 pm.
5.10.3. Antigen retrieval by microwaving or trypsinising
Antigen retrieval of certain antigens, in order to reverse cross-linking caused
by paraffin embedding, was carried out by tiypsinisation or microwaving of paraffin
sections. In the same way as untreated sections, sections for microwaving and
trysinisation were deparrafinised by incubation in xylene (Genta Medical) for 5-10 min
and rehydrated by passing through descending grades of alcohol to H20 (from
adsolute ethanol, to 75%, to 65%, to tap H20). Endogenous peroxidase activty was
blocked by incubating sections for 20 min in 1% hydrogen peroxide solution (Sigma)
(Appendix 1) followed by a 5 min wash in running water. Sections were then
incubated for 20 min at 37°C in 0.1% trypsin solution (Appendix 1) followed by a 5
min wash in running water and a rinse in TBS for 5 min. Alternatively section were
transferred to a microwavable container, immersed in excess citrate buffer (Appendix
1), covered to prevent evaporation, microwaved 3x 5 min at 700Watts, allowed to
cool in buffer for 20 min, followed followed by a 5 min wash in running water and a
rinse in TBS for 5 min. Sections were then used for immunohistochemical analysis.
5.10.4. Immunohistochemistry and immunocytochemistry
All immunohisto- and immunocytochemical staining was carried out in semi-
automated 'Sequenza' (Shandon) wet chamber, which allows staining of up to 50
slides simultaneously. Slides of tissue sections or cytospins were assembled with cover
plates submerged in TBS to stop creation of air bubbles and were transferred into the
sequenza rack. Assembled sections were preincubated with lOOpl of either 20%
normal rabbit serum in TBS (Sapu) or 20% normal swine serum in TBS (SeroTech)
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(depending on the species in which the secondary antibody was raised) to block non¬
specific secondary antibody binding sites. After 10 min preincubation 1 OOpl optimally
diluted primary antibody (diluted in 20% normal serum) was added to each well and
sections were incubated for 30 min at room temperature or over night at 4°C. Primary
antibody was washed off in two changes in 5 min intervals of TBS (sequenza well
filled twice). lOOpL of either swine anti-rabbit or rabbit anti-mouse horse radish
peroxidase (HRP) coupled secondary antibody (Dako) diluted 1:100 in normal serum
was then added to each well and incubated for 30 min, followed by two washes with
TBS as above.
Alternatively sections were incubated with a rabbit anti-mouse unlabelled secondary
antibody (Dako Z259) diluted 1:5 for 30 min, followed by two washes in TBS as
above. Sections were then treated with a secondary mouse alkaline phosphatase-anti
alkaline phosphatase monoclonal antibody (APAAP) (Dako D651) diluted 1:20 in
normal rabbit serum for 30 min, followed by two washes with TBS as above.
5.10.5. Visualisation with DAB
Immunecomplexes of tissue sections or cytospins treated with a HRP coupled
secondary antibody were visualised by incubation for 3-5 min with lOOp.1 3,3-
diaminobenzidine (DAB) (Sigma) substrate solution (Appendix 1). Slides were
washed in two changes in 5 min intervals of TBS (sequenza chambers filled twice),
followed by disassembly of the sequenza chambers and further 5 min wash under
running water. Sections were counter stained for -45 sec in Harris haematoxylin
(Shandon), washed under running water, stained in Scot's tap water substitute for
-45 sec, washed under running tap water, dehydrated by lmin incubation in ascending
grades of ethanol bath (from H20, 65% etnanol, 75% ethanol to absolute ethanol) and
transferred into xylene. Sections or cytospins were then mounted in the fume hood
with pertex mounting medium (CellPath).
5.10.6. Fast Red visualisation
Immunecomplexes of tissue sections treated with an APAAP coupled
secondary antibody were visualised by incubation for 30 min in the dark with 500ptl
Fast Red substrate solution (Appendix 1). Sections were washed and counter stained
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as described for DAB visualisation but were transferred into water and mounted with
aquamount (BDH).
5.10.7. ELISA
Serial dilutions of subunits of four recombinant caspase as well as the three
recombinant caspase 2 oligopeptides were made up in ELISA coating buffer
(Appendix 1) and lOOpl of each solution was added to separate wells of a 94 well
disposable ELISA microtiter plate (Corning). On each plate blanks wells coated with
coating buffer only followed by incubation with secondary antibody were included.
Plates were either coated for 3 hours at room temperature or were left over night at
4°C and the coating buffer was removed by shaking the plate out. Primary antibody
was diluted in antibody dilution buffer (Appendix 1). lOOpl of appropriately diluted
primary antibody was added to each well and incubated at room temperature for 2-3
hours. Antibody solution was removed and wells were automatically washed 3x in
ELISA wash buffer (Appendix 1) in a multi reagent washer (Dynatech MRW). Swine
anti-rabbit HRP coupled secondary antibody was diluted 1:1000 in dilution buffer.
lOOpl of the secondary antibody dilution was added to each well, incubated at room
temperature for 2-3 hours and plates were washed on the automated plate washer as
above. 1 OOpL of either ODP (O-Phenylenediamine dihydrochloride, Sigma) substrate
buffer (Appendix 1), producing a soluble end product that is yellow in colour or TMD
(Tetramethylbenzidine free base) substrate buffer (Appendix 1), producing a soluble
end product that is blue in colour was added to each well with a multipipetter to
ensure equal incubation time and was incubated for 20-30 min. The reaction was
stopped by addition of 50pl of 3N HCL (for ODP buffer), resulting in an orange
colour reaction or 50pl of 2M H2SO4 (for TMD buffer), resulting in a yellow solution
to each well. Absorbance was measured on a MR 5000 ELISA plate reader
(Dynatech) at 490nm (for ODP buffer) or 450nm (for TMD buffer) and the data was
analysed using BioLynx, Version 2.20 computer software (Dynatech Laboratories).
5.11. GENRAL CELL CULTURE TECHNIQUES
5.11.1. Routine culture maintenance
Jurkat, HeLa, H9, Priess, Panel, Mia and CF Pac cells were cultured in RPMI
medium supplemented with 10% foetal calf serum, glycine O.lmM, 1 unit/ml penicillin
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(GiBco BRL) and 100pg/ml streptomycin (GiBco BRL). Cultures were kept at a
temperature of 37°C, in a humidified atmosphere of 5% C02, 95% air and were
maintained in exponentially growing phase. Cells were passaged routinely at a 1:10
dilution, when about 75% confluence was reached, which provided about 7.5 x 10°
cells from a 175cm2 flask. To subculture cells, semiadherent Priess cells were
disaggregated by a sharp tap to the flask and the cell suspension, like other
nonadherent cells was transferred to Falcon tubes and centrifuged for 5min at
lOOOrpm in a bench top centrifuge (MSE), and then resupended in fresh medium.
Cultures of adherent cells were passaged, usually about 1:6-1:10, just before
confluence was reached. The medium was aspirated and the cells were washed once
with PBS. The PBS was aspirated and 5ml of trypsin for a 100cm2 flask was added,
dispersed evenly and the cells were incubated at 37°C for 3-5 min. As soon as the
cells started to detach they were dissociated by vigourous knocking of the side of the
flask with the palm of the hand. After checking the dissociation under the microscope,
10ml ofmedium was added and 1ml transferred to a fresh flask with 30ml of complete
medium.
5.11.2. Freezing
Cells when not required were stored in the vapour over liquid nitrogen. To
freeze down vials, a 175cm2 flask was grown to near confluence, trypsinised as
described above (adherent cells), pelleted by centrifugation for 5min at lOOOrpm,
washed once in sterile PBS, respun and then resuspended in 10ml of cold medium
containing 10% DMSO and 40% foetal calf serum (freezing mix) and 1ml transferred
to a cryotube (Nunc). Cells were then promptly transferred to a -80°C freezer
overnight at an approximate cooling rate of l°C/min, and moved to storage over
liquid nitrogen the following day.
5.11.3. Thawing
To bring frozen cells back to culture, a freezing vial was removed from liquid
nitrogen and thawed rapidly by the addition of 1ml pre-warmed medium. The cells
were washed in 10-20ml RPMI medium before replating.
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5.12. INDUCTION OFAPOPTOSIS INHUMAN CELL LINES
5.12.1. Treatment with etoposide
Human Jurkat T cells and Priess B cells were induced to undergo apoptosis by
incubation with 50p,M etoposide (in DMSO) added directly to the tissue culture
medium. Control cells were incubated with the equivalent amount of DMSO only. At
regular intervals of 10-12 hour time course, samples of cells were fixed to assess
apoptotic morphology (see below) and cell extracts were prepared for Western
blotting analysis (see above).
5.12.2. Treatment with anti-Fas antibody
For induction of apoptosis by anti-Fas treatment human Jurkat and Priess cells
in logarithmic growth phase were counted in a haemocytometer (improved Neubauer
counting chamber). The required number of cells (2 x 107 cells/time point) were
centrifuged at lOOOrpm for 5 min in a bench top centrifuge (MSE). The culture
medium was taken off, pelleted cells were washed in 15ml of sterile PBS, centrifuged
as above and put on ice. Cells were incubated on ice for 30 min with 200ng of anti-
Fas monoclonal antibody (clone CH11; Immunotech) per 1 x 106 cells. Antibody and
cells were mixed by gentle pipetting. Control cells were incubated on ice for 30 min
without the addition of anti-Fas antibody. Following incubation on ice cells were
resuspended in medium (20ml of medium/2 x 107 cells) and at regular intervals of a
10-12 hour time course, samples of cells were fixed to assess apoptotic morphology
(see below) and cell extracts were prepared for Western blotting analysis (see above).
5.12.3. Treatment with staurosporine
Human Jurkat T cells and Priess B cells were induced to undergo apoptosis by
incubation with lp.M staurosporine (in DMSO) added directly to the tissue culture
medium. Control cells were incubated with the equivalent amount of DMSO only. At
regular intervals of 10-12 hour time course, samples of cells were fixed to assess
apoptotic morphology (see below) and cell extracts were prepared for Western




Ceils for morphological analysis (1 x 106) were washed once in PBS,
centrifuged for 2 min at 6500rpm, resuspended in 50pl of PBS, fixed by the addition
of 50pl of 4% formaldehyde in PBS and stored at 4°C. 5pi of fixed cells were mixed
with 5pi of acridine orange (lOpg/ml in PBS) and a minimum of 500 cells were
scored under UV light on a Zeiss Axiphot fluorescent microscope for apoptotic
morphology.
5.13.2. Transmission electron microscopy
Tissue cultured cells were washed once in PBS, centrifuged for 2 min at
6500rpm, resuspended in 50pl of PBS, fixed by the addition of 50pl of 4%
formaldehyde in PBS and stored at 4°C until processed for electron microscopy. The
suspension of formaldehyde fixed cells was centrifuged for 2 min at 2000rpm and
resuspended and refixed in 3% glutaraldehyde containing 0.1M sodium cacodylate
buffer at 4°C for 30 min. Samples were centrifuged as above and washed in 0.1M
sodium cacodylate buffer at 4°C for 15 min. Following centrifugation as above
samples were post fixed in 1% osmium teroxide containing 0.1M sodium cacodylate
buffer at 4°C for 30 min. Samples were then dehydrated through various grades of
ethanol (from 10%, 50%, 75% to 100% ethanol), 3x 10 min incubation per grade up
with three changes of ethanol and centrifugation of samples was carried out as before.
Dehydrated samples were transferred into solvent resistant capsules and incubated in
two changes (10 min each) of propylene oxide, centrifuged in between steps. Samples
were impregnated in polyethylene capsule in warm araldite epoxy resin (enough resin
just to cover the sample) at 56°C overnight. The capsules were filled up with fresh
epoxy resin the following morning and incubated for an additional 2-3 days at 56°C.
Sections of approximately 50-60nm were cut on an ultramicrotome (LKB Nova),
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8.0 APPENDIX 2
Figure 1. pET vector diagram. Shown is the map for the pET23a(+) vector which is
identical to pET23d except of the following criteria: pET23d is a 3663bp plasmid; the
BamHl site is in the same reading frame as in pET23c containing a C-terminal
histidine tag (six histidines); an Ncol site is substituted for the Ndel site with a net
lbp deletion at position 238, as a result Nco 1 cuts pET23d at 234, and Nhel cuts at
229 (adapted from the pET System Manual, Novagen).
pET-23a(+)
(3666bp)
T? pranofer p lime r #69348-1
Bgl II T7 promoter Xte, its
AttTCTdSATCCCCCCAAArrAATACllACTCACTATAfiCSAJAeCACMCttTTTCCCTeTASAAATAATTTTiTTTAAtTTTAASAAfiSAeA
jWel_Wwl_ 77 "Tag pCT"2ta I EcoR I Sac I A?/l Xtol Hs-Tag*
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Figure 2. Control elements of the pET system. Caspase 2 polyucleotide sequences
cloned into the bacterial expression vector pET23dl-3. Shown is the induction of
caspase 2 expression by addition of IPTG to the E.coli BL21pLysS culture (adapted











Figure 3. Antigen for caspase 2 polyclonal and monoclonal antibodies. Structure of procaspase 2
with marked subunits (pl8 and p 12) and prudomain and linker region (black boxes). Inununogen of
commercial anti-caspase 2 antibodies depicted in relation to procaspase 2. A Inununogen for the
Transduction Laboratories anti-caspase 2 antibody, mouse monoclonal IgGl antibody, raised against
19.5kDa protein fragment (176 amino acids) corresponding to amino acids 225-401. including parts of
the large subunit, the small subunit and the linker region of procaspase 2. B Santa Cruz anti-caspase 2
(1CH-1 S/L) antibody, rabbit polyclonal IgG. raised against a peptide corresponding to amino acids 2-18









Figure 4. Antigen for caspase 3 monoclonal antibody (Transduction Laboratories). Structure of
procaspase 3 with indicated positions of subunits (pi7 and pi2) and prodomain (black box). IgGI mouse
monoclonal anti-caspase 3 antibody raised against a 24.7kDa protein fragment corresponding to amino acids
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Introduction
Apoptosis was first recognized as a distinctive
process because of its characteristic structural
changes. These affect the nucleus, cytoplasm,
cytoskeleton and plasma membrane coordi-
nately and occur regardless of the affected cell
type or lineage in response to both physiolo¬
gical and pathological stimuli. The cellular
triggers of apoptosis vary widely including
activation of molecules in response to particu¬
lar types of cell damage (eg. p53, ceramide)
and ligand binding to specific receptors (eg.
Fas, TNFR). Downstream of these triggers lie
further regulatory molecules which are
important in initiating or forestalling the final
common events but do not contribute direct¬
ly to them, such as the reaper gene product in
Drosophila and the various members of the
bcl-2, family. The effector events themselves
depend on activation of a set of proteases with
a cysteine in their active site and remarkably
conserved structure and function between
species. These cysteine proteases appear to be
directly responsible for the structural changes
of apoptosis and are the subjects of this article.
Current appreciation of the significance of
cysteine proteases as effectors of apoptosis
originated from the identification and cloning
of the C. elegans cell death gene, ced-3 (cell
t/eath abnormal). This gene, which is essential
for normal programmed cell death in the
nematode (Ellis, 1986) encodes a protein of
503 amino acids with 29% amino acid identi¬
ty to the human interleukin-1 (3 (IL-1 (3) con¬
verting enzyme (ICE) (Yuan, 1993; Thorn-
berry, 1992; Miura, 1993; Xue, 1996).
Structurally unrelated to any other known
class of proteases, ICE and Ced-3 are the
founder members of a growing new ICE-like
protease family. To date known family
members include ICH-l/NEDD-2 (Wang,
1994; Kumar, 1994), prICE (Lazebnik, 1994),
CPP32/Yama/Apopain (Fernandes-Alnemri,
1994; Tewari, 1995; Nicholson, 1995),
TX/ICH-2/ICErelII (Faucheu, 1995 Ka-
mens, 1995; Munday, 1995), ICErellll/TY
(Munday, 1995; Faucheu, 1996), Mch2 (Fer¬
nandes-Alnemri, 1995); Mch3/ICE-LAP3
Fernandes-Alnemri, 1995; Duan 1996),
CMH-1 (Lippke, 1996), FLICE/MACH
(Muzio, 1996; Boldin, 1996). Elere we discuss
the common structural features of the ICE-
like proteases, their substrates in apoptosis
and their regulation in terms of biochemical
interactions between individual family mem¬
bers and other components of the apoptotic
pathway.
Composition and Structure of ICE-Like
Proteases
Structural studies are more complete for ICE
than for any of the later discovered family
members. ICE was originally purified from
the cytosol of the human monocytic cell line
TFIP.l as a heterodimeric enzyme composed
of two subunits of 10 (p 10) and 20 (p20) kDa
molecular weight (Thornberry, 1992). ICE
cleaves the inactive 33 kDa IL-1 (3 precursor
(proIL-l(3) at Aspll6-Alal 17 to generate the
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17 kDa fully active cytokine IL-1(3. ICE
cDNA has an open reading frame of 1212
nucleotides encoding a proenzyme of 404
amino acids with a predicted molecular
weight of 45 kDa. The mature form of ICE is
derived from this 45 kDa precursor by pro¬
teolytic removal of the N-terminal 119 amino
acids and an internal fragment spanning resi¬
dues 289-316. Cleavage occurs by autocataly-
sis at Asp-X bonds where X is Serl04,
Asnl20, Ser298 or Ala317 (Thornberry, 1992;
Wilson, 1994) (Figure 1).
The catalytic mechanism and the substrate
specificity of ICE have been revealed by the
use of synthetic oligopeptide inhibitors.
These small peptides (usually four amino
acids) are engineered to mimic the proteolytic
substrate cleavage site of the enzyme and
contain the amino acid residues essential for
catalytic recognition. They are synthesised as
peptide aldehydes or chloromethylketones
and act as competitive inhibitors that un¬
dergo nucleophilic addition of the catalytic
cysteine to form thiohemiacetals and thio-
hemiketals (Thornberry, 1995). The synthetic
tetrapeptide acetyl-Tyr-Val-Ala-Asp-CHO
(Ac-YVAD-CHO) inhibits the catalytic
mechanism of ICE by binding covalently to
the sulphur atom of Cys285 (Thornberry,
1992). This type of observation, together with
results from site-directed mutagenesis led to
the classification of ICE as a cysteine protease
and demonstrate that ICE displays substrate
specificity for an aspartic acid residue at the
PI position (the first amino acid N-terminal
to the cleavage site). Although the catalytic
cysteine is located in the p20 subunit at posi¬
tion 285, X-ray crystallographic studies show
that the active site is formed by amino acids
from both subunits and that catalysis also
requires p20 subunit residues His237 and
Gly238. P20 amino acids Argl79, Gln283
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together with plO residues Arg341 and possi¬
bly Ser347 are the critical elements in the for¬
mation of the binding pocket for the carboxy-
late side chain of PI Asp (Walker; 1994;
Wilson, 1994). From crystallographic studies
it has been proposed that two p20/pl0 sub-
units heterodimerize to form the tetrameric
active enzyme (Thornberry, 1992; Wilson,
1994, Walker, 1994). Unless large conforma¬
tional changes accompany autoprocessing, it
is probable that the p20 and plO contributing
to each active site derive from different pre¬
cursor proteins. The p45 precursor protein
itself has been shown to form oligomers in
transfected COS cells. This oligomerization is
a seemingly prerequisite state for autoproc¬
essing to the active enzyme (Gu, 1995).
Global fold, topology and quaternary struc¬
ture of ICE is unlike that of proteases of other
classes (Wilson, 1994; Walker, 1994).
ICE and CPP32 (cysteine protease p32) are so
far the only family members with known
crystal structure. In CPP32 two p 17 and
p 12 subunits heterodimerize, as in ICE, to
form the active tetrameric enzyme (Rotonda,
1996). Sequence comparisons between the
other family members and ICE show approx¬
imately 30% amino acid identity and struc¬
tural analysis suggests that all members are
synthesized as inactive proenzymes in the
same way as ICE. The residues of ICE impor¬
tant for recognition of PI Asp and for cataly¬
sis are conserved in every member, together
with a pentapeptide QACRG, containing the
active site cysteine. This suggests that all
members share the same catalytic mechanism.
There is more diversity, however, in the ami¬
no acids that putatively line the groove where
the P2-P4 residues of the substrate lie, corre¬
sponding in ICE to Val338, Trp340, His342,
Pro343, Arg383 and Gln385. These amino
acids are most likely responsible for the dif¬
fering substrate affinities amongst the various
family members. Further differences exist
between individual family members in the
molecular weight of the proenzyme and the
two subunits of the active enzymes. The
CPP32 proenzyme for example lacks the 2
kDA linker peptide between the two subunits
and has a prodomain that is substantially
shorter than ICE (Nicholson, 1995). For most
of the other ICE-like proteases the exact
subunit sizes are still undetermined. Mole¬
cular masses have been predicted, however,
and together with sequence comparison
data suggest that ICFI-2/TX/ICErelII and
ICErellll/TY are likely to be proteolytically
processed to subunits analogous to those of
mature ICE. ICH-l/NEDD-2,2, Mch3/ICE-
LAP3 and CMH-1 are in sequence more
closely related to Ced-3 and CPP32, have
generally smaller molecular weight proen¬
zyme forms and are believed to be processed
to subunits equivalent of CPP32. The ICE-
like protease family has thus been further sub¬
divided into the ICE-subfamily and the Ced-
3 subfamily.
Involvement of ICE-Like Proteases in
Apoptosis
Definitive proof that a particular protein con¬
tributes to the effector pathway of cell death
requires that it is expressed in cells competent
to activate the pathway, that overexpression
initiates death and that downregulation or
specific inhibition block cell death. At present
very few of the ICE family proteases fulfill all
these requirements. Apoptosis has been in¬
duced in a variety of mammalian and insect
cells following overexpression of ICE and
most of the other members of the ICE-like
protease family (Miura, 1993). This evidence
alone is insufficient proof of a specific role
of those ICE-like proteases in cell death,
however, as introduction of other known pro¬
teases of entirely different specificities has
been claimed to induce death with many of
the characteristic morphological features of
apoptosis including membrane blebbing,
chromatin condensation and DNA fragmen¬
tation (Williams, 1994). Evidence for the
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physiological role of ICE-family proteases
derives from observation of the efficacy of
supposedly specific protease inhibitors
(natural or synthetic), the biology of
genetically altered ("knock-out") mice, and
protease activity in apoptotic cell extracts.
Natural inhibitors
The existence of natural macromolecular viral
inhibitors of ICE-like proteases, which also
inhibit apoptosis, provides suggestive evi¬
dence that apoptosis plays a significant role in
cellular anti-viral defence. Viral inhibitors of
ICE-like proteases include the cowpox virus
crmA and the baculovirus pi5 gene.
Induced expression of the cowpox virus gene
crmA, which encodes a 38 kDa protein of the
serpin family, suppresses ICE-activated
apoptosis in Rat-1 cells (Miura, 1993). CrmA
expression from a microinjected vector inhib¬
its the death of neurons that follows with¬
drawal of nerve growth factor (Gagliardini,
1994) or isolation from contact with extracel¬
lular matrix (Boudreau, 1995). Mammalian
MCF7 (breast epithelial) and BJAB (B-cell
lymphoma) cell lines stably transfected with
crmA are rendered resistant to TNF and Fas-
mediated apoptosis, showing no cytopathic
effect even at high doses of the death stimulus
(Tewari, 1995). Hence the death pathway in
all these systems converges on a CrmA-in-
hibitable step. Successful inhibition of certain
ICE-hke proteases however, appears to re¬
quire high levels of expression of the crmA
gene, not necessarily achieved during viral
infection. Studies of enzyme kinetics there¬
fore add important information. CrmA has a
10,000 fold preference for ICE over CPP32.
On the basis of the high sequence similarity
between CPP32 and Mch3/ICE-LAP3 the
latter might not be inhibited by CrmA during
cowpox virus infection. CrmA is known to
inhibit processing of IL-1(3 {Ray, 1992;
Komiyama, 1994), a substrate of ICE, and
thus these results are compatible with activa¬
tion of ICE in the final common pathway of
apoptosis. They leave unresolved, however,
the question which or how many other ICE-
like proteases may be involved, since struc¬
tural similarity between family members
would predict that many of these should also
be inhibited by CrmA.
P35 blocks apoptosis in baculovirus infected
insect cells, resulting in increased virus pro¬
duction {Crook, 1993; Clem, 1994) and can
block cell death in both vertebrate and inver¬
tebrate cells. Expression of p35 in Drosophila
melanogaster abrogates death induced by rea¬
per overexpression {White, 1996). P35 expres¬
sion in C. elegans and in Drosophila melano¬
gaster embryos also prevents their
physiological programmed cell death (Sugi-
moto, 1994; Hay, 1994) although crmA
expression has no antiapopotic effect. In
mammalian cells overexpression of p35 blocks
proteolytic activity of ICE and purified p35
inhibits at least three other family members
(ICH-1, ICH-2 and CPP32) {Bump, 1995). It
is thus possible that p35 has a broader specifi¬
city than CrmA. Interestingly, both p35 and
CrmA possess internal cleavage sites for ICE-
like proteases. Cleavage at these sites results in
a conformational change rendering the inhibi¬
tor less easily dissociable from the enzyme
and thereby prolonging its inhibitory effect.
In elegant experiments, the ability to arrest
programmed cell death in C. elegans embryos
was conferred upon CrmA by exchanging its
cleavage site for that of p35, suggesting that
cell specificity of these endogenous inhibitors
may be mediated by very subtle molecular
changes {Xue, 1995).
Synthetic inhibitors
Synthetic peptides which contain the cleavage
site for ICE in proIL-l(3 are suitable substra¬
tes for the enzyme. Such peptides competi¬
tively inhibit the cleavage of natural substrate
within cells and cell extracts, particularly if
presented as covalently binding aldehyde or
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chloromethylketone derivatives. A direct
copy of the cleavage site in proIL-lp (at
Asp27 and Aspll6) is Tyr-Val-His-Asp
(YVHD), but broad substitution in the P2
position is tolerated and in practice YVAD is
a better inhibitor of ICE (Thornberry, 1992).
YVAD coupled to a DEAE column has been
used to purify active ICE to homogeneity
from cytosolic extracts, demonstrating the
avidity and specificity of the peptide-enzyme
binding (Thornberry, 1992). It effectively
inhibits death in many although not all cir¬
cumstances. Thus YVAD-fmk completely
blocks death of Drosophila cells induced by
hyperexpression of reaper (Pronk, 1996). Ac-
YVAD-CHO inhibits chicken motoneuron
death induced by withdrawal of muscle-de-
rived trophic factor (Milligan, 1995). It also
blocks Fas-mediated apoptosis in many cell
types (Enari, 1995; Los, 1995). However,
apoptosis of macrophages induced in vitro by
treatment with 5mM ATP is not inhibited by
YVAD-cmk under conditions in which proc¬
essing of proIL-l(3 is completely abrogated
(Nett-Fiordalisi, 1995), suggesting that pro¬
teases of different specificity from ICE may
be responsible for this apoptosis. In support
of this, there is evidence for preferential in¬
hibition of other proteases in the ICE family
by other peptides. Thus Ac-DEVD-COOH
contains the protease cleavage site in poly
(ADP-ribose) polymerase (see below) and a
biotinylated form of this tetrapeptide has been
used as an affinity ligand to purify CPP32
from cytosolic extracts of the same cell type
from which ICE was purified by YVAD af¬
finity chromatography (Nicholson, 1995).
These experiments thus suggest that whilst
proteases identical or close to ICE in structure
may be responsible for the effector process in
Fas-induced killing, other triggers of death
may involve other proteases. In theory dif¬
ferent cell types may possess their own pro¬
teases, or there may be a cascade in which
activation of one protease (eg. ICE) leads to
the activation of other family members, and
different stimuli trigger different elements of
the cascade. Equally, it is possible that redun¬
dant parallel pathways exist of differing
relative importance in different cell types.
Unfortunately these issues are unlikely to be
clarified by use of the inhibitors alone, because
complete specificity of inhibition to any one
family member is improbable given the
known homologies of the substrate binding
site.
Knock-out mice
Insight into the potential redundancy of pro¬
teases has been gained from observations in
ICE knock-out mice. These develop normal¬
ly, appear healthy and are fertile. Their macro¬
phages are defective in processing and release
of IL-1|3 but sensitive to ATP-induced
apoptosis. Similarly thymocytes from ICE-
knock-out mice have been shown to be sensi¬
tive to dexamethasone and radiation induced
apoptosis (Kuida, 1995; Li, 1995). Hence
none of these stimuli has an absolute require¬
ment for ICE in engendering apoptosis in
these cells. In contrast thymocytes from these
ICE knock-out mice are resistant to anti-Fas
triggered apoptosis, establishing a unique role
for ICE in Fas-mediated apoptosis. Various
models can be built around these results, eg. a
linear 'cascade' in which ICE activated by Fas
is 'upstream' of other proteases, or two con¬
vergent pathways, one involving ICE and
triggered by Fas, the other accounting for
other stimuli for death. These models could
be definitively tested using knock-outs of
various other proteases (Figure 2).
Cell free systems
Cell free systems provide another powerful
approach for study of the effector mechanism
of apoptosis. They allow dissection of the
activation of the effector from the target struc¬
tures involved in the effector pathway itself.
Proteases or their inhibitors can be directly
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Fig. 2: Model for Fas and TNF induced apoptosis.
added to the system circumventing the per¬
meability barrier that the plasma membrane
presents in intact cells. Cell free systems there¬
by permit analysis of the role of individual
components of the pathway and provide
information about the identity and cellular
location of the substrates of the effector. In the
first description of such a system extracts
from chicken hepatoma ceils induced in HeLa
nuclei all the nuclear morphological changes
expected in apoptosis, including chromatin
condensation, dissociation of the nuclear
membrane and internucleosomal DNA frag¬
mentation (Lazebnik, 1993). The active prin¬
ciple turned out to be a cytoplasmic cysteine
protease named prICE (protease resembling
ICE). Its inhibition by TLCK (tosyl-L-lysyl
chloromethylketone) and YVAD-cmk and its
inability to cleave proIL-l(3 proved it could
not be ICE itself (Lazebnik, 1994). Several
other cell systems have since been described.
They have not only established that activation
of ICE family proteases is a key event during
apoptosis but have also led to the discovery of
downstream targets of these proteases (New-
meyer, 1994; Lazebnik, 1995; Enari, 1995;
Martin, 1995, 1996).
Targets for ICE-Like Proteases
Study of the proteolytically cleaved proteins
that appear during apoptosis has helped define
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the biology of the effector pathway and has
provided intriguing if still not definitive infor¬
mation on the plurality of the apoptotic pro¬
teases themselves. If the ICE-like proteases
are indeed in the final common path for
apoptotic effector events then their substrates
should include cell components that are res¬
ponsible for the structural changes observed
in apoptotic cell death. Candidate substrates,
known to undergo specific proteolytic cleav¬
age in apoptosis, include PARP (Kaufmann,
1993; Lazebnik, 1994), nuclear lamins
(Lazebnik, 1995), fodrin (Martin, 1995), U1
small nuclear ribonucleoprotein particle (U1
70) (Casciola-Rosen, 1994), growth arrest-
specific protein2 (Gas2) (Brancolini, 1995),
actin (Mashima, 1995\Kayalar, 1996), protein
kinase C8 (PKC8) (Emoto, 1995), sterol regu¬
latory element-binding protein (SREBP-1
and SREBP-2) (Wang, 1995, 1996), GDP
dissociation inhibitor (D4-GDI) (Na, 1996),
Retinoblastoma protein (RB protein) (An,
1996), the nuclear proteins DNA-dependent
protein kinase (Casciola-Rosen, 1995), histone
HI, topoisomerase I and II (Kaufmann, 1989;
Voelkel-Johnson, 1995) and the cell membrane
associated adenomatous polyposis coli pro¬
tein (APC) (Browne, 1994).
Proteolytic cleavage ofPARP
Proteolytic cleavage of PARP was originally
discovered in etoposide-induced apoptosis
and is an early event in apoptosis (Kaufmann,
1989; Althaus, 1987). PARP is a chromatin-
associated protein with a molecular weight of
116 kDa that catalyses the covalent attach¬
ment of ADP-ribose units from its substrate
NAD+ to numerous nuclear proteins includ¬
ing itself. The enzyme is strongly stimulated
by DNA strand breaks and activates DNA
ligase II. Internucleosomal DNA degrada¬
tion, characteristic of apoptosis, would thus
be expected to activate the enzyme resulting in
religation of the DNA fragments and con¬
sumption of NAD either of which could have
serious sequelae in aborting the process of
apoptosis. PARP is inactivated in apoptosis,
however, by cleavage into two fragments of
about 25 and 85 kDa, which isolates the
DNA-binding from the catalytic domain of
the protein (Lazebnik, 1994). The link be¬
tween PARP cleavage and ICE-like proteases
was established through the study of cell free
systems.
Candidate proteases for PARP cleavage
PrICE was the first ICE-like protease shown
to cleave PARP, producing a fragment of
approximately 85 kDa. This activity is inhib¬
ited by decamer peptides that span the PARP
cleavage site (Lazebnik, 1993). Several other
ICE-like proteases have since been shown to
have PARP cleavage activity in vitro.
CPP32, originally cloned from human Jurkat
T-lymphocytes was shown to be responsible
for PARP cleavage, both in a purified system
with recombinant CPP32 and purified PARP
and an overexpression system in stably trans-
fected MCF7 breast carcinoma and BJAB
lymphoma cell lines (Fernandes-Alnemri,
1994; Tewari, 1995). Both cleavage of PARP
and apoptosis were inhibited by CrmA
(Tewari, 1995). The role of CPP32 as the
PARP cleaving enzyme seems to be further
confirmed by several independent lines of evi¬
dence. The tetrapeptide aldehyde inhibitor
Ac-DEVD-CHO blocks PARP cleavage in
osteosarcoma cell extracts and attenuates the
occurence of nuclear changes driven by THP-
1 cell extract in a cell-free system (Nicholson,
1995). A cell-free system derived from anti-
Fas treated Jurkat cells (Fas extract) led to the
partial characterisation of an ICE-like pro¬
tease which promotes apoptotic changes in
isolated thymocyte nuclei (Schlegel, 1995).
Further characterisation of these cytosolic
extracts by immunoblotting with PARP
specific antibody and rabbit polyclonal anti¬
bodies specific for the pi 7 and pl2 subunits of
CPP32 showed that CPP32 activation, from
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its inactive proenzyme form to the active pi7
and pl2 subunit mature enzyme, correlated
with the onset of PARP cleavage. In the
presence of the tetrapeptide inhibitor Ac-
DEVD-CHO this cleavage was completely
inhibited, whereas CrmA did not interfere
with either PARP cleavage activity or nuclear
degradation activity (Schlegel, 1996).
There is also some evidence suggesting that
other members of the ICE-like protease fami¬
ly may be involved in PARP cleavage. Coex-
pression of human PARP with human ICE, or
the ICE homologs TX and NEDD-2 in COS
cells resulted in PARP cleavage, inhibited by
coexpression of CrmA (Gu, 1995). A com¬
parison of protein concentration, however,
showed that for ICE to cleave PARP a 50-
100-fold higher protein concentration is re¬
quired than to process proIL-l(3. Coexpres¬
sion of CMH-1, (standing for CPP32/Afch2
^omolog), in COS cells together with a trun¬
cated 45 kDa PARP polypeptide resulted in
PARP cleavage to a 31 kDa peptide similar to
that produced by ICE, TX and NEDD-2
{Lippke, 1996). CMH-1 was found to cleave
PARP at less than 3nM concentration within
30 min. hence showing similar kinetics to
PARP cleavage by CPP32 in the Fas cell-free
system. No cleavage of proIL-l(3 was found,
indicating that CMH-1, like CPP32, has a
preferred substrate specificity for PARP
{Lippke, 1996). Mch3 and ICE-LAP-3
(standing for 7C£-/ike apoptotic protease 3),
represent the same protease independently
cloned by two groups and this also has been
shown to inactivate PARP. Structurally Mch3
is the most closely related protease to CPP32
(58% sequence identity). Mch-3(ICE-LAP-
3), cloned from human Jurkat T cells has been
shown to cleave PARP in less than 15 min.
when incubated with either purified bovine
PARP or human Hela nuclei and this activity
is only weakly CrmA inhibitable {Fernandes-
Alnemri, 1995).
Two other ICE-like proteases have PARP
cleavage specificity. CED-3 cleaves PARP
into products indistinguishable from the pro¬
ducts generated by CPP32 and this cleavage is
inhibited by baculovirus p35 protein {Xue,
1995; Hugunin, 1996). Mch2 mammalian,
CED-3 /jomolog) with 38% sequence identi¬
ty with CPP32 and 35% identity with CED-
3 cleaves PARP to generate a major product of
approximately 83 kDa and a minor band at
about 57 kDa. In contrast PARP cleavage by
CPP32 at the DEVD site results in fragment
of 89.3 kDa predicted molecular mass. This
suggests that Mch2 cleaves PARP at a site
COOH-terminal to the DEVD site {Duan,
1996). This is consistent with the observation
that recombinant CPP32 cleaves synthetic
DEVD with a higher activity than Mch2.
Hence, CPP32 and the closely related ICE
family members (Mch2, Mch3 and CMH1)
are good candidates for the enzymes that
cleave PARP early in apoptosis. The question
arises whether PARP cleavage by CPP32 is
essential for apoptosis. This appears unlikely
since PARP knock-out mice are healthy and
fertile, with only a susceptibility to develop
skin disease, and without major disruption in
their patterns of developmental cell death
{Wang, 1995). Moreover, CPP32 in isolation
cannot provoke apoptotic changes when
added to healthy nuclei, showing that it is not
sufficient for induction of apoptosis {Nichol¬
son, 1995). CPP32 is thus likely to act in con¬
junction with other family members in the
apoptotic pathway and has been shown to
have at least one other substrate.
Multiple ICE-like proteases with capacity for
cleavage and inactivation of PARP not only
exist but can exist together in a single cell.
This suggests some functional redundancy
between individual family members but also
points towards the existence of other sub¬
strates which are not necessarily directly
involved in cell death. This redundancy might
be expected as it provides comprehensive pro¬
tection of cells against viral inhibitors and so
protects tissues against clonal expansion or
lysis of virus infected cells.
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Further substrates
Amongst other substrates cleaved by ICE-
like proteases are the nuclear lamins. Lamins
are intermediate filament proteins localized at
the nuclear envelope and probably involved in
nuclear envelope integrity and in organisation
of chromatin in interphase (Lazebnik, 1993).
Proteolytic cleavage of lamins A, B and C can
be reproduced by exposing normal nuclei to
cell free extracts with ICE-like protease
activity. Lamin proteolysis begins about ten
minutes after proteolysis of PARP has been
completed and has a different inhibitor pro¬
file, being sensitive to inhibition by TLCK
(tosyl-L-lysyl chloromethylketone) and up to
100-fold more sensitive to YVAD-cmk than
PARP (Lazebnik, 1995). Interestingly, addi¬
tion ofTLCK to S/M extracts inhibits the for¬
mation of apoptotic bodies but allows chro¬
matin condensation and DNA fragmentation
to occur. Hence, it is probable that lamin and
PARP cleavage are mediated by different
enzymes, with preferential control over dif¬
ferent elements of the process of apoptosis
and the PARP cleaving enzyme acting earlier
than the lamin-cleavage enzyme. Very recent
data seem to confirm this as Mch2 (but not
CPP32) has been shown to cleave lamin A
('Takahashi, 1996).
Fodrin is a cytoskeletal component cleaved
during apoptosis induced by a variety of stim¬
uli such as ligation of the CD3/T cell receptor
complex, Fas activation and treatment of cells
with staurosporine, glucocorticoid or syn¬
thetic ceramide. Fodrin or nonerythroid spec¬
trin is a multifunctional protein and a major
component of the cortical cytoskeleton. The
protein is composed of two subunits (alpha
and beta). The alpha subunit (molecular
weight approximately 240 kDa) is cleaved in
apoptotic cell extracts to a major detectable
band of about 150 kDa (Martin, 1995).
Cytoplasmic extracts of UV-irradiated or
anti-Fas-treated cells similarily contain a
fodrin-cleavage protease (Martin, 1995). It is
not yet established whether this cleavage is the
direct consequence of the activation of an
ICE-like protease or whether it is secondary
to proteolytic activation of the calcium-
dependent neutral protease calpain, whose in
vitro substrates include cytoskeletal proteins.
Membrane blebbing in apoptosis could be the
consequence of the disruption of the fodrin
network.
Another component of the microfilament
system, Gas2, has been shown to be cleaved in
nonadherent COS7 cells induced to undergo
apoptosis by serum withdrawal (Brancolini,
1995). Gas2 is a 35 kDa protein whose tissue
specific expression is increased during growth
arrest. It can induce alterations of the actin
cytoskeleton and of cell shape and this ability
is associated with proteolytic cleavage at an
aspartic acid residue near the C-terminus to a
31 kDa protein. This implies not only that
Gas2 is a potential target for an ICE-like pro¬
tease but also provides a mechanistic connec¬
tion between apoptotic proteases and cell
shape.
Actin may also be a target for ICE-protease
activity, as it is cleaved from its 42 kDa native
form to 15 and 30 kDa fragments in human
myeloid leukemia U937 cells induced to enter
apoptosis by the chemotherapeutic agent VP-
16 (Mashima, 1995). Purified G-actin incuba¬
ted with purified ICE results in cleavage into
41,30 and 14 kDa fragments. Actin cleavage in
apoptosis results in prevention of polymerisa¬
tion to its filamentous form and in incapacity
to inhibit DNasel. In this way actin cleavage
could be linked directly to plasma membrane
blebbing and oligosomal DNA fragmentation
{Kayalar, 1996).
Another potential substrate is the U1 small
nuclear ribonucleoprotein particle which is
essential for splicing of precursormRNA and
is cleaved from a 70 KDa fragment to a 40
KDa fragment in Hela cells induced to under¬
go apoptosis by serum withdrawal and UV
irradiation (Casciola-Rosen, 1994). This cleav¬
age and the apoptotic morphology are inhib-
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ited by iodoacetamide, TPCK and TLCK, an
inhibitor profile identical to that of ICE.
Studies on Fas- and TNF-induced cell death
in human lymphoma and breast carcinoma
cell lines reveal that cleavage of Ul-70 kDa is
inhibited by CrmA and correlates in time
course with PARP cleavage (Tewari, 1995). A
possible role of Ul-70 cleavage in apoptosis
might be the regulation of RNA splicing.
Recent studies on protein kinaseCS (PKC8), a
cytoplasmic myelin basic protein kinase,
demonstrate that the 78 kDa intact enzyme is
cleaved to a 40 kDa C-terminal fragment after
ionizing radiation of human U-937 cells
(Emoto, 1995). This cleavage which results in
activation of the enzyme occurs adjacent to an
aspartic acid residue and is inhibited by prein¬
cubation of the cells with the ICE protease
inhibitor YVAD-cmk. Recombinant ICE,
however, is unable to cleave the enzyme
which suggests the involvement of an ICE-
like protease other than ICE in the proteoly¬
tic activation of PKC8. The sterol regulatory
element binding-proteins are another sub¬
strate cleaved both in vitro and in vivo by
CPP32. Cleavage is inhibited by the tetra-
peptide Ac-DEAD-CHO. The physiological
function of such cleavage, however, is un¬
known {Wang, 1995, 1996).
Cleavage of cytoskeletal protein, such as
fodrin and actin, and GAS2 activation could
therefore all contribute to the morphological
changes and rearrangements characteristic of
apoptosis. Several other proteins appear to
undergo site specific proteolytic cleavage in
apoptosis even though it is not yet clear
whether an ICE family member is directly
involved. These include the nuclear proteins
histone HI, topoisomerase I and II (Kau,f-
mann, 1989; Voelkel-Johnson, 1995), D4-GDI
(Na, 1996), RB protein {An, 1996) and
adenomatous polyposis coli protein
{Browne, 1994). There is also exciting evi¬
dence that TNF and fas stimulation can ac¬
tivate acid sphingomyelinase {Wiegmann, 1994;
Grazia Cifone, 1994) so demonstrating a
connection between these signalling pathways
and ceramide production. Evidence that
sphingomyelinase activation is mediated by
proteolytic cleavage is still to be published.
It is of course possible that some of these pro¬
teolytic events represent a terminal state of
chaos in the dying cell, in which enzymes are
able to access and cleave proteins that are not
their natural substrates. The roles played by
apoptosis in biology and all that is currently
known for certain of the apoptosis proteases,
however, suggests another story: that apopto¬
sis is an entirely orderly process in which crit¬
ical elements in the cell are dismantled in a
predetermined sequence. While some events
appear to be triggered in parallel (eg. Ul-70
and PARP cleavage) others may be in series
(eg. PARP and lamins), possibly because of a
cascade-like central organisation of the ICE
family protease activation. Recent studies on
ICE and CPP32 activation in Fas-induced
apoptosis seem to be in favour of a cascade¬
like organisation of the ICE-like proteases.
Kinetic studies demonstrate an ICE-like pro¬
tease activity before CPP32-like activity and
peptide inhibitor studies indicate that the lat¬
ter activity depends on previous ICE-like
activity {Enari, 1996). The ICE-like proteases
thus have the capacity to contribute to multi¬
ple near-synchronous events in the nucleus
and the cytoplasm that could underlie the
long-known characteristic structural events of
apoptosis. How this cleavage activity of the
ICE-like proteases is regulated is still one of
the poorly understood phenomena of apopto¬
sis (Figure 3).
Regulation of the ICE-Like Proteases
Application of both cell-permeable synthetic
peptide and natural, macromolecular inhibi¬
tors as well as the identification of several
potential downstream targets have established
ICE-like proteases as effector molecules of
the apoptotic pathway. How this protease
activity is activated and regulated and where
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the ICE-like enzymes act in the pathway in
relation to other important regulatory genes
are only partially resolved. Multiple levels of
control probably exist for the regulation of
ICE protease activity within the cell. Control
could be achieved at the mRNA level through
transcriptional regulation and through alter¬
native splicing, at the protein level through
post-translational modification and proteoly¬
tic cleavage, through interaction with other
components of the cell death pathway which
either activate or inhibit the ICE-like protea¬
ses and by autocatalysis and interfamily inter¬
actions.
Northern blots demonstrate that mRNA
expression of all ICE-like proteases can be
detected in most human tissues. ICE mRNA
has been shown to be induced by loss of adhe¬
sion to extracellular matrix and by transcrip¬
tion factor IRF-1 (Boudreau, 1995; Tamura,
1995). Northern blotting analysis further
reveals the presence of splice variants of some
of the family members. Four isoforms of ICE
have been identified and cloned, named ICE
(3, X) b and € (Alnemri, 1995). Isoforms of
Mch2 (Mch2a and 3), ICH-l/NEDD-2
(termed ICH-IL and ICH-1S) and Mch3
splice variants a and (3 have also been
described {Fernandes-Alnemri, 1995; Wang,
1994). These isoforms arise by the usage of
alternative splice donor/acceptor sites and
result in an a/L full length isoform of the
enzyme and a truncated (3/S form of the en¬
zyme. Expression of the ICH-1S in Rat-1 cells
was shown to prevent cell death induced by
serum withdrawal {Wang, 1994). Potentially
these isoforms could regulate the enzyme
activity by acting as dominant negative inhibi¬
tors and interfere with the heterodimerization
of the active full length form of the enzyme
thereby forming inactive enzyme. The role of
the ICH-1S isoform of the enzyme as an inhib¬
itor of cell death is, however, controversial as
transfection of FDC-pl cells with NEDD-2s,
the mouse equivalent of ICH-1S, had no effect
on cell survival and therefore did not suggest
a major role in the regulation of apoptosis at
least in that cell type {Kumar, 1995).
So far no information is available on post-
translational glycosylation or phosphoryla¬
tion of the ICE-like proteases. Post-trans¬
lational activation by proteolytic cleavage,
however, is a general feature of the enzyme
family as decribed earlier. Most members of
ICE-like proteases
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Fig. 3: Substrate cleavage by ICE-like proteases.
138 B. Dost, A. H. Wyllie
the family exhibit autocatalytic cleavage and
activation when overexpressed in bacteria as
proenzymes. The extent to which this autoac-
tivation in authentic apoptosis occurs is still
uncertain, and activation of one family mem¬
ber by another in a cascade, as discussed
above, is also an attractive possibility. Thus TX
when overexpressed in COS cells has protea¬
se activity against the ICE precursor {Fau-
cheu, 1995). Mch3ct has a potential cleavage
site (amino acids 20-23, DSVD) which is very
similar to the CPP32 tetrapeptide substrate
DEVD, making Mch3a a possible substrate
for CPP32 (Fernandes-Alnemri, 1995).
CPP32 itself does not appear to undergo auto¬
catalytic cleavage. Its activation therefore
requires another aspartic acid specific protea¬
se. Purified ICE and FLICE have both been
shown to cleave CPP32 in vitro, indicating
that they may lie upstream of CPP32 in the
cascade (Tewari, 1995). The serine protease
granzyme B from the granules of cytotoxic T
lymphocytes (CTL) also activates CPP32 and
cleaves ICE (Darmon, 1995; Quan, 1996).
Cleavage of ICE by granzyme B, however,
does not lead to ICE activation (Darmon,
1994, 1995; Quan, 1996; Martin, 1996). This
not only suggests a role for CPP32 and
perhaps other ICE proteases in CTL mediated
cytotoxicity but also implies that various cell
death pathways, including granzyme B indu¬
ced apoptosis, converge into the same effector
pathway. These findings, together with the
data discussed earlier that indicate differing
substrate specificities for the ICE family, sup¬
port the concept that apoptosis is effected by
a central proteolytic cascade whose action in
sequence on substrates throughout the cell
effect its orderly disassembly. Granzyme B
gives the first indication that other non ICE-
like proteases interact and are part of this cas¬
cade. Studies on thymocyte apoptosis induced
by diverse stimuli confirm that proteases of
differing specificities are required for the
complete execution of apoptosis as different
inhibitors with a variety of specificties inhibit
the apoptotic process at various points
(Fearnhead, 1995; Zhivotovsky, 1995).
Further control of enzyme activity might be
achieved through hetero-oligomerisation.
Several members of the ICE-like protease
family can heterodimerize with one another,
such as CPP32 and Mch3 or ICE and TX, for¬
ming active heterodimeric enzyme complexes
and so compensating for mutational inactiva-
tion of individual subunits {Fernandes-
Alnemri, 1995; Faucheu, 1995; Gu, 1995).
Oligomerisation between different ICE-like
proteins might not only alter their substrate
specificities but could potentially modulate
their enzymic activity and stability.
Insight into the upstream regulation of the
ICE-like proteases activity is still limited.
Upstream regulation is likely to be achieved
by members of the Bel-2 family, the mamma¬
lian homologue of the nematode ced-9 nega¬
tive regulator of cell death. Be 1-2 has been
shown to effectively block cell death caused
by overexpression of ICH-1L cDNA {Miura,
1993) and a variety of other apoptotic stimuli.
Recent biochemical studies on Bcl-2, Bcl-xL
and the adenovirus E1B 19 kDa protein, a
viral homologue of Bcl-2, have, however,
clarified the order of the cell death pathway
components. Bcl-2 and Bcl-xL have been
shown to function upstream of the ICE-like
proteases CPP32 and ICE-LAP3 in the
pathway (Chinnaiyan, 1996) as overexpres¬
sion of bcl-2 or bcl-xL abrogates the proteo¬
lytic activation of these enzymes in stauro-
sporine induced apoptosis. Similarly bcl-2 and
adenovirus E1B kDa protein blockade the
CPP32 activation, cleavage of PARP and
apoptosis induced by ElA {Boulakia, 1996).
This negative regulatory role of Bcl-2 and Bcl-
xL, however, seems to be dependent on the
particular apoptotic stimulus as they are
unable to inhibit Fas/APO-1 or TNF induced
cell death. These pathways are inhibited by
CrmA, preventing subsequent PARP cleavage
and enzyme activation (Duan, 1996). Never¬
theless, immunoblotting with antibodies to
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active CPP32 and ICE-LAP3 has demon¬
strated that these ICE-like proteases are part
of the response to staurosporine, Fas/APO-1
and TNF induced cell death. It thus appears
that although different apoptotic stimuli
activate the same effector molecules it is not
necessarily by the same route, suggesting
distinct apoptotic pathways in these systems.
In the non Fas/APO-l/TNF cell death
pathway bcl-2, bcl-xL and E1B act either
upstream or at the activation step of CPP32
and ICE-LAP-3 and likely other members of
the family.
The most dramatic evidence for upstream
regulation of the ICE-like proteases comes
from very recent work on the proteins inter¬
acting with the cytosolic moiety of
CD95/Fas/APO-l and the TNFR. A new
member of the ICE-like protease family,
called FLICE/MACH contains a prodomain
homologous to FADD and an ICE-like pro¬
tease homology region corresponding to the
active enzyme subunits. FLICE/MACH has
been shown to interact with the receptor
death domain of FADD/MORTl and
TRADD which in turn form a complex with
activated Fas/Apo-1/CD95 or TNFR. Hence
this recent work demonstrates a direct non-
transcriptional pathway where Fas activation
leads to triggering of the protease cascade
(.Muzio, 1996; Boldin, 1996)
Conclusion
In the nematode a mutation or deletion of a
single gene, ced-3, abolishes cell death {Ellis,
1991). Regulation of cell death in higher orga¬
nisms is substantially more complex. Not
only are there multiple enzymes homologous
to Ced-3, forming the family of ICE-like
proteases, but these proteases appear to have
overlapping substrate specificities and might
all be involved in the apoptotic pathway in a
single cell type. Confronted with such com¬
plexity much remains to be defined. Knock¬
out mice, specific high titer antibodies and
more selective inhibitors, as more substrates
for other ICE family members are deter¬
mined, are required to define the role of in¬
dividual members. Despite its complexity and
redundancy, the ICE-family protease pathway
offers intriguing possibilities for specific,
selective pharmacological interventions in the
process of apoptosis.
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